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Abstract 
 
Introduction: 
 
There is accumulating evidence of an increased risk of cardiovascular morbidity and 
mortality in rheumatoid arthritis patients. A combination of both traditional 
cardiovascular risks and rheumatoid specific factors appear to be responsible for 
driving this phenomenon. Rheumatoid arthritis has been an orphan of cardiologists 
in the past and rheumatologists themselves are not good at CVD screening. 
Identifying the extent of preclinical atherosclerosis in RA patients will help us to 
appreciate the magnitude of this serious problem in an Irish population.  
 
Methods: 
 
We undertook a cross-sectional study of 63 RA patients and 48 OA controls and 
compared the 2 groups with respect to 1) traditional CV risks factors, 2) serum 
biomarkers of inflammation, including CRP, TNFα, IL6 and PAI-1, 3) carotid 
intima-media thickness (cIMT), carotid plaque and ankle-brachial index (ABI) as 
markers of pre-clinical atherosclerosis, 4) biochemical and ultrasonic measures of 
endothelial dysfunction and 5) serum and echocardiographic measures of diastolic 
dysfunction. Within the RA group, we also investigated for associations between 
markers of inflammation, subclinical atherosclerosis and diastolic dysfunction. 
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Results: 
 
Prevalence of traditional CV risks was similar in the RA and OA groups. A number 
of biomarkers of inflammation were significantly higher in the RA group: CRP, 
fibrinogen, IL-2, -4, -6, TNFα. PAI-1, a marker of thrombosis, correlated with 
disease activity and subclinical atherosclerosis in RA patients. With regard to 
subclinical atherosclerosis measures, RA patients had a significantly lower ABI than 
OA patients. Carotid plaque and cIMT readings were similar in RA and OA patients. 
Assessment of endothelial function revealed that RA patients had significantly 
higher concentrations of adhesion molecules, in particular sero-positive RA patients 
and RA smokers. Adhesion molecule concentrations were associated with markers of 
diastolic dysfunction in RA. Urine PCR, another marker of endothelial dysfunction 
also correlated with diastolic dysfunction in RA. Assessment of endothelial function 
with flow mediated dilatation (FMD) found no difference between the RA and OA 
groups. Disease activity scores in RA patients were associated with endothelial 
dysfunction, as assessed by FMD.  
 
Conclusions: 
 
We did not find significant differences in measures of subclinical atherosclerosis, 
flow mediated dilatation or diastolic function between RA and OA patients. This is 
most likely in part due to the fact that there is increasing evidence that OA has an 
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inflammatory component to its pathogenesis and is associated with metabolic 
syndrome and increased CV risk.  
We reported a significant association between urinary PCR and measures of diastolic 
dysfunction. Urinary PCR may be a useful screening tool for diastolic dysfunction in 
RA. The association between RA disease activity and measures of vascular function 
supports the theory that the excess cardiovascular burden in RA is linked to 
uncontrolled inflammation. 
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Chapter 1 
 
Introduction 
 
 
 
Rheumatoid Arthritis: 
 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis. It affects 
0.5% to 1% of the general population worldwide. The incidence in women is twice 
that in men. In Ireland, the exact prevalence has not been established, however 
studies in Dublin indicate a prevalence rate could be estimated at 0.5% (1). A more 
recent estimate from Arthritis Ireland (2009) suggests there are 40,000 individuals 
with rheumatoid arthritis in Ireland which would equate to a prevalence of 1.22% (2) 
Arthritis Ireland (2009) estimates that 70% of those affected by the disease in Ireland 
are women. Peak age of onset worldwide is between 35 to 45 years, again with 
geographic variances (3). 
The disease primarily affects synovial joints in a symmetrical pattern, particularly 
the small joints of the hands and feet.  Chronic inflammation produces joint damage 
mediated by cytokines, chemokines and metalloproteases and results in pain, 
deformity and functional limitation, causing substantial morbidity and accelerated 
mortality (4).  
Along with the synovial based inflammatory events, RA is associated with a number 
of important extra- articular manifestations, which significantly impact upon patient 
morbidity and mortality. Chief amongst these is the increase in cardiovascular risk 
amongst RA patients, which has been highlighted from an early stage in the disease 
process (5)  
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Excess mortality in RA is well recognized with standardised mortality ratios 2-3 
times those of the general population, a statistic unchanged over 40 years despite 
considerable advances in the treatment of both RA and cardiovascular disease. It is 
considered that up to 50% of the excess mortality in RA is attributable to a 
cardiovascular event (6).
 
A large US health study showed that women with RA were 
twice as likely to suffer from a myocardial infarction as age and sex matched 
controls (5). Furthermore, RA is associated with premature cardiovascular disease 
and shortens life expectancy by 3-18 years (5). Thus the failure to reduce mortality 
in patients with RA is doubly concerning in view of the major advances in the 
treatment of RA and in our understanding of the pathophysiology and treatment of 
coronary artery disease over the past four decades. 
 
 
Cardiovascular Disease: 
 
Cardiovascular disease (CVD) is the leading cause of death worldwide. There are 
approximately 18 million deaths worldwide from CVD each year and 2 – 3 times 
that many experience non-fatal cardiovascular events (7). 
Cardiovascular disease is the most common cause of death in Ireland. A significant 
proportion of these deaths are premature. According to the central statistics office, in 
2010 34% of all deaths in Ireland were due to diseases of the circulatory system (8). 
They occupied the 3
rd
 highest number of acute hospitals’ bed days and were the 5th 
most common reason for discharge from acute hospitals (9). The institute of Public 
Health in Ireland have predicted a significant rise in the prevalence of hypertension, 
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diabetes, coronary artery disease and stroke for the years 2015 and 2020 relative to 
2007 figures (10). Conditions of the cardiovascular system account for the largest 
fraction of the annual expenditure by the general medical services scheme and the 
drug payment scheme (11). 
 
Cardiovascular disease is the result of a pathological process known as 
atherosclerosis, which causes disease of the coronary, cerebral and peripheral arteries 
(12). Atherosclerosis begins in childhood with the development of fatty streaks, 
which are the initial histological phase and represent focal thickening of the intima 
with an increase in smooth muscle cells and extracellular matrix (13). These fatty 
streaks contain macrophages which become engorged with lipids and are known are 
foam cells, the hallmark of early atheroma. Fatty streaks evolve to form fibrous 
plaques and eventually, advanced lesions with a necrotic lipid rich core which can 
ultimately calcify (14). 
 
There are numerous factors involved  in the development of atherosclerosis 
including endothelial dysfunction, inflammatory cytokine and adhesion molecule 
activation and traditional risk factors, including smoking, hypertension and 
dyslipidaemia. 
The initial stage of atherosclerosis is persistent endothelial activation which results 
in endothelial dysfunction. LDL particles enter the intima from the vessel lumen and 
are modified and oxidized and then play an important role in inducing endothelial 
cell activation (15).  This dysfunction of the endothelial lining is characterized by an 
increased production of adhesion molecules, such as V-CAM and I-CAM and pro-
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inflammatory cytokines, such as MCP-1, interleukin-1 (IL1) and tumour necrosis 
factor-alpha (TNFα) and a reduction of nitric oxide levels (16).  
A number of cytokines, including IL-1 and TNFα, have a multitude of atherogenic 
effects (17). TNFα, a pro-inflammatory mediator, plays a critical role in driving the 
inflammation in RA and atherosclerosis. It triggers the upregulation of IL1, IL6, IL8, 
matrix metalloproteinases and prostaglandins (18).  
Inflammatory cytokines enhance the expression of cell surface molecules such as 
ICAM-1 and VCAM-1 on endothelial cells, smooth muscle cells, and macrophages. 
They are also involved in inducing cell proliferation and contributing to the 
production of reactive oxygen species. Other cytokines, such as interleukin-4 and 
interleukin-10, are antiatherogenic. Still others, such as interferon-gamma, have a 
variety of actions with both pro- and anti-atherogenic consequences.  
 
MCP-1 works by interacting with the CCR2 receptor on the surface of the 
monocytes. Within the intima, monocytes are then modified into macrophages. An 
important mediator of this process is macrophage colony-stimulating factor. The 
macrophages are capable of engulfing lipoproteins, in particular, oxidized LDL and 
then take on a foamy appearance (foam cells). Foam cells proliferate within the 
intima to form plaques. They produce a number of active substances, including 
metalloproteinases (MMPs), which can destroy the arterial extracellular matrix (19).  
T lymphocytes are another important cell in atheroma formation. Although they are 
much less abundant than macrophages in plaque, they actively participate in 
progression of the lesion. They appear to have a regulatory role over the plaque 
monocytes and macrophages. The Th1 cell subset of T lymphocytes are pro-
inflammatory, while Th2 cells tend to exert anti-inflammatory functions. (20).  
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After atheroma formation, inflammation is still further implicated in the 
atherosclerosis story. T lymphocytes, after migration into the intima, produce the 
pro-inflammatory CD40 cytokine, which in turn results in production of extracellular 
MMPs and the procoagulant tissue factor (TF). This tissue factor promotes a 
thrombogenic plaque (21). T lymphocytes also exert a negative effect on the 
collagen support system that keeps the fibrous cap of a plaque stable. Smooth muscle 
cell production of collagen is inhibited by interferon- γ produced by T lymphocytes 
within the plaque (22).  
 
A formed plaque is made up of a lipid core covered by a fibrous cap of extracellular 
matrix and smooth muscle cells. The base of the lesion contains lymphocytes and 
foam cells. A stable plaque typically contains a small lipid core and has a strong 
fibromuscular cap. A vulnerable or unstable plaque has a much larger lipid core, a 
larger quantity of active T cells and foam cells at the base, and a thin protective cap. 
The exact mechanism of plaque rupture is not known but MMPs, produced by 
macrophages may disrupt the thin cap of unstable plaques, leading to rupture. 
 
The traditional cardiovascular risk factors, including smoking, dyslipidaemia and 
diabetes play critical roles in the development of atherosclerosis.  
Smoking impacts on all stages of atherosclerosis, from the earliest stages of 
endothelial dysfunction, right through to acute clinical thrombotic events (23). It 
interferes with the body’s haemostatic processes by altering the function of 
endothelial cells (24). It has also been found to be associated with a number of 
inflammatory markers, including CRP, IL6 and TNF (25). 
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Abnormalities of lipid profiles play a critical role in atherosclerosis development and 
progression (26). Epidemiologic studies conducted in countries around the world 
have shown an increasing incidence of atherosclerosis when serum cholesterol 
concentrations were above 3.9 mmol/L (27, 28). Dyslipidaemia initially affects the 
endothelial cells, which upon activation express new adhesion molecules and 
chemotactic factors that provoke an inflammatory process (29).  
The pro-atherogenic lipid profile associated with diabetes is thought to be one of the 
main mechanisms by which diabetes increases cardiovascular risk. Diabetic patients 
have an increased production of VLDL in the liver and research has shown that this 
increased VLDL production is the main defect in atherogenic dyslipidaemia (30). 
The presence of type II diabetes mellitus is associated with acceleration of pre-
existing atherosclerosis to clinical cardiovascular events (31). 
 
 
Because of the seriousness of the acute manifestations of atherosclerosis, it is useful 
to detect it early in its course. The gold standard for imaging the coronary arteries is 
a coronary angiogram; however, there are a number of less invasive imaging 
techniques that are useful surrogates.  
 
Use of carotid ultrasound to measure intima-medial thickness (IMT) and the 
presence of plaque is a non-invasive method of assessing extra-coronary 
atherosclerosis. B-mode ultrasound is an easily assessable method of imaging the 
carotid arteries. A number of studies, including the Rotterdam study and the 
Cardiovascular Health Study have shown an association between carotid artery IMT 
and the risk of coronary heart disease events (32-34). 
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Measurement of carotid artery IMT and plaque appears to be a valuable screening 
tool; however, the above studies did not find evidence that treating patients based on 
IMT measurements would reduce their future risk of CVD events.  
 
Peripheral arterial disease can be detected by measuring the ankle brachial index. 
Ankle brachial index (ABI) is not only a marker of peripheral artery disease but also 
of generalized atherosclerosis. Reductions in ABI have been associated with the 
presence of cardiovascular risk factors and with higher rates of coronary and 
cerebrovascular disease (35, 36). In 2008, a meta-analysis performed by the Ankle 
Brachial Index Collaboration, reported that ABI provided independent risk 
information compared with the Framingham risk score (FRS) and also, an ABI < 0.9 
in combination with FRS, approximately doubled the risk of all cause and 
cardiovascular mortality and major coronary events across all Framingham risk 
groups (37). The advantage of ABI measurement is that it is easy to learn and can be 
performed in the doctor’s office, without having to refer to specialist centres, It is 
also a well-tolerated procedure and non- invasive. 
 
Endothelial dysfunction, one of the earliest steps in the development of 
atherosclerosis, is measured in research studies most commonly by non-invasive 
brachial artery ultrasound to assess flow-mediated dilatation (38). This procedure is 
much less invasive and better tolerated than the gold standard for diagnosis of 
endothelial dysfunction, intracoronary infusion of acetylcholine. It involves 
measurement of the change in diameter of a conduit artery after a period of induced 
ischaemia. It is primarily nitric oxide mediated and is reduced in people with CV risk 
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factors and atherosclerosis (39). It has been shown to correlate well with the 
endothelial vasodilator function of coronary vessls (40).  
 
Measuring markers of coagulation dysfunction can also provide useful information 
regarding cardiovascular risk. There is increasing evidence that markers of impaired 
fibrinolysis are associated with the development of coronary heart disease (41). 
Intravascular thrombosis is induced by the plasminogen activator / plasmin system. 
The most important inhibitor of this system is plasminogen activator inhibitor-1 
(PAI-1). PAI-1 has been shown to be associated with increased CVD risk in the 
general population (42). High circulating levels of PAI-1 have shown to significantly 
predict the onset of myocardial infarction (43) and  hypofibrinolysis due to high 
PAI-1 concentrations can be found in patients with high thrombotic risk, such as 
those with the metabolic syndrome and obesity (44). 
 
 
 
Heart Failure: 
 
Systolic heart failure has seen improvements in survival over recent years, however, 
heart failure overall is the only cardiac disorder that has not seen reductions in 
prevalence or significant improvements in survival over the last decade. It is the 
most common medical cause for hospitalization. Its prevalence increases with age 
and it affects about 8% of females and 10% of males over the age of 60 years (45). 
In 2008, there were more than 20,000 patients admitted with heart failure in Ireland, 
90% of which were emergency admissions (46). 
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Primary diastolic dysfunction is an important cause of heart failure, as it is often a 
silent alteration preceding systolic dysfunction. When diastolic dysfunction leads to 
symptoms of heart failure, it is known as heart failure with preserved ejection 
fraction (HF-PEF), previously known as diastolic heart failure. There is preservation 
of the ejection fraction in patients who have isolated diastolic heart failure. Diastolic 
heart failure accounts for up to 40 to 50% of all cases of heart failure. It is estimated 
that mortality rates for patients with diastolic heart failure are 4 times higher than 
those of the healthy general population (47). There are a number of clinical 
conditions which can result in primary diastolic heart failure. These include 
hypertension, obesity diabetes mellitus, coronary artery disease and restrictive and 
hypertrophic cardiomyopathies (48).  
 
Diastole refers to the phase of the cardiac cycle when the heart is relaxed. It is 
classically divided into 4 stages: isovolumetric relaxation, rapid filling, slow filling 
and atrial contraction(48). Diastolic function is basically a measure of left ventricular 
filling ability. In normal sinus rhythm, diastolic flow from the left atrium to the left 
ventricle across the mitral valve has 2 components:  the E wave, which represents 
early diastolic filling and the A wave, reflecting atrial contraction in late diastole. 
The E wave is influenced by the relative pressure gradient between the left atrium 
(LA) and left ventricle (LV) and the A wave is primarily influenced by LV 
compliance and LA contractility. Two other important components of diastolic flow 
are the isovolumetric relaxation time (IVRT) and the deceleration time (DT). The 
IVRT is the time interval from cessation of left ventricular outflow to the onset of 
mitral valve inflow. Deceleration time of the E velocity is the interval from peak E to 
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a point of intersection of the deceleration of flow with the baseline. It correlates with 
the time of pressure equalization between the LA and LV (49).  
   
Defects in distensibility, filling or relaxation of the left ventricle result in diastolic 
dysfunction (50). These defects lead to an increase in ventricular resistance as the 
ventricle loses its ability to accept an adequate blood volume. The LV becomes stiff 
and less compliant. The result is a rise in left ventricular diastolic pressure.  
 
 
The Mayo Clinic Echocardiography Laboratory uses a 4 stage grading system for 
diastolic dysfunction. Grade 1 is impaired myocardial relaxation. There is a 
prolongation of the isovolumetric relaxation time and the deceleration time. The 
mitral E velocity, which is a measure of the early transmitral gradient, is reduced and 
the A velocity or A wave, which represents atrial contraction, is increased. This 
results in an abnormal E/A ratio of less than one. During grade 2 of diastolic 
dysfunction, an increase in left atrial pressure combined with the abnormal 
myocardial relaxation of grade 1, gives rise to a pattern known as 
pseudonormalisation of mitral flow filling pattern. Here the deceleration time returns 
to normal and the E/A ratio is between 1 and 1.5. There are a number of techniques 
which can be utilised at the time of echocardiography to distinguish between a “true- 
normal” and “pseudo- normal” pattern, these include: positioning the patient in the 
upright-, sitting position, asking the patient to perform Valsalva manoeuvre or asking 
them to take sublingual nitroglycerin. These techniques decrease the pre-load and 
help to unmask any relaxation defect of the left ventricle.  In grade 3, the abnormal E 
/ A ratio reversal is associated with a restrictive pattern, whereby the E wave 
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deceleration time is reduced to less than 130 msec, but this normalises with the 
Valsalva manoeuvre. This is known a reversible restrictive diastolic dysfunction. 
Grade 4 occurs when this restrictive pattern is no longer reversible. 
 
The pulsed wave Doppler technique is used at the time of echocardiography, to 
detect diastolic dysfunction. In an apical 4-chamber view, a sample volume of 1 to 2 
mm is placed between the mitral leaflet tips during diastole to measure mitral 
velocities. A sample volume of 3-4 mm placed again between the tips of the mitral 
leaflets, measures the isovolumetric relaxation time.  Pulsed-wave Doppler has a 
drawback whereby it is affected by tachycardia, atrio-ventricular block and changes 
in pre- and after-load.  
Using tissue Doppler imaging (TDI) adds additional information regarding diastolic 
function. It involves recording an early diastolic mitral annulus velocity, e’. For this 
measurement the sample position must be at the mitral annulus and the velocity 
recorded at end-expiration. TDI allows measurement of velocities that represent 
longitudinal contraction (positive systolic wave, Sa) and relaxation (early negative 
diastolic wave, e’ and late negative diastolic wave, a’) (51). The e’ wave reflects the 
velocity of ventricular lengthening in early diastole.  
Tissue Doppler imaging appears to be independent of heart rate and pre-load which 
make it superior to traditional pulsed wave measurements. Using both the 
conventional pulsed wave velocity and TDI, the E/e’ ratio can be calculated and this 
is a validated reliable index for the estimation of pulmonary capillary wedge 
pressure. This non-invasive tool allows assessment of left ventricular pressures.  
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Cardiovascular Disease in RA: 
 
Similar to diabetic patients, people with RA have a 1.5 - 2.0-fold increased risk of 
developing coronary artery disease compared with the general population (52, 53). 
In a retrospective study of 603 RA patients, Maradit-Kremers et al found that RA 
patients has a significantly higher rate of myocardial infarction prior to the incidence 
of RA compared with non-RA controls . This CVD event risk was found to be 
independent of traditional cardiovascular risk factors. This suggests that the CVD 
risk associated with inflammatory arthritis precedes the diagnosis of RA. They also 
found that RA patients were less likely to receive coronary artery bypass grafting 
and had a higher rate of sudden death (54). Dhawan et al., reported that RA patients 
also have a two-fold increased risk of stroke compared with controls, and this risk 
rises to three-fold in those with the disease for a decade or more (55). Nicola et al 
reported that RA patients, in particular those who are rheumatoid factor positive, are 
twice as likely to develop heart failure as controls.  
 
 
Traditional and non-traditional risk factors for CVD in RA: 
 
As in the general population, the traditional cardiovascular risk factors such as male 
sex, age, diabetes, metabolic syndrome and dyslipidaemia are also implicated in 
CVD in RA patients (56). It is still unclear whether hypertension is more common in 
RA patients than the general population (57). However, it appears to be 
underdiagnosed and undertreated in RA (58). A number of factors associated with 
RA, such as inactive lifestyle, increased body fat composition relative to muscle 
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mass and medications, in particular, corticosteroids, are obvious potential causes of 
hypertension in RA. A direct link between inflammation and hypertension in RA has 
not been studied in detail, however; control of disease activity has been associated 
with improvements in blood pressure (59). 
 
An elevated BMI is considered a traditional cardiovascular risk factor. S. Gabriel and 
colleagues retrospectively studied 822 RA patients and 603 age and gender matched 
non-RA controls. They collected information on cardiovascular risks and outcomes 
(60). They found, as expected, that a low BMI in the non-RA cohort, was not 
associated with an increased risk of cardiovascular death. Conversely, they found a 
threefold increase risk of cardiovascular death associated with low BMI in the RA 
group. Even after correcting for traditional risk factors, including hypertension, 
smoking and diabetes mellitus, this association was still significant.  
Patients with RA have alterations in body composition, due to factors such as a 
sedentary lifestyle causing accumulation of fat and activation of the NF-κB pathway 
stimulating muscle breakdown. This can result in rheumatoid cachexia, which is 
characterised by low muscle mass and high fat mass (61). Perhaps this cachectic 
state, resulting in a low BMI, is in part due to chronic active inflammation, therefore 
suggesting that inflammation in RA may play a role in cardiovascular death.  
 
In the general population, elevations in total cholesterol and LDL cholesterol and 
decreased levels of HDL cholesterol are associated with cardiovascular events. This 
is not the typical lipid profile of a patient with active RA. Active RA is a catabolic 
state mediated by TNFα and other pro-inflammatory cytokines. These inflammatory 
mediators are associated with low total cholesterol and low HDL cholesterol.  
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The lipid pattern in RA is consistent with that seen in several other inflammatory 
conditions. Typically, RA patients have low total cholesterol, a low HDL and an 
elevated triglyceride level, resulting in an unfavourable ratio of total cholesterol to 
HDL (62). Markers of inflammation such as ESR and CRP have been shown to have 
an inverse association with HDL cholesterol, in RA patients (63). Lower total and 
LDL cholesterol levels have been shown to be associated with higher CV risk (64). 
. 
 
Smoking is the strongest known environmental risk factor for RA (65). The 
prevalence of cigarette smoking appears to be higher in RA patients as reported in a 
recent meta-analysis (OR 1.56, 95% CI 1.34, 1.80) (66). RA patients who smoke are 
more likely to be sero-positive for rheumatoid factor and it is these RF positive RA 
patients who tend to do worse from a cardiovascular point of view. They also have 
more severe joint disease and have an increased DMARD requirement (67).  
 
Current smoking status was found to contribute to CV risk in RA patients in a study 
by Gonzalez et al. However, its contribution to overall CV risk was less in RA 
patients than controls (68). Similar to low BMI and low total cholesterol being 
associated with increased CV risk in RA, this finding demonstrates that traditional 
CV risk factors appear to have a weaker association with CV events in RA patients 
compared to controls. 
 
A study in 2006 looked at Framingham risk score and coronary calcium scores in 
RA patients and controls. It found that patients with longstanding RA had a greater 
probability of having higher coronary calcium scores than controls with any level of 
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Framingham risk. It was concluded from the study that factors other than those in the 
Framingham risk score, contribute to the accelerated atherosclerosis of RA patients 
(69). Chung’s group have also found an association between the metabolic syndrome 
and RA. This association was found to be independent of body mass index, which 
suggests an inflammatory driving force for the development of metabolic syndrome 
(70).  
 
A number of disease markers for RA, including elevated ESR, CRP, anti-CCP-
antibodies, joint swelling and destructive changes in joint radiographs, have been 
shown to be significantly associated with increased risk of CV disease and death (71-
73). Subjects who have tested positive for rheumatoid factor have a significantly 
increased risk of MI and heart failure (74).  
Medications used for the treatment of RA can also affect CV risk. Glucocorticoid use 
dampens inflammation and helps mobility however; their use is associated with an 
increased risk of a number of CV risk factors, such as altered body fat composition, 
insulin resistance and dyslipidaemia. Presence of carotid plaque has also been 
reported to be associated with steroid use (75, 76).  
Goodson et al reported that NSAID use was not associated with increased CV death 
in patients with inflammatory arthritis (77). Disease control with both synthetic and 
biologic DMARDS appears to reduce CV risk. Methotrexate, the most commonly 
prescribed synthetic DMARD for the treatment of RA, was found to be associated 
with 21% fewer CV events, according to a recent meta-analysis (78).  
Barnabe et al found that anti-TNF therapy appears to be associated with reduced risk 
of CV events (79). Factors that promote atherosclerotic complications such as 
elevated platelet levels, circulating cytokine levels and leucocyte trafficking are all 
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reduced by blockade of TNF-α (80). TNF inhibitors also seem to have beneficial 
effect on insulin resistance (81), lipid profile and carotid atherosclerosis (82, 83).  
Studies so far on the effect of TNF blockade on endothelial function in RA show 
short-term benefits only and more long-term follow-up studies are required to assess 
this further (84, 85).   
 
 
Another theory that may explain the increased prevalence of CVD in RA is that both 
diseases may share common genetic risk factors. The main susceptibility gene for 
RA development in northern European populations is HLA-DRB1 (86). This gene 
has been shown to be associated with disease severity. Specific HLA-DRB1 
genotypes, including HLA-DRB1*0404 and HLA-DRB1*0401 are associated with 
severe disease and extra-articular manifestations (87). In 2008, Farragher et al 
reported that the HLA-DRB1 genotype predicted all-cause and CVD mortality in RA 
patients. In particular, the HLD-DRB1*0404 and *0401 alleles were associated with 
a high hazard ratio for CVD mortality (88). The fact that these alleles are associated 
with more severe RA, suggest that the link reported above with CVD mortality could 
be due to a high inflammatory burden driving both diseases.  
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Carotid IMT in RA: 
 
A number of studies have found that cIMT, a marker of subclinical atherosclerosis, 
is increased in RA patients compared with healthy controls due to the inflammatory 
burden of the disease (89-92). One study also reported that the annual rate of 
progression on cIMT was higher in RA than non-RA patients and correlated with 
markers of RA disease activity (93).  
Carotid IMT is associated with longstanding disease (94) but there is also evidence 
that it is abnormal within 1 year of RA symptom onset (95). Gonzalez-Gay et al 
followed up RA patients without clinical evidence of CVD and found that cIMT had 
a high predictive power for development of CV events over a 5 year period (96). 
 Plaque, as well as IMT, is also more common in RA patients than controls (91).  
 
 
PVD in RA: 
 
Studies examining the relationship between RA and peripheral vascular disease have 
been very limited. Perhaps this is because researchers have tended to concentrate on 
coronary artery disease instead, due to the increased mortality associated with it. 
Also, clinicians may erroneously attribute symptoms of peripheral vascular disease 
to the arthritis itself. 
The prevalence of PVD in RA has been reported as 10% (97). Similar to the general 
population, this rate increases with age and in the presence of coronary artery 
disease. Del Rincon et al did report a higher rate of arterial obstruction in RA 
patients compared with controls, independent of traditional CV risks  (98). Contrary 
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to this study, a 10 year follow-up study of over 800 RA patients did not find a 
difference in the incidence of PVD compared with that in non-RA controls (99). 
 
 
Endothelial dysfunction in RA: 
 
Patients with RA have been shown to have evidence of abnormal flow mediated 
dilatation, a measure of endothelial dysfunction, early in the course of their disease 
and this is present prior to any cardiovascular symptoms (100).  Markers of disease 
activity and cardiovascular risk are associated with abnormal brachial artery flow 
mediated dilatation in RA (101, 102).  There is also evidence that treatment of 
inflammation in RA patients is associated with improvements in brachial artery flow, 
however it is not yet proven whether these effects are long-lasting (103).  
 
Microalbuminuria, another marker of endothelial dysfunction, is a more frequent 
finding in RA patients than in non-RA controls (104). However, whether it is 
associated with other markers of CV disease in RA patients, has not being 
investigated extensively. 
 
 
Haemostasis in RA: 
 
Studies in the general population have found the process of atherosclerosis is 
associated with alterations of biomarkers of haemostasis. Patients with acute MI and 
unstable angina have elevated levels of markers of thrombosis (105). In an earlier 
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study, Johansson et al found that the tPA/PAI-1 complex was independently 
associated with the development of a first-ever stroke, supporting the hypothesis that 
disturbances in fibrinolysis precede cerebrovascular events (106).  
In RA populations, there is evidence that CVD risk correlates with abnormalities of 
the coagulation system. Having a diagnosis of RA has been found to predict 
increased levels of PAI-1 and fibrinogen, and inhibitors of the fibrinolytic system are 
elevated in RA patients (107).  Some earlier studies of coagulation in RA found 
similar results (108, 109). Sodergren et al reported that carotid intima-media 
thickness and endothelial dysfunction in RA patients were associated with markers 
of haemostasis (110). An increase in biomarkers of haemostasis leads to a pro-
thrombotic state and these alterations may be one of the mechanisms by which RA 
patients are at an increased risk of CV events. 
 
 
Diastolic dysfunction in RA: 
 
Disease duration and the age of onset of rheumatoid arthritis have been shown to 
correlate with the presence of diastolic dysfunction on echocardiography (111, 112).  
Rexhepaj et al found a higher prevalence of LV diastolic dysfunction in RA patients 
without visible evidence of CV disease, compared to controls. They looked at LV 
diastolic function in 80 RA patients and found a significantly lower early diastolic 
flow velocity and E/A ratio in the RA group (113).  
Heart failure in RA is more likely to be associated with a preserved ejection fraction 
and less likely to display the typical symptoms and signs of heart failure, compared 
to hear failure in non-RA patients. One suggested reason for this is that diastolic 
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function in RA patients may be inherently different from that in non-RA groups 
(114).  
 
A limited number of studies have assessed the incidence and prevalence rates for 
congestive heart failure (CHF) in rheumatoid arthritis. In a population-based study 
by Gabriel et al, medical records of 450 RA patients were compared to those of 450 
age and sex matched non-RA controls. Over a thirty-year period they found 78 cases 
of incident CHF in the RA group, compared with 54 cases in the non-RA group, 
relative risk 1.6 (95% CI 1.12-2.27). This risk of incident CHF did not hold through 
for osteoarthritis (OA) patients compared to non- OA controls (115). In a follow-on 
study of the same cohort of patients, Nicola et al found an increased risk of incident 
CHF in rheumatoid factor positive and negative patients compared to non-RA 
controls (hazard ratio 2.29 and 1.34) (116).  
In 2003, Wolfe et al published data on the lifetime prevalence of CHF in RA 
patients. Using a combined cohort of RA patients from more than 700 community-
based rheumatology practices, they found an adjusted lifetime relative risk of CHF 
of 1.43 (95% CI 1.24-1.33) in the RA group compared to OA patients and an 
adjusted lifetime prevalence of CHF of 2.34% in the RA group compared to 1.64% 
in the OA group (117).  
There is an excess of CHF related mortality in RA patients that was first described 
by Mutru et al in 1989. They found that RA patients who were age- and gender- 
matched to controls, had a higher CHF- attributed mortality in both males and 
females ( p = 0.004, p = 0.042, respectively) (118).  
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Risk assessment in RA: 
 
 
In 2009, the CARRE investigation, a cross-sectional study looking at CVD 
prevalence in RA and diabetic patients found that cardiovascular affection in RA was 
much higher than in controls and similar to that of diabetic patients (119). Van Halm 
et al reported a CVD prevalence of 5% in the control group, 12.4% in the diabetic 
group and 12.9% in the RA group. Compared to the non-diabetic controls, the 
relative risk of CVD was 2.3 in diabetic patients and 3.1 in RA patients. After 
adjustment for traditional CV risks, the relative frisk of CVD was still high, 2.0 in 
diabetic patients and 2.7 in RA patients. The authors concluded that CV risk factors 
only partially explained the increased risk in the RA group and that RA itself, like 
diabetes, should be considered a separate risk factor. This highlights that CV 
screening and treatment in RA patients needs to be a priority for clinicians. 
 
Because of findings from the CARRE study and others mentioned above, the 
European League Against Rheumatism, in 2010, developed a set of evidenced-based 
recommendations for CV risk management in RA patients (120). These 
recommendations include that RA should be regarded as a condition associated with 
a higher CVD risk, due to increased prevalence of traditional risk factors and the 
inflammatory burden. They advise that adequate control of disease activity is 
necessary to lower CV risk. If there are no national guidelines for CV risk 
assessment, the Systematic Coronary Risk Evaluation 
(SCORE) model or the Framingham risk score should be used to assess risk. Peters 
et al advised that score models should be adapted for RA patients by introducing a 
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1.5 multiplication factor when the RA patient fits 2 of the following criteria: disease 
duration of greater than 10 years, anti-CCP antibody or rheumatoid factor positive 
and presence of certain extra-articular manifestations (vasculitis, pericarditis and 
pleuritis).  
Because of the potential anti-inflammatory role of statins, ACE-inhibitors and 
angiotensin blockers, these medications should be used when treatment for 
dyslipidaemia and /or hypertension is required. Caution is also advised by the expert 
group with respect to use of NSAIDs, particularly in those RA patients with 
documented CV risk. They advise using the lowest possible corticosteroid dose.  
 
The EULAR expert committee reiterated that although rheumatologists are now 
starting to acknowledge the increased CV risk in RA, attention needs to be given to 
detecting and managing these risks. 
  
 
Osteoarthritis: 
 
Osteoarthritis (OA) is a common and disabling degenerative joint disease with 
increasing prevalence and socioeconomic impact. It is the most common chronic 
joint disorder, resulting in pain, deformity and eventually, disability. The American 
College of Rheumatology defined OA as “ a heterogeneous group of conditions that 
lead to joint symptoms and signs, which are associated with defective integrity of 
articular cartilage, in addition to related changes in the underlying bone at the joint 
margins” (121).  
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The age-standardized and sex-standardized incidence of hand, hip and knee OA is 
100/100,000 person-years, 88/100,000 person-years and 240/100,000 person-years, 
respectively (122).   
The incidence of OA in Ireland is increasing. There are 2 main reasons for this, one 
is the aging population, who have an increased prevalence of OA and the other is the 
obesity epidemic, which is a major risk factor for development of OA. 
 
 
 Reasons for undertaking this research: 
 
We undertook this study to investigate the degree of sub-clinical atherosclerosis in 
our RA patients. Cardiovascular disease is common but is under-diagnosed and 
under-investigated in RA patients. Given the extent of the excess cardiovascular 
morbidity and mortality associated with RA we felt it was important to characterise 
the degree of this serious extra-articular manifestation in our RA cohort. The 
magnitude of pre-clinical atherosclerosis in RA has not been studied extensively in 
an Irish population to date and we fell that this area should be high priority for 
rheumatologists.  
Heart disease and other chronic diseases have been described by Ban Ki Moon as a 
“public health emergency in slow motion” (123).  
 
 
 
 
 
 39 
 
Hypothesis: 
 
Our hypothesis was that patients with rheumatoid arthritis are more likely to display 
evidence of pre-clinical atherosclerosis compared to patients with osteoarthritis, due 
to the inflammatory effects of their disease on vascular function. 
 
 
 
Our aims were as follows: 
 
To conduct a cross-sectional comparison of patients with rheumatoid arthritis and 
patients with a non-inflammatory arthritis, namely osteoarthritis, attending a hospital 
based rheumatology clinic in order to:  
A) Quantify the difference in prevalence between the 2 groups regarding: 
A1) Presence of subclinical atherosclerosis using 1) ultrasound measured carotid 
intima- media wall thickness and presence of carotid plaque and 2) measurement of 
ankle-brachial index as a marker of peripheral vascular disease 
A2) Presence of functional impairment of the vasculature by assessment of 
endothelial dysfunction as measured by 1) brachial artery ultrasound to measure 
forearm flow mediated dilatation 2) a panel of vascular active factors, including 
plasminogen activator inhibitor type 1, E-selectin, P-selectin and intracellular 
adhesion molecules and 3) spot urine albumin creatinine ratio  
A3) Presence of established end organ damage by assessment of left ventricular 
systolic and diastolic dysfunction using transthoracic echocardiography and 
measurement of  brain natrurietic peptide (BNP). 
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B) Determine the Presence, Strength, Significance and Independence of the 
association of RA with above outcomes using binary logistic regression and 
adjusting for established and novel cardiovascular risk factors,. 
 
C) Quantify the agreement and explore the Potential Cost Effectiveness of  
(i) BNP as a measure of left ventricular dysfunction  
(ii) Spot urine albumin creatinine ratio as a measure of endothelial dysfunction. 
 
These investigations conducted by a collaboration of highly experienced 
cardiologists, rheumatologists and radiologists will provide important mechanistic 
insights into occurrence and potential determinants of cardiovascular disease and 
facilitate the training of the applicant in rigorous, high quality patient centered 
clinical research.  
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Chapter 2 
 
Materials and Methods 
 
 
 
 
Patient Recruitment: 
 
Ethical approval for this study was granted by the Ethics Department for Teaching 
Hospitals on Cork, Ireland. The study commenced in July 2007. Study patients were 
recruited consecutively from the rheumatology and orthopaedic outpatient 
departments, of a tertiary referral centre, Cork University Hospital. Patients with a 
diagnosis of rheumatoid arthritis, as defined by the ACR criteria (1) for 3 years or 
more were eligible for study inclusion. Osteoarthritis patients were recruited as the 
control population. Exclusion criteria for both groups were age less than 18 years 
and greater than 65 years, a previous diagnosis of coronary artery disease, 
cerebrovascular disease, peripheral vascular disease, carotid artery disease, previous 
cardiac bypass surgery or coronary artery stenting, current pregnancy or pregnancy 
in the previous 3 months, current or previous diagnosis of malignancy.  
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Baseline Demographic Data: 
 
After written informed consent was given, each recruit was assigned an individual 
study number and identity was known only to the primary physician. The patients 
completed an in-depth questionnaire (appendix A), with assistance from a physician. 
Details of background medical history, current and previous treatments, family and 
social history, and traditional cardiovascular risks were recorded. Disease activity 
and impact on quality of life were assessed using validated measures. These included 
a Health Assessment Questionnaire (HAQ), short form-36, physician and patient 
visual analogue scales and a disease activity score (DAS-28), which is a calculation 
involving tender and swollen joint count, general health status and ESR.  
A systematic chart review was also carried out to quantify duration and mean doses 
of each anti- rheumatic treatment used and to look for documented evidence of extra- 
articular manifestations of RA and complications. A physical examination was 
carried out by the physician. An electrocardiogram was performed on all participants 
and an early morning urine specimen was collected for calculation of 
microalbumin:creatinine ratio.  A database was established for storage of and access 
to information collected from the questionnaires and chart review. 
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Phlebotomy: 
 
 
Each study participant donated a morning sample of 30mls of blood, after a 10 hour 
fast. Venous blood was drawn for: 
a) Traditional risk factors and baseline bloods: 
1. Fasting cholesterol – HDL, LDL, Triglycerides 
2. Fasting Glucose, HBA1c 
3. Urea, Creatinine and electrolytes, calculation of estimated GFR by MDRD 
4. Thyroid function tests 
5. Full Blood Count 
b) Rheumatoid specific factors 
       1.    IgM rheumatoid factor 
2.  Anti- CCP antibody  
3.  ESR, high sensitivity CRP 
4. ANA, ENA 
c) Vascular specific factors and markers of clotting 
1. N-terminal pro-Brain Naturietic peptide 
2. Plasminogen activator inhibitor type 1 
3. Adhesion molecules: Intracellular adhesion molecule (ICAM), vascular cell 
adhesion molecule (VCAM), E- selectin, P- selectin, L- selectin 
4. Cytokines: Il-1α, Il-1β, Il-2, Il-4, Il-6, Il-8, Il-10, TNFα, INFγ, VEGF, EGF, 
MCP-1 
5. D-dimers, fibrinogen 
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Brain Naturietic Peptide: 
 
Blood was collected at the time of transthoracic echocardiography for measurement 
of serum NT-pro BNP. Samples were collected in a clotted bottle and centrifuged at 
5000 rpm for 20 minutes at 4 degrees Celsius. The serum was pipetted into aliquots 
and stored at minus 80 degrees and samples were analysed in batches. The Roche 
cobas proBNP II kit was used on an Elecsys 1010 analyzer in the department of 
biochemistry, in Cork University Hospital, to analyse all serum samples. Samples 
were analysed according to the manufacturers’ standard operating procedures.  
 
 
 
Plasminogen Activator Inhibitor-1: 
 
 
A blood sample was taken at the time of echocardiography and collected in a plastic 
tube containing sodium citrate to measure PAI-1 activity and PAI-1 antigen levels. 
Blood samples were centrifuged at 5000 rpm for 20 minutes at 4 degrees Celsius. 
The upper 2/3 of plasma was extracted from the sample and this was re-centrifuged 
for a further 20 minutes to remove any platelets. Again the upper 2/3 was removed 
and divided into aliquots. Three 500ul aliquots were collected for each patient. 
Aliquots were transferred on ice for storage in a minus 80 degree Celsius freezer and 
stored for analysis at a later stage.  
When samples were collected for all the study recruits, the aliquots of frozen plasma 
were transported on dry ice to Professor Nuala Booth, Department of Molecular and 
Cell Biology, University of Aberdeen, Institute of Medical Sciences. PAI-1 antigen 
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level was measured by quantitative ELISA and a specific activity assay was utilized 
to measure PAI-1 activity levels according to the manufacturer’s instructions. 
 
 
 
Cytokine and Adhesion Molecule Analysis: 
 
The cytokine profile of each serum sample was analysed quantitatively using a 
multiplex chemi-luminescent array (Randox), a high fidelity system capable of 
determining the concentration of IL-1α, -1β, -2, -4, -6, -8, -10, TNFα, IFNγ, VEGF, 
EGF and MCP-1. The protocol followed the manufacturer’s instructions and entailed 
the incubation of 100 µl of un-diluted sample, calibrator or control on a biochip pre-
coated with immobilized capture antibody, to which 200 µl of assay diluents had 
been added. Following a 1 hour incubation at 37°C on a thermoshaker (370rpm) 
each well was washed twice with wash buffer (Tris buffered saline) and 300µl of 
conjugate (HRP-labelled detection antibodies) was added. This was incubated for a 
further hour at 37 °C on the thermoshaker (370 rpm) prior to 2 further washes. At 
this time 250 µl of a 1:1 combination of luminal and peroxide was added and 
incubated in the dark for 2 minutes. Samples were then analysed using the 
EVIDENCE Investigator platform. EVIDENCE software was then used to determine 
the intercalated x-values from the resultant standard curve, the results expressed as 
pg/ml. 
The same multiplex chemi-luminescent immunoassay (Randox) was used to analyse 
the adhesion molecule profile. The Randox adhesion molecule biochip array 
simultaneously and quantitatively measured E-selectin, L-selectin, P-selectin, 
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intracellular adhesion molecue-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1). 
 
 
Ankle Brachial Index: 
 
Ankle brachial index was performed in the usual manner. Blood pressure was 
recorded in both arms after a period of at least 15 minutes rest. The highest systolic 
reading of the 2 was used in the index calculation. For ankle pressure measurement, 
the cuff was placed around the calf and it was then inflated 20mmHg above the 
upper limb systolic pressure. Using a handheld Doppler ultrasound probe over the 
dorsalis pedis, the pressure at which arterial pulsation was first heard, was recorded 
and used in the calculation. ABI for each leg was calculated as a ratio of ankle 
pressure to upper limb systolic pressure. A mean of both lower limb ABIs was then 
calculated. A reading of 0.96 or higher was taken as normal. 
 
                        
                           Ankle Pressure (mmHg) 
                        ______________________ 
 
                        Highest Arm Pressure (mmHg) 
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Transthoracic Echocardiography: 
 
Prior to commencement of patient recruitment, the technique of transthoracic 
echocardiography was learned. Transthoracic echocardiography and tissue Doppler 
imaging were studied over a 12-month period. Seven hundred and eighty 
echocardiograms were performed under supervision of the chief cardiac physiologist. 
Two courses in echocardiography were completed as part of pre-study training: 
Philips Echocardiography Course (2006) and Echocardiography in Practice, 
Waterford Regional Hospital (2006). The Echo Manual by Jae K. Oh was used as 
educational tool and reference point (2).  Transthoracic echocardiography was 
performed on all patients by the PhD student.  Intra- and interobserver variability 
was accounted for by co- imaging at the time of echocardiography, by a blinded 
echocardiographic physiologist and reporting was conducted by a cardiologist 
unaware of patients’ diagnoses. Recommendations from the Guidelines and 
Standards Committee of the American Society of Echocardiography in collaboration 
with the European Association of Echocardiography, for the use of 
echocardiography in clinical trials (3) and for the evaluation of left ventricular 
diastolic function by echocardiography (4) were followed. 
A Vivid–I GE-Medical portable echocardiography machine was used with a 2.5Hz 
probe.  The patients were positioned in left lateral decubitus position to obtain 
parasternal and apical views. A customized echocardiography bed was used. The 
patient’s identification details were entered prior to commencing the ultrasound and 
a sharp electrocardiographic tracing with clear R and P waves was available on 
screen prior to scanning. All images were acquired at end-expiration. Depth, size and 
gain settings were adjusted during each study as required.  
 66 
 
The examination began by placing the transducer in the left parasternal region, at the 
level of the 3
rd
 or 4
th
 intercostal space. A long-axis view image of the left ventricle 
was recorded. The aortic root, aortic valve leaflets, left atrium and mitral valve 
leaflets were also visualised in this view. Colour flow imaging in this plane was used 
to assess mitral and aortic valve competency. M-mode echocardiography was 
performed in this parasternal long axis view. An M-mode cursor was placed across 
the mid-ventricular line, at a level just below the free edge of the anterior mitral 
leaflet, to calculate left ventricular diameter in systole, LVDS (mm), left ventricular 
diameter in diastole, LVDD (mm), inter-ventricular septal wall thickness in diastole, 
IVSTD (mm) and left posterior wall diameter in diastole, LPWDD (mm), (figure 
2.1). Ejection fraction and fractional shortening were calculated based on the above 
measurements.   
A second M-mode cursor was placed across the aortic valve level of the long-axis 
parasternal view. This was used to measure the dimension of the left atrium, LA 
(cm) at end-systole. LA dimension was taken as the largest distance between the 
leading edges of the posterior aortic wall and the posterior LA wall.  Peak early (E) 
and late (A) opening of the mitral valve were recorded by passing an M-mode cursor 
across the anterior mitral leaflet, using the long-axis parasternal view again.  
The transducer was then rotated 90 degrees clockwise into a parasternal short axis 
(PSAX) view, so the plane of the ultrasound beam was perpendicular to the plane of 
the long axis of the LV. The LV was assessed in a cross-sectional plane at the level 
of the mitral leaflets. By tilting the transducer inferiorly, the anterolateral and 
posteromedial papillary muscles were visualised. Left ventricular wall motion was 
assessed in this plane. Tilting further inferiorly, the LV apical wall motion was 
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assessed in a transverse plane. Changing to a superior tilt on the transducer, the 
trileaflet aortic valve and right ventricular outflow tract were visualised.  
 
 
Figure 2.1 M-mode echocardiogram across the left mid-ventricle, with parasternal long-axis 2D 
echocardiographic guidance. RV, right ventricle; IVS, interventricular septum; LV, left ventricle; 
LVPW, left ventricular posterior wall. (5)  
 
 
Apical images were also recorded with the patient in the left lateral decubitus 
position. The transducer was placed over the point of maximal apical impulse. An 
apical 4 chamber view was found and the image orientated so that the apex was 
visualised at the top of the image. The notch on the transducer was pointing 
superiorly so that the left ventricle was displayed on the right side of the image. All 4 
chambers were assessed in this plane, the atrial septum was visualised in its entirety 
and the inferior pulmonary views were seen emptying into the left atrium. All LV 
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segments were reassessed in this view, particularly the apex, which was often seen 
more clearly here than in the previous parasternal views (figure 2.2). 
Tilting the transducer slightly superior and a small clockwise rotation at the same 
time, revealed the apical 5-chamber, long axis view. This allowed assessment of the 
left ventricular outflow tract and the aortic valve. Colour flow was used to assess the 
mitral, tricuspid and aortic valve competencies in the apical images. A further 
clockwise rotation of the transducer displayed an apical 2-chamber view of the left 
side if the heart. In particular, it was useful for visualising the inferior LV wall. 
 
 
 
Figure 2.2   2D echocardiographic image of an apical 4-chamber view. LV, 
left ventricle; LA, left atrium; RV, right ventricle; RA, right ventricle; MV, 
mitral valve; TV, tricuspid valve; IVS, interventricular septum; IAS, 
interatrial septum. 
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Returning to the apical 4-chamber view to assess diastolic function, both Pulsed-
wave Doppler (PWD) and Tissue Doppler Imaging (TDI) were utilised. Mitral 
inflow was measured with PWD to assess LV filling. A 1 to 2 mm sample volume 
was placed at the mitral leaflet tips during diastole to measure the inflow velocity 
pattern. Spectral gain and wall filter settings were optimized to display a crisp 
waveform. Sweep speed was set at 100mm/s, at end-expiration. Measurements 
recorded were early diastolic velocity (E wave) m/s, late diastolic filling velocity (A 
wave) m/s, the E/A ratio and deceleration time in milliseconds (DT). Valsalva 
maneuver was performed by each subject, in the sitting position, to unmask any 
pseudonormal pattern of filling. A standard grading system for diastolic dysfunction 
was used for grouping subjects’ results: grade 1 is impaired relaxation with normal 
filling pressure; grade 2 is a pseudonormalized pattern; grade 3 represents restrictive 
filling (figure 2.3). 
Tissue Doppler imaging is the method of choice for recording longitudinal velocities 
of the mitral annulus (6). 
 In the apical 4-chamber view, the ultrasound beam was positioned perpendicular to 
the lateral annulus and a 5 mm sample volume was placed over the lateral portion of 
the mitral annulus. Doppler gain was reduced to minimise background noise and 
obtain a clear signal. Spectral recondings were again taken at end-expiration, at a 
sweep speed of 50-100mm/s and measurements reflected an average over 3 
consecutive cardiac cycles. The waveform generated 3 distinct velocities: systolic 
(S'), early diastolic (E') and late diastolic (A') velocities. A smaller sample volume of 
2mm was then positioned over the septal (medial) portion of the mitral annulus and 3 
medial anular velocities generated.  
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Figure 2.3 Schematic representation of normal and abnormal mitral 
inflow and mitral annulus velocities. E, E wave, peak early diastolic 
velocity; A, A wave, late diastloic filling velocity; E', E prime, early 
diastolic annular velocity; A', A prime, late diastolic annular velocity. 
 
 
 
Limitations of transthoracic echocardiography in assessment of diastolic function:  
 
Doppler echocardiographic measurements of diastolic function may vary from day to 
day in the same patient, depending on preload and afterload. Assessing LV filling 
with PW doppler of  mitral inflow can give rise to a difficulty in recognising 
pseudonormalization and diastolic heart failure in patients with a normal ejection 
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fraction, because similar values for LV filling patterns can be seen in healthy normal 
subjects and patients with cardiac disease (4).  
For this reason, the American Society of Echocardiography recommend using 
multiple measures to assess diastolic function . Sinus tachycardia and first-degree 
AV block can result in fusion of the early (E) and late (A) atrial velocities, this may 
result in a reduction in E/A ratio and deceleration time. Use of the Valsalva 
maneuver to identify a pseudonormal mitral inflow pattern can be difficult for 
patients to perform and it is not standardized. It is another reason to combine Tissue 
Doppler Imaging with mitral inflow velocities in the overall assessment of diastolic 
function. With regard to TDI, there are potential technical limitations, if proper 
attention to  sample size, sample location, gain and filter is not ensured.  
 
 
Limitations to echocardiographic measurements in this study: 
 
Pulmonary venous flow was not assessed as part of the workup for diastolic function 
in this study. High quality images of the pulmonary vein are difficult to obtain and 
measurements derived from pulmonary venous flow are no longer felt to add 
significant information to assessment of diastolic function, when parameters such as 
mitral inflow velocity and tissue doppler imaging are available (3). 
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Carotid Artery Ultrasound: 
 
Patients attended the radiology department for carotid ultrasound examination. B 
mode ultrasound using a Toshiba Xario system and linear array 7mHz probe was 
used and scans were performed by a trained radiographer.   
IMT (intima-media thickness) values were obtained at specific points for the right 
and left common carotid artery and for both the right and left internal carotid artery 
(RCCA, RICA, LCCA, LICA), (figure 2.4).  An average of three readings was taken 
for each variable and a composite value, expressed in mm was recorded.  Each of the 
4 vessels was assessed for presence of plaque. Plaque was defined as a distinct 
protrusion > 1.5mm into the vessel lumen. This was recorded as either present or 
absent. If present, plaque size was recorded and expressed in mm. Both the 
radiographer performing the examination and the radiologist reading and interpreting 
the scans, were blinded to the identity of the study subjects and are unaware of 
whether they formed part of RA or OA group.  
Based on recommendations from the American Society of Echocardiography (7, 8), 
carotid intimal medial thickness (cIMT) values were reported as a mean of the cIMT 
from the left and right common carotid arteries. A mean cIMT of greater than 0.9mm 
was considered abnormal (9). 
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Figure 2.4 IMT of Common Carotid Artery 
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Flow Mediated Dilatation of Brachial Artery: 
 
Prior to commencement of patient recruitment, the technique of flow-mediated 
dilatation (FMD) of the brachial artery was learned. Thirty brachial artery 
ultrasounds for flow mediated dilatation were observed and ninety practice scans 
were then performed under supervision by a trained technician in the field, prior to 
scanning study patients. 
 
Subjects presenting for baseline measurement of FMD fasted for at least 8 hours 
prior to the study and were studied in a quiet temperature controlled room (22°C). 
Advice was given to withhold all vasoactive medications for at least 4 half lives. 
Subjects were also advised to avoid exercise and foods which have clear-cut FMD 
effects such as caffeine, high fat foods and Vitamin C, and (where relevant) to desist 
from smoking for at least 6 hours prior to the study. 
 
A Philips HDI 3000 Ultrasound machine was used for all studies (Philips Healthcare, 
Netherlands). A linear array transducer with a broadband multiple frequency of 7-12 
MHz, attached to a high-quality mainframe ultrasound system, was used to acquire 
images with sufficient resolution for real time analysis by the image acquisition 
software. Timing of the cardiac cycle was carried out by the image acquisition 
software analysis of continuous real-time digital ECG input; this will be described 
later. 
Each subject was positioned supine with the dominant arm in a formed foam mould 
to allow the subject to rest comfortably for the duration of the study. A standard 
automated blood pressure cuff (Omron
TM 
705 IT, Omron Healthcare Europe B.V.) 
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was attached to the non-dominant (non-study) arm and blood pressure and heart rate 
were measured on a regular basis throughout the study. The brachial artery was 
imaged above the antecubital fossa in the longitudinal plane – See Figure 2.5. 
A segment with clear anterior and posterior intima lumen interfaces was selected for 
continuous 2D grey-scale imaging. A stereotactic probe-holding device was custom-
developed and used for all of the FMD studies. During image acquisition, anatomical 
landmarks such as veins and fascial planes were used to help maintain the same 
image of the brachial artery throughout the study.  
 
 
 
 
 Endothelium-Dependant Dilatation 
 
To create a flow stimulus in the brachial artery, a blood pressure cuff is placed below 
the antecubital fossa on the mid-forearm. A baseline, resting 2D ultrasound image is 
then acquired for 2-5 minutes. Following this, the blood pressure cuff is inflated to 
50mm Hg above the recorded stable systolic blood pressure for complete occlusion 
of arterial forearm inflow for 5 minutes. This forearm ischaemia produces dilation of 
downstream resistance vessels via auto-regulatory mechanisms. On release of the 
cuff, a brief hyper-perfusion state through the brachial artery is induced to 
accommodate the dilated resistance vessels. The resulting increase in shear stress in 
the brachial artery causes the brachial artery to dilate and the longitudinal image of 
the artery is recorded continuously for the next 2 minutes. The FMD, defined as the 
percentage increase in mean diameter over a 10 second interval, 55 seconds after 
 76 
 
tourniquet deflation, is automatically averaged and calculated by the software from 
diastolic vessel diameters, using the following formula: 
 
                              Maximum diameter – baseline diameter 
                                   baseline diameter X 100%  
 
The accepted normal FMD routinely reported in the scientific literature is 4% change 
or more from baseline for the brachial artery. One not infrequently reported 
measurement is absolute change of brachial artery diameter (in mm). However, the 
most widely cited FMD measurement in the literature is percentage change of FMD 
from baseline. 
 
 
 Endothelium-Independent Vasodilatation with Nitroglycerin 
Following a rest period of 10 minutes to allow a return of brachial artery diameter to 
resting, steady state perfusion, a further baseline scan is obtained. An exogenous NO 
donor is then administered in the form of a single dose of sublingual nitroglycerin 
spray (0.4 mg). This is given to determine the maximum obtainable vasodilator 
response, and to serve as a measure of endothelium-independent vasodilation which 
indicates vascular smooth muscle function. Peak vasodilation occurs 3-4 minutes 
after nitroglycerin administration and the brachial artery image is continuously 
captured during this time period. 
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Limitations of FMD technique 
 
High resolution ultrasound assessment of brachial artery reactivity is technically 
challenging. To ensure satisfactory application of the FMD technique, the author was 
initially trained in principles and technical aspects of 2D and Doppler 
ultrasonography, especially of the upper limb. Venous and arterial ultrasonography 
was observed during the training period. Multiple training scans (>50) were 
performed on normal healthy subjects in order to accurately identify normal brachial 
artery anatomy and also to perfect the FMD technique prior to initiation of the 
studies described. Training in use of the edge detection software and its 
interpretation was also carried out prior to research data collection. Training scans 
were carried out under supervision and intra-observer and inter-observer variability 
was established (until an acceptable reproducibility with a mean difference of 2% to 
3% in FMD over time was achieved). In training and test subjects, all baseline scans 
were repeated within 7 days of the initial scan to ensure satisfactory reproducibility. 
Use of objective edge detection and analysis software reduced observer bias. 
Standardised documentation for data collation was developed and protocols were 
derived to standardise FMD measurement and analysis. 
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 Edge Detection/FMD Analysis Software 
Edge or image acquisition software – Vessel Image Analysis (V.I.A.) from M.D. 
Medic Ltd., UK - allows the real-time capture of vessel diameter by the use of a 
personal computer equipped with a frame grabber software device connected to the 
ultrasound system. Integral to the software is an artificial neural network vessel wall 
detection software system which automatically detects and tracks the anterior and 
Figure 2.5 – Flow Mediated Dilatation is evaluated by the use of high resolution ultrasound. EID, 
endothelium dependant dilatation; GTN, Glyceryl Trinitrate; PC, personal computer with image 
acquisition software; U/S, high resolution ultrasound 
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posterior artery walls within an area of interest defined by the sonographer. – see 
Figure 2.6 
 
 
 
 
 
 
 
 
The vessel diameter is then determined by averaging a large number of local vessel 
diameters (determined by the region of interest specified by the sonographer). The B 
Figure 2.6 
(A) The brachial artery is imaged such that the media–lumen interface is clearly seen.  
(B) The arterial media–lumen interface is automatically located and tracked within the region of 
interest. 
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mode images are processed at 25 frames/second and the vessel diameter, including 
diameter changes over the cardiac cycle is displayed in real time – see Figure 2.7 
 
 
 
 
 
 
Figure 2.7 
The mean vessel diameter within the region of interest is displayed in real time at 25 
frames/second. This allows the operator to optimise image quality continually. 
 
The wave-form shown represents 
the range in artery diameter from 
maximum at peak-systole 
and minimum at end-
diastole  
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At a sampling rate of 25 frames/second, it is possible to optimise ultrasound imaging 
parameters at the start of the scan. A stereotactic clamp is used to hold the transducer 
and a fine movement screw gauge is incorporated into the stereotactic clamp to allow 
for fine adjustments of the transducer (to accommodate subject movement). The 
software also saves a two dimensional image of the brachial artery over the scanning 
area to allow for comparison with repeated tests. 
There are distinct advantages to the use of automated image analysis software. It 
allows wall tracking to be optimised throughout the study, avoiding loss of data 
because of limited image quality. Other commonly used techniques require vessel 
images to be stored on a computer disk or videotape for later off line analysis. Image 
storage for post-hoc analysis carries the risk of image degradation from video 
recording and from working through the image processing steps. Operator 
intervention to optimise images stored conventionally is also at risk of 
observer/interpreter bias. 
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 Statistical Calculations: 
 
A power calculation was performed prior to the study for 80% power. Exploratory 
data analysis on the data set was conducted including examination of significant 
outlying or clinically improbable values. Internal consistency checks on repeated 
measurements were also performed. The distribution, central tendency and variance 
of variables in the overall study population and of subgroups defined by the primary 
explanatory variable were examined using both tabular and visual approaches. 
Independent t-tests were used to compare normally distributed data and the non-
parametric test, Mann Whitney-U was used to compare non-normally distributed 
data. Chi
2
 testing was employed to compare categorical variables. Bivariate 
correlation was used to investigate for statistically significant associations between 
continuous variables. Binary logistic regression was used to investigate for evidence 
of an association between a number of outcome variables and independent 
covariates. P < 0.05 was taken as significant. 
Analyses were conducted using SPSS® version 20 statistical software, with the 
advice and assistance of Prof Joseph Eustace (Director, Clinical Research Facility, 
University College Cork and Associate Professor of Statistics, Johns Hopkins 
Department of Biostatistics). 
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Chapter 3 
Demographics, Disease Activity Scores and Baseline Bloods 
 
Introduction: 
 
At the time of initial screening of patients for study entry, we collected data on 
patient demographics. This information included disease duration, current and 
previous medication use, family and personal medical history, baseline traditional 
cardiovascular risk factors and arthritis disease activity scores.  
 
Of particular interest to us were patients’ traditional cardiovascular risk factors. 
It is still unclear whether hypertension is more common in RA patients than the 
general population (1). A recent met-analysis of 7 RA case-control studies did not 
find an increased prevalence of hypertension in RA patients compared with controls 
(2). The relative risk of hypertension in RA needs to be investigated with 
longitudinal studies in the future. 
 
The prevalence of dyslipidaemia does not appear to be higher in RA patients 
compared with controls, despite the increased risk of CVD in RA (2, 3). 
Inflammation associated with RA and some of the treatments for RA are associated 
with changes in lipid profiles. 
Consistent with other inflammatory conditions, RA is associated with low total 
cholesterol, low HDL concentrations and elevated triglyceride levels (4). The 
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proinflammatory cytokines driving the inflammatory effects of RA are linked with a 
low total and HDL cholesterol. 
 
Changes in lipid profile as a result of treatment with TNF inhibitors and anti-IL6 are 
common. TNF blockers appear to elevate total cholesterol and HDL levels but do not 
affect LDL levels (5).  
This dual effect results in a stable atherogenic profile. The improvement in lipid 
profile with TNF inhibitors occurs mainly in treatment responders, suggesting that 
the benefit for lipids is via control of inflammation rather than a direct effect on 
cholesterol by anti-TNF therapies(6). Treatment of RA with anti-IL6 therapy, 
tocilizumab, is associated with elevations in total and LDL cholesterol. Whether 
these effects are long standing or not  and whether they impact on CV risk is 
currently being investigated (Roche H-L. A study of the effect of tocilizumab on 
markers of atherogenic risk in patients with moderate to severe rheumatoid arthritis 
(7).  
 
Statin therapy in RA has been shown to have a dual benefit. Expected reductions in 
total cholesterol and LDL levels have occurred along with improvements in disease 
activity and inflammatory markers (8).  
 
Insulin resistance appears to be associated with RA. Chung et al studied 124 RA 
patients and found that 54% of them have evidence of insulin resistance (9). This is 
higher than rates of 40% which have been recorded in the general population (10). 
Data is conflicting with regard to whether diabetes mellitus has a higher prevalence 
in RA patients compared to the general population. RA treatments have different 
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effects on glucose control. Corticosteroids increase the risk of diabetes; however 
hydroxychloroquine and TNF inhibitors have been shown to be associated with a 
reduced risk of future diabetes mellitus (11).  
Smoking rates are decreasing in the general population; however it is still an 
important modifiable CV risk factor. It is also the strongest known environmental 
risk factor for RA (12). Sero-positivity in RA is linked to smoking and also to a more 
aggressive disease (13).  
 
With regard to baseline phlebotomy, we were particularly interested in lipid and 
glucose profiles in the RA group for reasons mentioned above. 
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Aims: 
 
We aimed to characterise patients’ baseline demographic details and compare 
demographics and disease activity scores in RA and OA patients. We aimed to assess 
patients’ traditional cardiovascular risk factors at baseline and compare these in RA 
and OA patients. 
At the time of study entry blood samples were drawn for baseline routine bloods and 
fasting lipid and glucose profiles. We aimed to compare lipid and glucose readings in 
RA and OA patients. 
 
 
Methods: 
 
After informed consent was given and inclusion and exclusion criteria were met, 
each patient completed a study questionnaire regarding length of diagnosis, current 
treatments, smoking status, education level and family history. A number of disease 
activity and quality of life measures were also assessed at this time (see chapter 2 for 
more detail). A review of each patient’s medical notes was performed to cross check 
background medical information. 
A physical examination was performed on all recruits. Weight, height, waist 
circumference, hip circumference, blood pressure and heart rate were recorded. 
Blood was drawn for full blood count, coagulation screen and d-dimers, renal and 
liver profile, thyroid function, fasting lipid and glucose profile, rheumatoid factor 
and anti-CCP antibodies. 
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Baseline ECG was also performed in all patients to screen for previous silent 
myocardial events. 
 
Statistical Methods: 
 
All demographic variables and blood result variables were checked for normal 
distribution. If variables were normally distributed, means were quoted and t-tests 
utilised to compare groups. If variables were not normally distributed, medians were 
quoted and non-parametric analysis, in the form of Mann-Whitney U test was 
performed for comparisons. Bivariate correlations and binary logistic regression 
were used to assess for associations between fasting glucose and lipid profiles and 
markers of atherosclerosis. 
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Demographic Results: 
 
347 patients were screened for suitability to enter the study. After inclusion and 
exclusion criteria were applied as discussed in chapter 2, a total of 111 subjects were 
recruited for the study. The majority of exclusions were due to either a documented 
prior history of cardiovascular disease or were currently being investigated for 
cardiac sounding symptoms and signs.  
Sixty-three recruits had a diagnosis of rheumatoid arthritis (RA) and 48 had 
osteoarthritis (OA).  
A summary of demographic findings are presented in table 3.1. 
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Characteristics Rheumatoid 
Arthritis 
       n = 63 
Osteoarthritis 
      n = 48 
P value 
Age,mean (SD), yrs 50.57 (7.57) 50.58 (7.14) 0.993 
Female, n (%) 40      (63.5) 39      (81.2) 0.057 
Duration of disease, median (IQR) 7        (4-11) 6        (3-9) 0.227 
Current Smoker (%) 31.7 20.8 0.200 
Smoking Pack Years,median (IQR) 20      (10-30) 15     (10-20) 0.193 
Alcohol units/wk, median (IQR) 7.5      (3-10) 7        (3-12) 0.787 
Not working due to disease, n 9 3 0.226 
Current NSAID use, n 28 12 0.035* 
Current selective COX2 NSAID use, n 4 3 0.983 
Current steroid use, n (%) 29      (46) NA  
Mean steroid dose, mg  (SD) 7.93   (3.32) NA  
Current DMARD use, n (%) 46     (73) NA  
Current Biologic use, n (%) 34     (53.97) NA  
Current Statin, n (%) 11     (17.5) 11    (22.9) 0.475 
Hypercholesterolaemia, n (%) 12      (19) 14    (29.17) 0.212 
Hypertension, n (%) 12      (19) 10    (20.8%) 0.815 
Diabetes, n 1 0  
Joints Replaced, n (%) 5        (7.9) 2     (4.2) 0.418 
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Family History of MI, n (%) 16     (25.4) 29   (60.4) <0.001* 
Weight (kg), mean (SD) 72.55 (14.54) 75.21 (13.56) 0.323 
BMI (kg/m
2
), mean (SD) 26.20 (3.48) 28.05 (4.31) 0.017* 
Waist/Hip ratio, mean (SD) 0.86   (0.10) 0.85  (0.06) 0.287 
HAQ, median (IQR) 0.375 (0.125-0.75) 0.250 (0-0.625) 0.135 
SF36 PCS, mean (SD) 48.15  (7.42) 48.04 (8.73) 0.296 
SF36 MCS, mean (SD) 53.25  (5.83) 52.43 (5.94) 0.473 
General Health Score, mm, median 
(IQR) 
30   (17.5-37.5) 20  (10-30) 0.025* 
Physician VAS disease activity(mm), 
median (IQR) 
20   (10-30) 10 (10-20) <0.001* 
Patient VAS disease activity (mm), 
median (IQR) 
20   (10-30) 10  (3-20) 0.004* 
WOMAC, median (IQR) NA 8 (3-12.5)  
Tender Joint Count, median (IQR) 3     (0-6) NA  
Swollen Joint Count, median (IQR) 4     (1.5-6) NA  
DAS28ESR, mean (SD) 3.62  (1.33) NA  
DAS28CRP, mean (SD) 3.55  (1.24) NA  
 
 
 
 
 
 
 
Table 3.1: Baseline demographic and disease activity scores for RA and OA patients. P 
<0.05 is taken as significant. RA = rheumatoid arthritis, OA = osteoarthritis, SD = 
standard deviation, n = number of patients, IQR = interquartile range, MI = myocardial 
infarction, BMI = body mass index, HAQ = health assessment questionnaire, SF36 PCS = 
short form 36 physical component score, SF36 MCS = short form 36 mental component 
score, VAS = visual analogue scale, WOMAC = Western Ontario and McMaster 
Universities osteoarthritis index, DAS 28 = disease activity score for 28 joints. 
 93 
 
 
Gender: 
 
71.2% of the total study population were female. Commencing the study were 40 
females with rheumatoid arthritis and 23 males. 39 females and 9 males with a 
diagnosis of osteoarthritis were included (table 3.2, figure 3.1). 
 
 
 
 
 
 
 
 
 
 Male  (%) Female (%) Total  (%) 
RA 23     (36.5) 40   (63.5) 63     (100) 
OA 9       (18.8%) 39   (81.2) 48     (100) 
Total 32 79 111 
Table 3.2: Breakdown of study groups by gender 
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Age: 
 
Mean age of the total study group was 50.58years (+/- 7.35SD), range 30 to 63 years. 
Mean age in the osteoarthritis group was 50.58 years (+/- 7.136SD), range 32 to 62. 
In the rheumatoid group, 50.57 years (+/- 7.566SD) was the mean age and ages 
ranged from 30 to 63 years, figure 3.2. There was no significant difference in ages 
between RAs and OAs, p = 0.993. 
 
Figure3.1: Gender distribution according to diagnosis  
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Disease Duration: 
 
Disease duration was not normally distributed. Median duration of diagnosis for RA 
and OA groups inclusive was 6yrs (IQR4-9.5; range 1 to 28 years). The median 
length of diagnosis at study entry point was 6yrs (3-9) for osteoarthritis (range 1 to 
20 years). 7yrs (4-11) was the median duration of disease for the rheumatoid arthritis 
group (range 1 to 28 years). Using a Mann-Whitney U test, we found no difference 
in disease duration between RA and OA patients, p=0.227. 
Figure 3.2: Boxplot of age in RA and OA 
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66.7% of cases of rheumatoid arthritis and 14.6% of OA cases were diagnosed by a 
consultant rheumatologist. The remainder were given a diagnosis by their GP (figure 
3.3) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Breakdown according to source of diagnosis 
 97 
 
Education Level:  
 
There was no significant difference between RA patients and OA patients with 
regard to education level when all levels of education were analysed together, 
however there was a significant difference in the number of RA patients and OA 
patients attending 3
rd
 level education, (2 vs. 8, respectively), p = 0.014, (table 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Education Completed RA  
% 
OA 
% 
p 
Primary school 7.9 4.2 NS 
Junior certificate 41.3 39.6 NS 
Leaving certificate 47.6 39.6 NS 
3
rd
 level education 3.2 16.7 0.014* 
Table 3.4: Comparison of RA and OA patients’ education level, p, significance level 
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Occupation: 
 
Occupation types were similar between the 2 groups, p = 0.429 (table 3.5). 14.3% of 
the RA group and 14.6% of the OA group were unemployed (not disease-related). A 
further 14.3% of the RA group and 6.3% of the OA group were unable to work due 
to their disease. This difference between RA and OA patients was not significant, 
Fisher’s exact test, p =0.226. 3.2% of the RA group and 6.3% of the OA group were 
retired. There was no significant difference between the 2 groups with regard to 
employment status, p = 0.515, (figure 3.4). 
 
Occupation RA 
n = 63 
OA 
n = 48 
Working in the home 12 8 
Labourer 25 16 
Semi-professional 20 13 
Professional 4 8 
Self-employed 2 3 
 
 
Table 3.5: Groups according to occupation 
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Figure 3. 4: Comparison of current employment status 
between groups 
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Medications: 
 
DMARD Use: 
 
Within the RA group, methotrexate was the most commonly prescribed disease 
modifying anti-rheumatic drug (DMARD). 39 of 63 RA patients were taking 
methotrexate at the time of the study. All patients taking methotrexate were also on 
folic acid. A small percentage of RA patients were taking an alternative DMARD 
(table 3.6 and figure 3.5). 27% (17/63) of the RA group were not taking any 
DMARD at the time of the study. 54% of RA patients had been on a different 
DMARD in the past, methotrexate again being the most common one.  
 
 
 
 
 
 
 
 
 
 
 
Table 3.6: Summary of DMARDs used in RA patients 
DMDMARD Frequency % 
Methotrexate 39 61.9 
Leflunomide 3 4.8 
Hydroxycholoquine 1 1.6 
Sulphasalazine 1 1.6 
Azathioprine 2 3.2 
None 17 27 
 101 
 
 
 
Figure 3.5: Current DMARD use in RA group 
 
 
Biologic use: 
 
34 (53.97%) RA patients were on a biologic agent for treatment of their disease at 
the time of the study. 21 were taking etanercept, 11 adalimumab and 2 rituximab 
(figure 3.6). 19% of the group had been on another biologic prior to their current 
treatment. 
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NSAIDs: 
 
Of the total study group of 111 patients, 40 were taking a non-selective COX 2 
nonsteroidal anti-inflammatory (NSAID) medication when entering the study. 28 of 
these patients had rheumatoid arthritis. This was significantly higher than the number 
of OAs currently taking an NSAID, p = 0.035 (figure 3.7). Diclofenac was the most 
commonly prescribed non-selective COX 2 NSAID. Naproxen was the 2
nd
 most 
commonly prescribed (table 3.7, figure 3.8).  
Figure 3.6: Current biologic usage 
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15 RA patients and 24 OA patients had never been on a non-selective COX2 NSAID 
for their disease, prior to the study. Diclofenac was the most commonly prescribed 
non-selective COX2 NSAID prior to the study, followed by ibuprofen (table 3.8, 
figure 3.9). 
4 RA patients and 3 OA patients were on a selective COX2 NSAID at the time of 
study entry. They were either taking celecoxib or etoricoxib. 3 of the RA group had 
been taking rofecoxib in the past (table 3.9). 
OA patients who were taking an NSAID regularly were found to have a significantly 
higher weight and waist circumference than OA patients not taking an NSAID, 
p=0.045 and p=0.036, respectively. Blood pressure did not differ significantly 
between patients taking a regular NSAID and those not, p=0.567. 
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P = 0.035* 
Figure  3.7: Difference in current NSAID use between RA and OA patients 
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NSAID RA      (%) OA      (%) Total    (%) 
None 35       (55.6) 36        (75) 71         (64) 
Diclofenac 15       (23.8) 9          (18.8) 24         (21) 
Naproxen 9         (14.3) 1          (2.1) 10          (9) 
Ibuprofen 2          (3.2) 2          (4.2) 4           (3.6) 
Meloxicam 2          (3.2) 0           (0) 2           (1.8) 
Table 3.7: Breakdown of current non-selective 
COX2 NSAID use 
Figure 3.88: Graphic representation of nonselective COX 2 
NSAID use 
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NSAID RA     (%) OA     (%)   Total    (%)   
None 15      (23.8) 24      (50%)       39       (35.1) 
Diclofenac 29       (46) 15       (31.3) 44       (39.6) 
Ibuprofen 13       (20.6) 7         (14.6) 20        (18) 
Meloxicam 0         (0) 2         (4.2) 2          (1.8) 
Naproxen 3         (4.8) 0          (0) 3          (2.7) 
Nimesulide 3         (4.8) 0          (0) 3          (2.7) 
Table 3.8: Breakdown of previous n on-selective COX2 
NSAID use 
Figure 3.9: Graphic representation of prior use of non-selective COX2 
NSAIDS 
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Prednisolone: 
 
29 people (46%) in the RA group were on steroids at study entry. The mean dose of 
prednisolone was 7.93mg (+/- SD 3.32). Maximum dose of current steroid use was 
15mg. None of the OA group was taking steroids. 52 (82.5%) of the RA group had 
been steroids at some stage since their diagnosis. Mean prednisolone dose in female 
patients with RA was 7.5mg (+/-2.99), compared with 8.89mg (+/03.97) in male 
RAs, p = 0.368. Data was also collected on the maximum steroid dose for each 
patient. Steroid doses ranged from 0 – 40mg. There was no significant difference in 
 RA 
n 
OA 
n 
Current COX2        
Celecoxib 1 1 
Etoricoxib 3 2 
Previous COX2   
Celebrex 6 0 
Etoricoxib 3 2 
Rofecoxib 3 0 
Table 3.9: current and previous COX2 NSAID use 
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males and females with regard to maximum steroid doses (20 [10-20] vs. 15[10-20]), 
p = 0.382. 
 
 
Statins: 
 
There was no significant difference between number of RA patients and OA patients 
taking statins. 11 (17.5%) of the RA group and 11 (22.9%) of the OA group were 
taking a statin. Atorvastatin was the most commonly prescribed in both groups (table 
3.10). Nobody was taking a fibrate or ezitimibe at the time of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statin Type RA    (%) OA    (%) Total   (%) 
None 52    (82.5) 37    (77.1) 89     (80.2) 
Atorvastatin 9      (14.3) 5      (10.4) 14     (12.6) 
Pravastatin 0       (0.0) 2      (4.2%)   2       (1.8%) 
Simvastatin 0       (0.0) 1      (2.1%) 1       (0.9%) 
Rosuvastatin 2       (3.2) 3      (6.3%) 5       (4.5%) 
Table 3.10: Breakdown of Statin types between the groups 
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Other Cardiac Medications: 
 
There was no significant difference between the 2 groups with regard to use of 
cardiac medications. 2 RA patients and 2 OA patients were taking NS Aspirin. In the 
RA group, 3 were taking an ACE inhibitor and 3 an angiotensin receptor blocker. In 
the OA group, 2 were taking an ACE inhibitor and 5 people were on an angiotensin 
receptor blocker. One OA patient and 4 RA patients were on beta-blockers when 
entering the study. 2 RA patients and 1 OA patient were taking a calcium channel 
blocker. None of the RA group was taking a loop diuretic but 4 were on a thiazide 
diuretic at study entry. In the OA group, 1 patient was on a loop diuretic and 6 were 
taking a thiazide diuretic. 
 
 
 
Non-cardiac Medications: 
 
30.2% of the RA group were taking calcium and vitamin D supplementation and 
14.3% were on a bisphosphonate. In the OA group, 6.3% were on calcium and 
vitamin D supplementation and 1 patient (2.1%) was on a bisphosphonate. 
There was a significant difference between the 2 groups with regard to 
bisphosphonate use, p = 0.026 and calcium/vitamin D use, p = 0.02. 
There was also a significant difference in use of proton pump inhibitors (PPI) 
between the 2 groups, p <0.001. 33/63 of RA group were on a PPI and 5/48 of the 
OA group. Antidepressants were being taken by 5 of the RA group and 2 of the OA 
group.  
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Family History: 
 
30.2% (19/63) of the RA group and 16.7% (8/48) of the OA group had a first degree 
relative with a diagnosis of rheumatoid arthritis, p = 0.1. There was a significant 
difference in family history (1
st
 degree relative) of myocardial infarction between the 
groups (table 3.11).  
RA patients with a family history of MI had a significantly higher systolic blood 
pressure than those with no family history of MI, 140.73 mmHg (SD14.47) versus 
129.23 mmHg (SD 13.03), p=0.031. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family Cardiac History  RA    (%) 
N=63 
OA    (%) 
N=48 
P value 
Myocardial Infarction 16     (25.4) 29     (60.4) <0.001* 
Cardiac angioplasty+/- stenting 2        (3.2) 1        (2.1) 0.725 
Coronary artery bypass grafting 2        (3.2) 6        (12.5) 0.060 
Stroke 10      (15.9) 13      (27.1) 0.149 
Peripheral artery disease 1         (1.6) 0         (0) 0.381 
Table 3.11: Comparison of cardiac family history between the groups 
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Smoking status: 
 
54% (29/63) of the RA group were either current (31.7%) or former (22.2%) 
smokers. 30% of the female RA patients were current smokers and 15% were former 
smokers. 34.8% of male RA patients currently smoked and the same number were 
ex-smokers. 
52.1% of the OA group were either current (20.8%) or former (31.3%) smokers. 
20.5% OA females currently smoke and 30.8% were previous smokers. 22.2% OA 
males currently smoke and 33.3% of them were previous smokers. 
There was no significant difference between the number of smokers in the RA and 
OA groups (p = 0.355), also of note, there was no significant difference between the 
numbers of female RA and OA smokers (p = 0.222) or male RA and OA smokers (p 
= 0.705) (tables 3.12 and 3.13). 
 
Smoking distribution 
 
diagnosis 
Total osteoarthritis rheumatoid 
Smoker Never n 23 29 52 
%  47.9% 46.0% 46.8% 
Current n 10 20 30 
%  20.8% 31.7% 27.0% 
Former N 15 14 29 
%  31.3% 22.2% 26.1% 
Total N 48 63 111 
%  100.0% 100.0% 100.0% 
 
Table 3.12: Illustrating % of smokers and ex-smokers in the study group. 
 112 
 
 
 
 
Smoking distribution between the sexes in the RA group 
 
SEX 
Total female male 
Smoker Never N 22 7 29 
%  55.0% 30.4% 46.0% 
Current N 12 8 20 
% 30.0% 34.8% 31.7% 
Former N 6 8 14 
%  15.0% 34.8% 22.2% 
Total N 40 23 63 
%  100.0% 100.0% 100.0% 
 
 
 
Table 3.13: Illustrating % of male and female smokers in the RA group 
 
 
 
Smoking Pack Years: 
 
The median smoking pack years for the total study group is 20yrs (IQR 10-27.5), for 
the RA group 20yrs (IQR 10-30) and 15yrs (IQR 10-20) for the OA group. There 
was no significant difference between the 2 groups (p = 0.193). 
The median smoking pack years for both female and male OAs was 15yrs (IQR 10-
20). The median smoking pack years for both female and male RAs was 20yrs (IQR 
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15-30). There was no statistically significant difference in smoking pack years 
between females in the OA group or RA group (p = 0.645) or between males in the 
OA and RA groups (p = 0.189).  
 
 
 
Alcohol Consumption: 
 
57.7% (64/111) of the total study group drank alcohol. 54% (34/63) of RA patients 
consumed alcohol and 62.5% (30/48) of the OA group consumed alcohol. The 
median units of alcohol consumption per week in the RA group was 7.5 (IQR 3 – 10) 
and 7 (IQR 3 – 12) in the OA group. There was no significant difference between the 
2 groups (p = 0.787). The median weekly alcohol consumption in females was 4.5 
units (IQR 2 – 9.5) and in males was 12units (IQR10 – 20), this difference was 
significant, p <0.001 (figure 3.10). 
Within the RA group, median alcohol consumption among females was 4 units/wk 
(IQR2 2 – 10) and 10 units/wk (IQR 10 – 16) among males,  p = 0.001. Within the 
OA group, median alcohol consumption among females was 5 units/wk (IQR 2.5 -
8.5) and 20units/wk (IQR 12 -20) in the males, p = 0.005. Examining females 
separately, there was no significant difference in alcohol consumption rates between 
RA patients and OA patients (p =0.611). The same was found for male RA patients 
versus male OA patients (p = 0.337). 
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Other medical conditions: 
 
One male in the RA group had type 2 diabetes mellitus (DM). Nobody in the OA 
group had DM. 19% (12/63) of the RA group and 20.8% (10/48) of the OA group 
had a diagnosis of hypertension (HTN) prior to entering the study, this difference 
was not significant, p =0.815 (table 3.14). 23.4% (26/111) of the total study group 
had a diagnosis of hypercholesterolaemia, 12 patients (8 females and 4 males) were 
from the RA group and 14 patients (11 females and 3 males) from the OA group. 
There was no significant difference between the numbers of RA and OA patients 
with an elevated cholesterol, or between females and males with 
hypercholesterolaemia (p = 0.212, p =0.806 respectively).  
Information was also collected on presence of coexisting autoimmune conditions. 
Figure 3.10: Comparison of alcohol consumption between all    
females and males 
p<0.001 
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Nobody in the study had a diagnosis of Addison’s disease, alopecia, autoimmune 
hepatitis, coeliac disease, vitiligo or Sjogren’s syndrome. There was no history of 
Felty’s syndrome. 
7 RA patients (4 females and 3 males) had a diagnosis of Raynauds syndrome, 
compared with none in the OA group (p = 0.017). 9 people had a diagnosis of 
hypothyroidism (2 RAs and 7 OAs, p = 0.038) (figure 3.11). There was nobody with 
a history of hyperthyroidism in the study. 
With regard to family history of autoimmune diseases other than RA, one OA patient 
had a 1
st
 degree relative with systemic lupus erythematosus, as did 1 RA patient. 3 
OA patients had a 1
st
 degree relative with coeliac disease and 2 RA patients had a 
positive family history for coeliac disease.    
7.9% (5/63) RA patients and 4.2% (2/48) OA patients had a history of joint 
replacement performed because of their disease. 
 
 
 
 RA OA 
Hypertension present, n (%) 12 (19%) 10 (20.8) 
No diagnosis of hypertension, n (%) 51 (81) 38 (79.2) 
 
 
 
 
 
 
 
 
Table 3.14: Hypertension in the OA and RA 
groups 
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Menopause: 
 
27/40 (67.5%) of the female RA patients and 25/39 (64%) of the female OA patients 
were postmenopausal. The mean age of menopause in the RA group was 48.4yrs 
(SD+/-2.97) compared with 48.1yrs (SD+/-2.93) in the OA group, p ,= 0.727. 
 
 
 
 
 
P=0.038 
Figure 3.11: Hypothroidism in OA vs RA 
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Clinical Examination: 
 
Mean heart rate in the RA group was 73bpm (13.06), compared with 74bpm (6.85) 
in the OA group, p = 0.472. Heart rates were similar among males in the RA and OA 
groups (RA 74bpm+/-10.18, OA 74bpm+/- 5.36), p = 0.802, and also among females 
(RA 72bpm+/-14.52, OA 75bpm+/- 7.21), p = 0.361. 
 
 
Blood pressure was measured after a 15 minute period of rest. Mean blood pressure 
in the RA group was 128.86/79.83 (SD 11.03, SD 7.77) and 131.71/79.47 (SD14.04, 
SD8.35) in the OA group. There was no significant difference in systolic or diastolic 
blood pressure readings between RA and OA patients, p=0.276 and p=0.829, 
respectively. Males with RA had higher systolic and diastolic blood pressure 
compared to females with RA, p=0.000 and p=0.000. OA males had a significantly 
higher diastolic blood pressure than females, p=0.049 (table 3.15). 
 
One RA patient had a joint effusion at the time of examination. Seven RA patients 
had subcutaneous nodules associated with their disease, while 1 OA patient had 
evidence of Heberden’s nodes on hand examination.  
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 Mean systolic blood 
pressure, 
mmHg (SD) 
p Mean diastolic blood 
pressure, 
mmHg (SD) 
p 
RA Males 141.32 (10.29) 0.000* 85.89 (5.78) 0.000* 
Females 120.00 (12.89) 75.66 (7.27) 
OA Males 134.33 (10.46) 0.102 83.44 (5.03) 0.049* 
Females 127.36 (10.85) 78.85 (8.14) 
 
 
Table 3.15: Comparison of systolic and diastolic blood pressure in male and female 
RA and OA patients. SD, standard deviation; p, significance level. 
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Weight: 
 
Weight was normally distributed among the study group. It ranged from 50 to 115kg. 
Mean weight in the RA group was 72.55kg (SD+/- 14.54) compared with 75.21kg 
(SD+/- 13.56) in the OA group (p = 0.323). Mean weight for all the females was 
68.95kg (SD+/- 12.58), compared with 85.43Kg (SD+/- 10.48) for males (p <0.001). 
Difference in weight between the sexes was also significant within the disease 
groups (RA p<0.001, OA p<0.001). There was a significant difference in weight 
between female RA patients and female OA patients (table 3.16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sex RA OA P value 
Female 65.32kg(SD+/- 10.49) 72.67kg(SD+/-13.56) 0.009 
Male 85.12kg(SD+/-11.85) 86.22kg(SD+/-6.2) 0.734 
Table 3.16: Comparison of weight between the sexes in RA and OA 
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Height: 
 
 
Height was normally distributed in the study group. Mean height of females was 
161cm (SD+/- 6.79), compared with 174cm (SD+/- 5.97) for males, p <0.001 (figure 
3.12). Height is the RA group (165.76cm+/-8.98) was similar to that in the OA group 
(163.60+/-8.36), p =0.215. Also, there was no significant difference in height 
between females with RA or OA (p = 0.845) or between males with RA or OA (p = 
0.452). 
 
 
 
 
 
 
 
 
 
 
P<0.001 
Figure 3.12: Boxplot comparing male and female height 
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Body Mass Index: 
 
 
Mean body mass index (BMI) for the study group was 26.99 kg/m
2
 (+/- 3.95). Mean 
BMI in the RA group was 26.20 kg/m
2
 (+/- 3.48) compared with 28.05 kg/m
2
 (+/-
4.31) in the OA group, p = 0.017 (table 3.17). Mean BMI for all the females was 
26.50kg/m
2
 (+/- 4.13)   compared with 28.23kg/m
2 
(+/- 3.21) for all males, p = 
0.021. For a breakdown of BMI within the diagnostic groups see table 3.18. 
 
 
 
 
 
 
 
 Mean BMI (kg/m
2
) in females 
(SD) 
Mean BMI (kg.m
2
) in males 
(SD) 
P  
RA 25.02 (3.01) 28.24 (3.34) 0.000* 
OA 28.01 (4.58) 28.21 (3.02) 0.876 
P  0.001* 0.982  
 
 
 
 
 
Patients’ BMI was also categorized into underweight / normal weight / overweight / 
obese. A BMI of less than 18.5kg/m
2
 was considered underweight; BMI between 
18.5 kg/m
2
 and 25kg/m
2
 was considered normal, BMI greater than 25kg/m
2 
but less 
than 30kg/m
2 
 was overweight and BMI greater then 30kg/m
2
 was obese. The RA 
group were more likely to have a normal BMI compared with the OA group, p = 
0.006 and female RA patients were more likely to have a normal BMI compared 
Table 14: comparison of weight by sex and diagnosis 
Table 3.17: Mean BMI kg/m
2 
(SD) within the groups. 
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with male RA patients, p = 0.016. There was a significant difference in the number 
of male and female obese patients in the RA group, p = 0.008. 
 
 
BMI category RA female 
n 
RA male 
n 
OA female 
n 
OA male 
n 
Underweight 0 0 1 0 
Normal 23 6 9 1 
Overweight 16 11 20 5 
Obese 1 6 9 3 
 
 
 
 
Waist Hip Ratio: 
 
Mean female waist circumference was 86.06cm (+/- 10.64), compared with mean 
male waist circumference of 97.28cm (+/- 8.29), p < 0.001. Within the female 
population there was a statistically significant difference in waist circumference 
between the RAs and OAs, (83.56cm [11.14] and 88.62cm [9.58], p = 0.034). Hip 
circumference was also significantly smaller in RA females compared with OA 
females (101.40cm [7.13] and 106.18cm [10.47], respectively), p = 0.021. Male hip 
circumference was significantly smaller in the RA group compared with the OA 
group, (105.35cm [6.57] and 109.78cm [3.87] respectively), p =0.027. This was not 
the case for male waist circumference, p = 0.866.  
Table 3.18: Number of patients in each BMI category 
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However, waist hip ratio (WHR) was similar between the RA group (0.86+/-0.10) 
and the OA group (0.85+/-0.06), p = 0.287. Within the diagnostic groups, there was 
no significant difference in waist hip ratio in females or in males (table 3.19).  
 
 
 RA OA P value 
Female WHR 0.83 (+/-0.08) 0.84 (+/-0.05) P = 0.447 
Male WHR 0.93 (+/-0.09) 0.89 (+/-0.08) P = 0.260 
.  
 
 
 
 
 
 
General Health Measures and Disease Activity Scores: 
 
 
Median general health (GH) score for the total group, as measured on a 100mm 
visual analogue scale, was 25 (IQR 10-30). The median OA GH score was 
significantly better than the RA score (OA 20mm [10-30], RA 30mm [17.5-37.5]), p 
= 0.025. There was no statistically significant difference in GH scores between 
males and females (table 3.20). 
RA patients on steroids has a significantly worse general health score compared with 
RA patients not taking steroids, 30mm (20-40) compared with 20mm (10-30), 
p=0.037. Within the RA group, CRP correlated significantly with GH score, r=0.336, 
p=0.007. 
 
Table 3.19: Comparison of Waist Hip Ratio in male and females with RA and OA 
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Short Form 36  
 
 
Physical component score: 
 
 
The mean physical component scores (PCS) were similar in the RA and OA groups 
(RA 48.15+/- 7.42, OA 48.04+/- 8.73), p = 0.946, and between males and females 
(males 49.32+/- 7.62, females 47.61+/- 8.11), p = 0.296. Examining females 
separately, the mean PCS was similar in the RA (47.89+/-7.93) and OA (47.31+/-
8.39) groups, p = 0.753. The same was true for male RA patients compared with 
male OA patients (48.59+/- 6.58, 51.19+/- 10.00, respectively), p = 0.486. 
PCS did not differ between the different treatment groups with rheumatoid arthritis, 
except in the case of current steroid use where those RA patients taking steroids has 
 RA OA P value 
Female GH score 30 (10-40) 20 (10-30) P = 0.110 
Male GH score 30 (20-32.5) 15 (10-20) P = 0.057 
P value  P = 0.994 P = 0.324  
Table 3.20: Difference in median (IQR) GH score between females and 
males in RA and OA groups 
 
 125 
 
a significantly worse PCS, 45.03 (SD7.77) compared to those not on steroids, 50.80 
(SD6.03), p=0.002, (figure 3.13). 
 
 
 
 
 
Figure 3.13: Boxplot comparing physical component score in RA patients taking 
steroids with RA patients not taking steroids.  
 
 
 
 
 
P= 0.002* 
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Mental Component Score: 
 
Mean mental component scores (MCS) were not significantly different between the 
RA and OA groups (53.25+/- 5.83, 52.43+/-5.94, respectively), p = 0.473, or 
between males and females (53.18+/-3.47, 52.78+/-6.61 respectively), p = 0.673. For 
a breakdown of MCSs within the RA and OA groups see table 3.21. RA patients 
who were on a DMARD or an NSAID at the time of the study had a significantly 
worse MCS than RA patients not taking a DMARD or NSAID, p=0.005 and 
p=0.031, respectively. However, those RA patients on a biologic agent had a better 
MCS than RA patients not taking a biologic DMARD, p=0.01. 
 
 
 
 RA OA P value 
Female mean MCS (SD) 53.35 (6.77) 52.19 (6.28) 0.436 
Male mean MCS (SD) 53.06 (3.82) 53.50 (2.50) 0.704 
P value 0.827 0.329  
 
 
 
 
 
 
 
 
Table 3.21: Comparison of mean MCSs in males and females with 
RA and OA 
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Health Assessment Questionnaire: 
 
Median health assessment questionnaire (HAQ) score for the RA group was 0.375 
(0.125-0.750), compared with 0.25 (0-0.625) for the OA group, p = 0.135.There was 
a significant difference between HAQ scores of males and females (0.25 [0-0.375], 
0.5 [0.125-0.75], respectively), p = 0.002. HAQ scores within the diagnostic groups 
for males and females are detailed in table 3.22 and figure 3.14. 
RA patients on steroids had a significantly higher HAQ than RA patients not on 
steroids, 0.5 (0.25 – 1.25) versus 0.25 (0.125 – 0.625), p=0.025. RA patients with a 
family history of CVD had a significantly higher HAQ than those with no family 
history of CVD, 0.625 (0.25 – 1.125) versus 0.25 (0.125 – 0.625), p=0.032. 
 
In the OA group, the HAQ was significantly worse in patients who were overweight 
or obese, p=0.029. 
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 RA OA P 
value 
Median HAQ score (IQR) in 
females 
0.563 (0.188-
0.938) 
0.375 (0.125-
0.688) 
0.033* 
Median HAQ score (IQR) in 
males 
0.25   (0-0.375) 0        (0) 0.381 
P value 0.002* 0.101  
Table 3.22: HAQ scores in RA and OA patients 
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Figure 3.14: Boxplot comparing HAQ scores in RA and OA females 
P = 0.033 
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Visual Analogue Scale: 
 
A visual analogue scale (VAS) of physician’s assessment of disease activity revealed 
a median VAS for the total study group of 10mm (10-30). The median OA 
physician’s VAS was 10mm (10-20), compared with 20mm (10-30) for the RA 
group, p < 0.001.  When all females were compared, there was a significant 
difference between the RA and OA groups (20mm [10-30], 10mm [10-20], 
respectively), p = 0.003. The same was found when comparing RA males to OA 
males (20mm [15-25], 10mm [10-10], respectively), p = 0.011.  
Patients scored a visual analogue scale as a self- assessment of pain. Median VAS 
for pain was 20mm (10-30) in both males and females. The scores were significantly 
worse for RA patients compared with OA patients and also for female RA patients 
compared with female OA patients (table 3.23).  
 
 
 RA OA P value 
Median pain VAS in females (IQR) 20 (10-30) 10 (10-20) 0.033* 
Median pain VAS in males (IQR) 20 (15-30) 10 (10-20) 0.044 
 
 
 
 
 
 
Table 3.23: Median (IQR) VAS for self-assessment of pain in both groups. 
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A patient self-assessment for disease activity was also scored on a visual analogue 
scale. Results are reported as medians (interquartile range). RA patient scores for 
disease activity were significantly worse than OA patient scores (20mm [10-30], 
10mm [3-20], p = 0.004). Male RA patients also had a significantly worse disease 
activity VAS than male OA patients (RA 20mm [15-25], OA 10mm [0-10], p = 
0.017). There was no significant difference between female RA patients activity 
VAS and female OA patient activity VAS (20mm [10-30], 10mm [7.5-20], 
respectively), p = 0.06. 
 
 
Disease Activity Scores for Rheumatoid Arthritis: 
 
In the RA group, tender and swollen joint counts were recorded for calculation of the 
disease activity score 28 ESR (DAS28ESR) and CRP (DAS28CRP).  
28 female RA patients and 17 male RA patients had 1 or more tender joints on 
clinical examination. The median tender joint count for all the RAs was 3 (0-6). The 
median tender joint count (TJC) was 2.5 (0-7) for females and 4 (0.5-4.5) for males, 
there was no significant difference between males and females, p = 0.839.  
 
RA patients who were on a DMARD at the time of the study had a higher median 
tender joint count than those not on a DMARD (3.5[0-6] vs. 2 [1-6]), however the 
difference was not statistically significant, p = 0.844. Number of tender joint in those 
currently on a biologic agent compared to those RA patients not currently on a 
biologic agent was not significantly different (3.5 [1-7], 3 [1-6], respectively), p = 
0.967.  
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There was no significant difference in number of tender joints in RA patients 
currently taking an NSAID compared with those not currently on an NSAID (2.5[0-
7.5], 4 [0-5.5], respectively), p = 0.933).  
With regard to steroid use, the number of tender joints was similar in RA patients 
currently on prednisolone and those not currently taking prednisolone (3[1-7], 2.5[0-
6], respectively), p = 0.208. Current smokers had a TJC of 3.5(1-6), compared with 
3(0-6.5) in the non-smokers, p = 0.549.  
 
 
33 females with RA and 18 males with RA had 1 or more swollen joints on 
examination. Median number of swollen joints for the total RA group was 4 (1.5-6). 
Median number of swollen joints in the females was 4.5 (2-6.5) and 3 (1-4.5) in the 
males, p = 0.094. RA patients currently on a DMARD, biologic, steroid or NSAID 
did not have a statistically significant difference in median swollen joint count 
compared with those RA patients not taking any of the above medications. Current 
smoking status did not affect the median number of swollen joints. 
 
DAS28 ESR was normally distributed in the RA group. Mean DAS 28 ESR for the 
total RA group was 3.62 (+/- 1.33). There was no significant difference between 
male and female DAS28 ESR scores, p = 0.23. DAS28 ESR scores were also 
analysed based on current medications and smoking status (table 3.24). 
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  DAS28ESR 
Mean(SD) 
P value 
Current 
DMARD 
Yes 3.49 (1.25)  
0.226 No 3.99 (1.51) 
Current  
Biologic 
Yes 3.62 (1.51)  
0.993 No 3.62 (1.11) 
Current 
NSAID 
Yes 3.66 (1.20)  
0.835 No 3.59 (1.44) 
Current  
Steroid 
Yes 3.94 (1.05)  
0.077 No 3.36 (1.49) 
Current  
Smoker 
Yes 3.92 (0.99)  
0.171 No 3.45 (1.45) 
 
 
 
 
Disease activity was also examined as a categorical variable, using a DAS28ESR of 
>3.2 as a measure of active disease, to compare patients with moderate or high 
disease activity in RA to those with low disease activity or remission. 43 of the 63 
RA patients had a DAS28ESR of greater than 3.2. RA patients with a high 
DAS28ESR had significantly worse scores for general health, health assessment 
questionnaire and visual analogue scales (table 3.25).  
 
Table 3.24: Breakdown of DAS28 ESR scores based on 
medications and current smoking status 
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 DAS28ESR < 
3.2 
DAS28ESR > 
3.2 
P 
General health score 20 (10 – 27.5) 30 (20 – 40) 0.000* 
HAQ 0.188 (0 – 
0.375) 
0.5 (0.25 – 0.75) 0.005* 
VAS physician assessment of disease 
activity 
10 (10- 20) 20 (20 – 30) 0.000* 
VAS patient assessment of pain 10 (9 – 20) 20 (20 -35) 0.001* 
VAS patients assessment of disease 
activity 
10 (5 – 20) 20 (15 – 40) 0.000* 
 
Table 3.25: Comparison of health and disease activity scores in RA patients with low 
and high disease activity using DAS28ESR. Results are all median values with inter-
quartile range.  
 
 
 
DAS28 CRP was also measured in the RA group. Mean DAS28 CRP for the RA 
group was 3.55 (+/-1.12). DAS28 CRP scores were similar among males and 
females (3.45 [+/- 0.88], 3.60 [+/- 1.24], respectively), p = 0.579. DAS28 CRP 
scores were also analysed based on current medications and smoking status (table 
3.26). There was a statistically significantly higher DAS28 CRP in RA patients 
currently on steroids compared with those not on steroids, p = 0.03 (figure 3.15). 
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  DAS28CRP 
Mean(SD) 
P value 
Current 
DMARD 
Yes 3.52 (1.09)  
0.801 No 3.61 (1.23) 
Current  
Biologic 
Yes 3.49 (1.17)  
0.646 No 3.62 (1.07) 
Current 
NSAID 
Yes 3.58 (1.09)  
0.825 No 3.52 (1.15) 
Current  
Steroid 
Yes 3.87 (0.92)  
0.030* No 3.27 (1.21) 
Current  
Smoker 
Yes 3.66 (0.91)  
0.563 No 3.50 (1.21) 
 
 
 
 
Table 3.26: Breakdown of DAS28 CRP scores based 
on medications and current smoking status 
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Figure 3.15: Boxplot comparing DAS28 CRP scores in RA patients on steroids 
with those not on steroids 
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Western Ontario and McMaster Universities Osteoarthritis Index: 
 
Impact of disease on OA patients was assessed using a scale called Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC). This resulted in a score 
for pain, stiffness, physical function and total score for each patient.  
Looking at WOMAC pain score as an ordinal variable, the median score was 2 (1 -4) 
for all OAs. Median score for pain in those OA patients currently on an NSAID was 
not significantly different from that of patients not currently taking NSAIDs, (2 [1-
5], 1 [1-3], respectively), p = 0.134 (table 3.27).  
Median score for stiffness in the total OA group was 1 (IQR 1-2) out of a possible 
maximum of 8. Median stiffness score in OA patients currently on an NSAID was 
1.5 (1-2.5) compared with a score of 1 (1-2) in those not on an NSAID, p = 0.183.  
The median score for physical function in the total OA group was 5 (1-8.5). 12 of the 
OA group were on an NSAID at the time of the study and their median physical 
function score was 5.5 (2-12) compared with a score of 5 (1-8) in those not on an 
NSAID, p = 0.451. Pain, stiffness and physical function scores were combined to 
give a total WOMAC score for each OA patient. Median total WOMAC score was 8 
(3-12.5) for the total OA group. Being on an NSAID or not did not affect the total 
WOMAC score, p = 0.404. OA patients who were overweight or obese had a 
significantly worse total WOMAC score, p=0.041. 
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Table 3.27: Comparison of WOMAC score components in OA patients on an 
NSAID and those not taking an NSAID. WOMAC, Western Ontario and McMaster 
Universities osteoarthritis index; p, significance level. 
 
 
 
 
 
 
 
 
 
 
 
 Current NSAID No current NSAID p 
WOMAC total score, median (IQR) 9 (4.5 – 11) 8 (3 – 11) 0.260 
WOMAC pain score, median (IQR) 2 (1- 5) 1 (1-3) 0.134 
WOMAC stiffness score, median (IQR) 1.5 (1-2.5) 1 (1 -2) 0.183 
WOMAC physical function score, median (IQR) 5.5 (2-12) 5.0 (1-8) 0.451 
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Baseline Phlebotomy: 
 
All patients had bloods taken for full blood count, urea, creatinine and electrolytes 
(table 3.18). Blood samples were taken to measure d-dimers, as a marker of 
coagulation, however, IgM Rheumatoid factor positivity interferes with the d-dimer 
assay, so these results not analysed as they not were felt to be accurate measurements 
of coagulation in our RA group.  
Serum calcium was significantly higher in the OA group, p=0.001. Within the OA 
group, smokers had a significantly higher serum calcium than non-smokers, 
2.52mmol/l (SD 0.09) compared with 2.45mol/l (SD 0.09), p=0.032. 
Glomerular filtration rate (eGFR) was calculated using the validated MDRD 
formula. eGFR was significantly lower in the OA group, 73.98ml/min (SD 11.53) 
compared with79.51ml/min (SD13.57) in the RA group, p=0.022. 
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Table 3.28: Comparison of mean values for routine bloods in RA and OA patients. 
SD, standard deviation; p, significance level; RA, rheumatoid arthritis; OA, 
osteoarthritis 
 
Within the RA group, values for routine bloods were similar across the different 
treatment groups, except in the case of current steroid use. This group had a 
significantly higher total white cell count than RA patients not on steroids, 8.31 
x10
9
/l (SD 2.31) compared with 7.05 x10
9
/l (SD 1.87), p=0.025.  
 
RA patients with low disease activity, as characterised by a DAS28ESR less than 
3.2, had significantly lower white cell counts and higher albumin level compared 
with RA patients whose DAS28ESR was greater than 3.2 (table 3.29). There was a 
 RA OA p 
Hb (g/dl) 13.52 (SD 1.24) 13.79 (SD 1.07) 0.225 
WCC (x10
9
/l) 7.63 (SD 2.16) 6.55 (SD 1.79) 0.005* 
Plts (x10
9
/l) 266 (SD 60.03) 274 (SD 65.33) 0.556 
Urea (mmol/l) 5.9 (SD 1.73) 5.3 (SD 0.78) 0.020* 
Creatinine (umol/l) 81 (SD 13.54) 81 (SD 9.32) 0.854 
Calcium (mmol/l) 2.40 (SD 0.09) 2.46 (SD 0.09) 0.001* 
Sodium (mmol/l) 141 (SD 2.14) 141 (SD 2.24) 0.487 
Potassium (mmol/l) 4.5 (SD 0.39) 4.5 (SD 0.51) 0.815 
Albumin (g/l) 37.5 (SD 3.12) 39.7 (SD 2.73) 0.000* 
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significant correlation between ESR and haemoglobin level and ESR and albumin in 
the RA group, r = -0.413, p=0.001 and r= -0.432, p=0.000. Albumin also correlated 
with Il6 and Il8 concentrations, r= -0.376, p=0.004 and r = -0.315, p=0.017. Platelets 
in the RA group correlated with a number of adhesion molecules (table 3.30) and 
also with E/A ratio on transthoracic echocardiogram, r = -0.307, p=0.017. 
 
Thyroid function was assessed by measuring TSH and T4 levels. These were not 
normally distributed so medians are quoted and non-parametric tests used for 
comparisons. There was no significant difference in TSH or T4 levels between RA 
and OA patients (table 3.31). TSH levels in the RA group correlated significantly 
with general health status, r=0.320, p=0.011. 
 
 
 
 DAS28ESR <3.2 DAS28ESR > 3.2 p 
WCC (x 10
9
/l) 6.66 (SD 1.54) 8.08 (SD 2.27) 0.016* 
Albumin (g/l) 38.75 (SD 2.55) 36.88 (SD 3.22) 0.029* 
 
Table 3.29: Comparison of WCC and albumin concentration in RA patients with low 
and high disease activity. DAS28ESR; disease activity score 28 joint count with 
ESR; SD, standard deviation. 
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 Correlation with platelets, r p 
VCAM 0.025 0.844 
ICAM 0.256 0.050* 
E-selectin 0.396 0.001* 
P-selectin 0.404 0.001* 
L-selectin 0.281 0.027* 
 
Table 3.30: Correlation between platelet count and adhesion molecules in RA group. 
R, correlation coefficient; p, significance level 
 
 
 
 
 Median TSH, mIU/l 
(IQR) 
p Median T4, pmol/l 
(IQR) 
p 
RA 1.54 (0.96 – 2.640 0.115 16.35 (14.80 – 18.50) 0.938 
OA 2.04 (1.24 – 3.32) 16.55 (15.10 – 18.20) 
 
 
 
Table 3.31: Comparison of serum TSH and T4 in RA and OA patients. IQR, 
interquartile range 
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Serum Concentrations of Antibodies in RA: 
 
Anti-CCP antibody and rheumatoid factor levels were checked in all patients. They 
were not normally distributed so median values are reported.. Median anti-CCP 
antibody in the RA group was 144AU/ml (27.5 – 500) and median rheumatoid factor 
level was 114IU/ml (29.75- 323.75). Nobody in the OA group tested positive for 
anti-CCP antibody. The median rheumatoid factor level in the OA group was 
1.9IU/ml (0 -10).  
 
RA smokers had significantly higher anti-CCP antibody and rheumatoid factor levels 
than non-smokers (table 3.32). Smoking pack years correlated significantly with 
anti-CCP antibody and rheumatoid factor levels, r = 0.386, p=0.002, and r = 0.410, 
p=0.001. 
 
 Smokers Non-smokers P 
Anti-CCP antibody, AU/ml (IQR) 411.50 (202 – 800) 94 (6.1 – 306.5) 0.001* 
Rheumatoid factor, IU/ml (IQR) 187 (57.1 – 604) 91 (11.85 – 304) 0.033* 
 
Table 3.32: Difference between RA smokers and non-smokers with respect to anti-
CCP antibody and rheumatoid factor levels. 
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Fasting Lipid and Glucose Profiles: 
 
Fasting glucose and lipid profile are reported as means. There was no significant 
difference in mean fasting glucose, cholesterol, LDL, HLD or triglycerides between 
RA and OA patients (table 3.33). 47 (75%) patients with RA had a fasting 
cholesterol of greater than 5mmol/l compared with 31 (66%) patients with OA, p 
=0.323. Of the 78 patients with an elevated serum cholesterol, only 15 (19%) were 
taking a statin at the time of study entry. No patients were taking a fibrate or 
ezetimibe.  
 
 RA OA p 
Mean fasting glucose, mmol/l (SD) 4.92 (0.91) 4.92 (0.56) 0.998 
Mean total cholesterol, mmol/l (SD) 5.43 (0.80) 5.41 (0.81) 0.889 
Mean LDL, mmol/l(SD) 3.25 (0.58) 3.22 (0.79) 0.804 
Mean HDL, mmol/l (SD) 1.59 (0.46) 1.58 (0.44) 0.945 
Mean triglycerides, mmol/l (SD) 1.50 (0.89) 1.31 (0.68) 0.205 
 
 
Table 3.33: Comparison of fasting lipid and glucose profile in RA and OA. SD, 
standard deviation 
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RA males had a significantly higher fasting glucose and triglyceride level than 
females with RA, p=0.003 and p=0.005, respectively. Serum HDL was significantly 
higher in females than males, in both the RA and OA groups, p=0.000 and p=0.000, 
respectively. Fasting glucose and lipid profiles were similar in RA patients on 
disease modifying therapy or steroids and RA patients not on these medications.  
Fasting glucose and triglyceride concentration were higher in RA patients who were 
current or exsmokers, compared with non-smokers (table 3.34). RA and OA patients 
who had a high BMI, had a significantly higher triglyceride concentration than their 
counterparts with a normal BMI, p=0.026 and p=0.088, respectively. There was a 
significant correlation between HDL and markers of body mass in both the RA and 
OA groups (table 3.35). Triglyceride concentration was also significantly higher in 
anti-CCP antibody positive RA patients compared with anti-CCP antibody negative 
RA patients, 1.60mmol/l (SD0.99) versus 1.21mmol/l (SD0.36), p=0.033. 
OA and RA patients with a high PAI-1 activity result had a significantly lower HDL 
compared with OA and RA patients with PAI-1 activity in the normal range (table 
3.36). PAI-1 antigen correlated with HDL and triglyceride concentrations in both RA 
and OA patients (table 3.37) 
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 Positive smoking 
history 
Non-
smokers 
p 
Mean fasting glucose, mmol/l (SD) 5.27 (1.04) 4.50 (0.45) 0.000* 
Mean fasting cholesterol, mmol/l 
(SD) 
5.53 (0.83) 5.31 (1.04) 0.269 
Mean LDL, mmol/l (SD) 3.34 (0.58) 3.16 (0.59) 0.256 
Mean HDL, mmol/l (SD) 1.53 (0.54) 1.66 (0.35) 0.296 
Mean triglycerides, mmol/l (SD) 1.79 (1.00) 1.15 (0.35) 0.003* 
 
 
 
Table 3.34: Comparison of fasting glucose and lipid profile in RA smokers and non-
smokers. SD, standard deviation; p, significance level. 
 
  Correlation with HDL concentration, r p 
RA Waist circumference (cm) -0.327 0.014* 
Weight (Kg) -0.391 0.003* 
BMI (kg/m
2
) -0.284 0.034* 
OA Waist circumference (cm) -0.482 0.000* 
Weight (kg) -0.437 0.002* 
BMI (kg/m
2
) -0.382 0.009* 
 
Table 3.35: Correlations between markers of body mass and serum HDL 
concentration 
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 Elevated PAI-1 activity Normal PAI-1 activity p 
HDL, mmol/l (SD) 
In OA group 
1.19 (0.03) 1.58 (0.44) 0.000* 
HDL, mmol/l (SD) 
In RA group 
1.32 (0.32) 1.65 (0.49) 0.014* 
 
Table 3.36: Comparison of serum HDL concentrations in patients with high and 
normal PAI-1 activity, SD, standard deviation, p, significance level 
 
 
  Correlation with PAI-1 antigen, r P 
RA HDL, mmol/l -0.363 0.009* 
Triglyceride, mmol/l 0.335 0.015* 
OA HDL, mmol/l -0.304 0.047* 
Triglyceride, mmol/l 0.321 0.036* 
 
Table 3.37: Correlation between PAI-1 antigen concentration and lipid profile in RA 
and OA patients 
 
 
RA patients with evidence of atherosclerotic plaque on ultrasound had a more 
abnormal lipid profile than those with no plaque (table 3.38). RA patients with 
evidence of diastolic dysfunction on transthoracic echocardiogram had a less 
favourable lipid profile than RA patients with normal diastolic function (table 3.39). 
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In both RA and OA patients, there was a significant correlation between lipid profile 
and E/e’, as a marker of diastolic dysfunction on echocardiography (table 3.40). 
 
 
 Evidence of carotid 
plaque 
No evidence of carotid 
plaque 
P 
Serum LDL, mmol/l 
(SD) 
3.67 (0.50) 3.15 (0.54) 0.033* 
Serum HDL, mmol/l 
(SD) 
1.33 (0.31) 1.65 (0.46) 0.040* 
 
 
Table 3.38: Comparison of lipid profile in RA patients with and without carotid 
plaque 
 
 Evidence of diastolic 
dysfunction 
Normal diastolic 
function 
p 
Total cholesterol, 
mmol/l (SD) 
5.79 (0.64) 5.37 (0.79) 0.048* 
Serum LDL, mmol/l 
(SD) 
3.55 (0.54) 3.14 (0.59) 0.025* 
 
Table 3.39: Comparison of lipid profile in RA patients with and without evidence of 
diastolic dysfunction 
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 Correlation with E/e’, r p 
RA Total cholesterol 0.255 0.077 
LDL 0.508 0.001* 
OA Total cholesterol 0.316 0.034* 
LDL 0.227 0.139 
 
Table 3.40 Correlation between E/e’ and lipid profile in RA and OA. 
 
 
 
Using logistic regression analysis, diastolic dysfunction, peripheral vascular disease 
and endothelial dysfunction were not found to be associated with fasting glucose or 
lipid profile, in either the RA or OA group (table 3.41). However, carotid subclinical 
atherosclerosis was found to be associated with fasting glucose in the RA group, OR 
(95%), 5.03 (1.08, 23.43), p=0.039. After simultaneous adjustment for hypertension, 
serum cholesterol and smoking, this association was no longer significant, OR 
(95%), 3.50 (0.80, 15.30), p=0.096. 
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 Fasting lipid 
profile 
OR (95% CI) 
p Fasting glucose 
OR (95%CI) 
p 
RA Endothelial dysfunction 0.24 (0.00, 
62.49) 
0.611 0.98 (0.46, 
2.07) 
0.954 
Peripheral vascular 
disease 
1.15 (0.02, 
70.07) 
0.948 1.32 (0.51, 
3.40) 
0.565 
Subclinical 
atherosclerosis 
0.59 (0.14, 2.49) 0.472 5.03 (1.08, 
23.43) 
0.039* 
Diastolic dysfunction 0.77 (0.19, 3.19) 0.721 1.38 (0.62, 
3.08) 
0.434 
OA Endothelial dysfunction 1.29 (0.51, 3.26) 0.590 0.16 (0.39, 
6.73) 
0.493 
Peripheral vascular 
disease 
1.81 (0.11, 
28.99) 
0.676 1.84 (0.08, 
44.42) 
0.708 
Subclinical 
atherosclerosis 
1.94 (0.69, 5.40) 0.208 1.76 (0.39, 
8.02) 
0.465 
Diastolic dysfunction 0.378 (0.08, 
1.87) 
0.234 0.91 (0.24, 
3.48) 
0.892 
Table 3.41: Association between markers of atherosclerosis and diastolic dysfunction 
and fasting lipid and glucose profiles in RA and OA patients. OR, odds ratio; CI, 
confidence interval; p, significance level 
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Metabolic Syndrome: 
 
Based on the National Cholesterol Education programme adult treatment panel III 
(NCEP ATPIII) criteria (14), we investigated whether any of our cohort had a 
diagnosis of the metabolic syndrome. No one had a prior diagnosis of the metabolic 
syndrome. We found that 7 RA patients and 7 OA patients fitted the diagnostic 
criteria, p = 0.775, Fisher’s Exact test.  
 
 
 
Electrocardiogram: 
 
We found no evidence of ischaemic changes on the ECGs of our RA and OA groups. 
Also, none of our study group had evidence of atrial fibrillation or other arrhythmias.  
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Discussion: 
 
Demographic and Disease Activity: 
 
Mean age was 50.58 years (SD 7.35) and was similar in RA and OA patients. Over 
2/3’s of our study group were females. Disease duration did not differ significantly 
between RA and OA patients. 
Methotrexate was the most commonly prescribed DMARD for RA, with 62% of 
patients taking it. Just over half of the RA group were taking a biologic DMARD; 
etanercept was the most commonly prescribed one. Use of NSAIDs was significantly 
higher in the RA group and diclofenac was the most commonly prescribed NSAID. 
Quite a significant proportion of RA patients were taking corticosteroids at the time 
of study recruitment, however, mean doses were low and the maximum daily dose 
was 15mg. Statin use was approximately 20% in both groups. Use of other cardiac 
medications was similar in RA and OA patients. Bisphosphonates and calcium 
supplements were more commonly prescribed in RA patients 
A significantly higher proportion of OA patients had a family history of myocardial 
infarction. Later in the study we corrected for this, using logistic regression analysis, 
when comparing RA and OA patients with respect to presence of subclinical 
atherosclerosis. 
 
 
Unemployment rates were similar in the 2 groups, with just under 15% of RA 
patients unable to work to due to their disease, compared with 6% of the OA group. 
OA patients were more likely to have attended 3
rd
 level education. There is evidence 
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that level of education is linked to functional status in RA patients and inability to 
work due to disability is related to both the physical and psychological impact of a 
chronic illness (15, 16). 
 
Just over 50% of RA patients were either current or former smokers. Rates were 
similar in OA patients. A meta-analysis by Boyer et al found that cigarette smoking 
rates are higher in RA patients than the general population (2). Smoking cessation 
strategies need more attention in these groups and patient education regarding 
smoking risks should come not only from public health campaigns and general 
practitioners but also from their rheumatologist. 
 
Approximately 20% of both RA and OA patients had a prior diagnosis of 
hypertension. Prevalence of hypercholesterolaemia was similar in the 2 groups. 
There was 1 RA patient with diabetes mellitus and nobody in the OA group had it.  
 
A number of anthropometric measurements differed between the 2 groups. OA 
patients had a significantly higher BMI than RA patients and females with OA had a 
larger waist circumference, however waist hip ratio was similar in the 2 groups. 
Research has shown that low rather than high BMI in RA patients is associated with 
CV risk. Gabriel et al found a threefold increase in risk of cardiovascular death in 
RA patients with a low BMI and this remained after correction for traditional CV 
risks (17). This seems counter-intuitive but low BMI in RA patients reflects the 
rheumatoid cachexia associated with chronic inflammation that is linked to CV risk.  
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RA patients’ general health scores were worse than their OA counterparts. In 
particular, RA patients on steroids and with elevated CRP had worse general health.  
The Short Form 36 (SF-36) was summarized into physical and mental component 
scores. There was no difference in these scores between RA and OA patients. 
However, RA patients on biologic agents has significantly better mental component 
scores than those not on a biologic agent. 
The Short Form 36 is a generic measure of health status and quality of life and has 
been validated for use in RA (18). It gives a subjective measure of how the patient 
feels and not just a measure of their disease. Use of DMARD therapy in RA is 
associated with long-term beneficial effects on physical function and clinically 
meaningful improvements in Short Form 36 scores have been documented (19). 
 
We also collected data from a health assessment questionnaire (HAQ), a frequently 
used tool in RA patients in the clinical setting. Female patients with RA had a 
significantly worse HAQ than females with OA. Not surprisingly, we found that RA 
patients on corticosteroids reported a higher HAQ score than those not on 
corticosteroids. This reflects the fact that disease activity impacts on health quality in 
general.  
 
Also of interest is the fact that overweight OA patients reported a significantly 
higher HAQ score than those with a normal BMI. 
 
Both physician and patients’ assessment of disease activity and pain were assessed 
using visual analogue scales and RA patients fared worse in all these measures 
compared to OA patients. 
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While the mean DAS28ESR score, a measure of disease activity in RA, was not 
particularly high at 3.62, when DAS28ESR was analysed as a categorical variable 
quiet a significant proportion of RA patients had active disease, with 68% of them 
having a DAS28ESR of greater than 3.2. RA patients with a DAS28ESR of greater 
than 3.2 had significantly worse general health and quality of life scores. 
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
was used to assess patient pain and function in the OA group. OA patients being 
treated with anti-inflammatory medication did not have better scores than those not 
on NSAIDs. Not surprisingly, overweight and obese OA patients had worse pain and 
function scores than those with a normal BMI.  
 
 
Baseline Phlebotomy: 
 
OA patients had a higher corrected calcium concentration than RA patients, although 
calcium concentrations for both groups were in the normal reference range. Whether 
this is of any clinical relevance or not is not known. OA patients may have relatively 
higher serum calcium concentrations due to increased cartilage and bone turnover. 
 
Glomerular filtration rate was lower in the OA group. Reasons one might expect for 
this would be an older population or more extensive use of NSAIDs. However, mean 
age was similar in our RA and OA groups and current NSAID use was actually 
higher in the RA group. One potential reason for this difference in eGFR is that OA 
patients may have had a greater cumulative dose of NSAIDs since their diagnosis, 
however this is not information we had to hand at the time of analysis. 
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Albumin is a recognised marker of disease activity in RA and other chronic 
inflammatory states. It is therefore not surprising that levels correlated with ESR, 
white cell count, pro-inflammatory cytokine concentrations and disease activity 
scores. 
 
The relationship we found between smoking status and antibodies for RA are in line 
with numerous other studies (20, 21). Exposure to tobacco smoke is a known risk 
factor for the development of anti-CCP antibodies. Linn-Rasker et al found that 
tobacco exposure increased  the risk of developing anti-CCP antibodies only in RA 
patients who tested positive for the shared epitope, suggesting that this relationship is 
specific for RA patients, as they did not such a relationship with undifferentiated 
arthritis (20).  
 
Fasting lipid and glucose profiles were similar in RA and OA patients. Concerning 
though is the number of patients with an elevated serum fasting cholesterol who are 
not on standard treatment.  
 
It was interesting to note that RA females had a more favourable lipid profile than 
RA males. As expected, abnormalities of lipid profile tended to cluster with other 
CV risks. RA smokers had higher concentrations of triglycerides than non-smokers. 
BMI was also related to triglyceride concentrations. 
Triglyceride levels were worse in sero-positive RA patients. RA patients who are 
anti- CCP antibody positive have a more aggressive form of the disease and it makes 
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sense that these patients who suffer from more extensive extra-articular 
manifestations, are also at a higher CVD risk than sero-negative RA patients. 
A study of 80 RA patients by Arnab et al reported that anti-CCP antibody was 
associated with subclinical atherosclerosis, in the form of carotid intima-media 
thickness and also with left ventricular diastolic dysfunction, while this association 
was not seen in RA patients who were anti-CCP antibody negative (22). 
HLD concentrations in both our RA and OA groups correlated negatively with PAI-
1, a marker of thrombosis. PAI-1 concentrations, along with other inhibitors of the 
fibrinolytic system, are associated with increased CVD risk in the general population 
(23). Coagulation factors have been found in higher circulating concentrations in RA 
patients and a diagnosis of RA can predict increased levels of PAI-1 (24).  
Our finding of an association between lipid profile and markers of thrombosis 
support the multifactorial nature of CVD development.  
 
 
RA patients with evidence of atherosclerotic plaque on ultrasound had a more 
abnormal lipid profile than those with no plaque. As discussed in more detail in 
chapter 6 on subclinical atherosclerosis, serum LDL appears to be a marker for 
subclinical carotid atherosclerosis in RA patients. This finding reinforces the 
importance of thorough screening for CV risks. 
 
Although the association we found between LDL and carotid disease was just for the 
presence of plaque, other recent studies have also reported a correlation with carotid 
intima-media thickness (cIMT) (25, 26).  
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Fasting glucose also correlated with subclinical atherosclerosis in the RA group. 
Diabetes has been linked to the presence of carotid disease in RA patients without 
overt cardiovascular symptoms. Ajeganova et al found that cIMT after a 5 year 
follow-up period was associated with a diagnosis of diabetes in RA patients (27). In 
2005, Del Rincon et al also described an strong association between diabetes and 
sub-clinical carotid disease in RA patients (28).  
The presence of diastolic dysfunction was associated with a less favourable lipid 
profile in the RA group. Serum LDL concentrations were higher in those with 
evidence of diastolic dysfunction on transthoracic echocardiography. These findings 
tie in with research in the general population that has found an association between 
risk of diastolic heart failure and presence of hyperlipidaemia (29, 30). 
Aiming for strict targets with respect to lipid concentrations, may have favourable 
effects not only atherosclerotic burden but also myocardial function.  
We have shown that both RA and OA patients have features of the metabolic 
syndrome which go unrecognised in the rheumatology clinic. A recent meta-analysis 
of metabolic syndrome in RA by Zhang J et al identified a significant association  
between  these 2 diseases, with an overall odds ratio of 1.24 (95% CI, 1.03, 1.50) 
(31).  
 
The US National HANES study reported that metabolic syndrome was more 
prevalent in patients with OA (32). Also, the Michigan Bone Health and Metabolism 
Study found that 2 or more cardiometabolic risk factors were associated with 
persistent knee pain in obese females (33). 
 
 159 
 
ECG:  
 
On electrocardiogram examination, we did not find incident atrial fibrillation (AF) or 
any other arrhythmia. Lindhardsen et al conducted a large scale population based 
study and found that of 18,247 patients, who developed RA over a 13 year period, 
744 developed atrial fibrillation and 718 developed stroke (34). They reported that 
the overall incidence of AF in RA patients was 40% higher than in the general 
population. The absolute risk ranged from 25% to 70%, depending on patient age. 
However, the strength of the association that Lindhardsen et al found is limited by 
that fact that information on traditional cardiovascular risk factors, potential 
confounders, was not always available. It would be interesting in the future to 
follow-up our RA cohort over time to assess the incidence of AF and other 
arrhythmias and compare with the above study. 
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Conclusions: 
 
As described above, RA patients tend to have worse general health and disease 
activity scores than OA patients. Also, general health measures give us useful 
information regarding wellbeing and physical functioning. They highlight that 
DMARD usage has health benefits that extends beyond merely controlling RA 
disease activity.  
 
We found a high rate of smoking, past and present, in both groups. This is an 
important modifiable risk factor to concentrate on in general and also in particular in 
sero-positive RA patients because smoking is linked to seropositive disease, which is 
the more aggressive form of RA. 
 
The lower BMI in our RA group and the fact that this has been shown to be 
associated with increased CV risk in other studies, highlights the point that RA 
patients may not have the typical body habitus of patients we consider to be at 
increased CV risk. Rheumatologists need to be cognisant of the fact that even though 
RA patients may not be overweight, they are still at an increased risk of future CV 
events.  
The number of both RA and OA patients who had an elevated fasting serum 
cholesterol and were not on treatment demonstrates that traditional CV risks are not 
being targeted appropriately by rheumatologists. There are 2 reasons for this; either 
rheumatologists are so consumed with controlling disease activity and concentration 
on monitoring patients on a multitude of DMARD medications that they do not 
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consider CV screening or patients are screened for CV risks but we are unequipped 
to deal with actual management of these risks. 
 
 
The associations we found between anti-CCP antibody positivity and lipid profile in 
RA patients reinforces the importance of assessing CV risks in RA patients, in 
particular those who are sero-positive.  
 
 
Metabolic syndrome exists in conjunction with inflammatory arthritis but is not 
being recognised during routine clinical assessment. Education of health care staff 
regarding the features of metabolic syndrome should improve this and hence have a 
positive impact on overall cardiovascular health in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 162 
 
References: 
 
1. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. 
Hypertension in rheumatoid arthritis. Rheumatology. 2008;47(9):1286-98. Epub 
2008/05/10. 
2. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. 
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint, 
bone, spine : revue du rhumatisme. 2011;78(2):179-83. Epub 2010/09/21. 
3. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, 
Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for 
cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid 
arthritis patients? Annals of the rheumatic diseases. 2008;67(1):64-9. Epub 
2007/05/23. 
4. Toms TE, Panoulas VF, Smith JP, Douglas KM, Metsios GS, Stavropoulos-
Kalinoglou A, et al. Rheumatoid arthritis susceptibility genes associate with lipid 
levels in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 
2011;70(6):1025-32. Epub 2011/03/15. 
5. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic 
review of the effect of TNF-alpha antagonists on lipid profiles in patients with 
rheumatoid arthritis. Clinical rheumatology. 2010;29(9):947-55. Epub 2010/04/13. 
6. Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, 
Nurmohamed MT. Beneficial effect of 1-year etanercept treatment on the lipid 
 163 
 
profile in responding patients with rheumatoid arthritis: the ETRA study. Annals of 
the rheumatic diseases. 2010;69(11):1929-33. Epub 2010/05/26. 
7. H-L. R. A study of the effect of tocilizumab on markers of atherogenic risk in 
patients with moderate to severe rheumatoid arthritis. 
http://clinicaltrials.gov/show/NCT00535782  
8. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, 
et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, 
randomised placebo-controlled trial. Lancet. 2004;363(9426):2015-21. Epub 
2004/06/23. 
9. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. 
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis 
and systemic lupus erythematosus define potential mechanisms. Arthritis and 
rheumatism. 2008;58(7):2105-12. Epub 2008/06/26. 
10. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. 
Relationship to insulin resistance of the adult treatment panel III diagnostic criteria 
for identification of the metabolic syndrome. Diabetes. 2004;53(5):1195-200. Epub 
2004/04/28. 
11. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. 
Association between disease-modifying antirheumatic drugs and diabetes risk in 
patients with rheumatoid arthritis and psoriasis. JAMA : the journal of the American 
Medical Association. 2011;305(24):2525-31. Epub 2011/06/23. 
 164 
 
12. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, 
duration, and cessation, and the risk of rheumatoid arthritis in women. The American 
journal of medicine. 2006;119(6):503 e1-9. Epub 2006/06/06. 
13. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and 
rheumatoid arthritis. Seminars in arthritis and rheumatism. 2001;31(3):146-59. Epub 
2001/12/12. 
14. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol 
Education Program - Adult Treatment Panel III, International Diabetes Federation, 
and World Health Organization definitions of the metabolic syndrome as predictors 
of incident cardiovascular disease and diabetes. Diabetes care. 2007;30(1):8-13. 
Epub 2006/12/29. 
15. Callahan LF, Pincus T. Formal education level as a significant marker of 
clinical status in rheumatoid arthritis. Arthritis and rheumatism. 1988;31(11):1346-
57. Epub 1988/11/01. 
16. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in 
rheumatoid arthritis is predicted by physical and psychological health status: a 7-year 
study from the Oslo RA register. Scandinavian journal of rheumatology. 
2005;34(6):441-7. Epub 2006/01/06. 
17. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. 
Annals of the rheumatic diseases. 2010;69 Suppl 1:i61-4. Epub 2010/01/09. 
18. Jenkinson C, Layte R, Coulter A, Wright L. Evidence for the sensitivity of 
the SF-36 health status measure to inequalities in health: results from the Oxford 
 165 
 
healthy lifestyles survey. Journal of epidemiology and community health. 
1996;50(3):377-80. Epub 1996/06/01. 
19. Strand V. Longer term benefits of treating rheumatoid arthritis: assessment of 
radiographic damage and physical function in clinical trials. Clinical and 
experimental rheumatology. 2004;22(5 Suppl 35):S57-64. Epub 2004/11/24. 
20. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg 
M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies 
only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. 
Annals of the rheumatic diseases. 2006;65(3):366-71. Epub 2005/07/15. 
21. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et 
al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-
DR (shared epitope)-restricted immune reactions to autoantigens modified by 
citrullination. Arthritis and rheumatism. 2006;54(1):38-46. Epub 2005/12/31. 
22. Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P. Anti-
CCP antibody in patients with established rheumatoid arthritis: Does it predict 
adverse cardiovascular profile? Journal of cardiovascular disease research. 
2013;4(2):102-6. Epub 2013/09/13. 
23. Fibrinogen Studies C, Danesh J, Lewington S, Thompson SG, Lowe GD, 
Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular 
diseases and nonvascular mortality: an individual participant meta-analysis. JAMA : 
the journal of the American Medical Association. 2005;294(14):1799-809. Epub 
2005/10/13. 
 166 
 
24. Dimitroulas T, Douglas KM, Panoulas VF, Toms T, Smith JP, Treharne GJ, 
et al. Derangement of hemostasis in rheumatoid arthritis: association with 
demographic, inflammatory and metabolic factors. Clinical rheumatology. 
2013;32(9):1357-64. Epub 2013/05/16. 
25. Solomon A, Woodiwiss AJ, Abdool-Carrim AT, Stevens BA, Norton GR, 
Dessein PH. The carotid artery atherosclerosis burden and its relation to 
cardiovascular risk factors in black and white Africans with established rheumatoid 
arthritis: a cross-sectional study. The Journal of rheumatology. 2012;39(9):1798-806. 
Epub 2012/07/04. 
26. Targonska-Stepniak B, Drelich-Zbroja A, Majdan M. The relationship 
between carotid intima-media thickness and the activity of rheumatoid arthritis. 
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal 
diseases. 2011;17(5):249-55. Epub 2011/07/23. 
27. Ajeganova S, Ehrnfelt C, Alizadeh R, Rohani M, Jogestrand T, Hafstrom I, et 
al. Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine 
are independently associated with carotid artery atherosclerosis 5 years after 
rheumatoid arthritis onset--a prospective cohort study. Rheumatology. 
2011;50(10):1785-93. Epub 2011/07/12. 
28. del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative 
contribution of cardiovascular risk factors and rheumatoid arthritis clinical 
manifestations to atherosclerosis. Arthritis and rheumatism. 2005;52(11):3413-23. 
Epub 2005/10/29. 
 167 
 
29. Gianotti G, Cenni A, Bianchi G, Masetti M, Zappoli P, Muscari A, et al. 
Diastolic dysfunction and cardiovascular risk in old subjects: Possible association 
with NAFLD? Archives of gerontology and geriatrics. 2014;58(2):188-95. Epub 
2013/11/26. 
30. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler 
RJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic 
function independent of left ventricular mass. European heart journal. 
2007;28(5):553-9. Epub 2007/02/22. 
31. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, et al. The risk of metabolic 
syndrome in patients with rheumatoid arthritis: a meta-analysis of observational 
studies. PloS one. 2013;8(10):e78151. Epub 2013/11/10. 
32. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of 
cardiovascular disease risk factors among US adults with self-reported osteoarthritis: 
data from the Third National Health and Nutrition Examination Survey. The 
American journal of managed care. 2002;8(15 Suppl):S383-91. Epub 2002/11/06. 
33. Sowers M, Karvonen-Gutierrez CA, Palmieri-Smith R, Jacobson JA, Jiang 
Y, Ashton-Miller JA. Knee osteoarthritis in obese women with cardiometabolic 
clustering. Arthritis and rheumatism. 2009;61(10):1328-36. Epub 2009/10/01. 
34. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen 
JH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish 
nationwide cohort study. Bmj. 2012;344:e1257. Epub 2012/03/10. 
 
 
 168 
 
Chapter 4 
 
Serum, Plasma and Urinary Markers of Inflammation, Endothelial 
Dysfunction and Thrombosis  
 
Introduction: 
 
Atherosclerotic plaques have characteristics similar to the inflamed joint in RA. 
They both display enhanced expression of adhesion molecules and pro-inflammatory 
cytokine-secreting cells (1). Endothelial dysfunction, the earliest stage of 
atherosclerosis, has been reported in RA patients, independent of their age, duration 
of disease and disease activity (2). 
It is now widely accepted that systemic markers of inflammation are independent 
predictors of coronary heart disease in adults with or without pre-existing heart 
disease (3). 
There is a wide range of biomarkers currently available for the assessment of 
inflammation, endothelial function and altered coagulation. Some, including PAI-1 
and CRP are used in the clinical setting to assess CVD risk while others, such as pro-
inflammatory cytokines and adhesion molecules tend to be utilised in the research 
setting. 
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Traditional Inflammatory markers in CVD: 
 
ESR and CRP are non-specific inflammatory markers, but when elevated predict 
future cardiovascular events and mortality in RA patients (4, 5), and in the general 
population (6). Gabriel et al, in a prospective study of 603 RA patients, reported a 
two-fold higher hazard of cardiovascular death in RA patients with 3 or more ESR 
measurements of ≥ 60mm/hr (7).  
CRP is often considered merely as a marker of inflammation; however there is 
evidence to support its role as a strong inflammatory mediator. In inflamed 
tissues, CRP activates immune cells and is involved in triggering a cascade of 
events, including chemokine release from monocytes and up-regulation of 
adhesion molecules (8). Multiple prospective studies of healthy subjects have 
shown that CRP predicts myocardial infarction mortality (9) and stroke (10). 
Danesh J et al previously showed that after correction for age, smoking and other 
cardiovascular risk factors, CRP was still strongly associated with CVD(11). 
 
Hyperuricaemia is associated with coronary heart disease, stroke and 
hypertension, however it is still unclear whether serum uric acid level is an 
independent risk factor for cardiovascular disease (12). Kim et al, in a recent 
meta-analysis, found a modest association between elevated uric acid levels and 
CHD events. This was independent of traditional CVD risk factors and was more 
pronounced in females (12). 
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Cardiovascular risk appears not only to be associated with elevated levels of uric 
acid but also with levels in the accepted normal reference ranges (13). 
Feig et al report that the association between uric acid and CVD remains 
controversial, with Framingham Heart Study experts arguing that it should not be 
relied on as a risk factor (14). The general consensus currently is that 
asymptomatic hyperuricaemia should not be treated with allopurinol and futher 
research is required to gain understanding of the biologic function of uric acid. 
 
Adhesion molecules in RA and CVD: 
 
Measurement of adhesion molecule levels is one method of assessing endothelial 
function. Adhesion molecules are biomarkers of endothelial activation and activated 
endothelial cells express increased amounts of V-CAM and I-CAM and selectins. 
These molecules are involved in monocyte adherence and rolling to the endothelial 
surface (15). Selectins mediate the initial ‘tethering’ of leucocytes to the endothelial 
layer, while integrins and members of the immunoglobulin superfamily, V-CAM and 
I-CAM are responsible for firm adhesion and transendothelial migration of 
leucocytes (16).  
 
All selectins and members of the immunoglobulin superfamily are also abundantly 
expressed in arthritic synovial tissues (17). Cell to cell and cell to extracellular 
matrix interactions via adhesion molecules are important in the role of synovial 
 171 
 
inflammation. However, further studies in arthritis are required to define their role 
and whether they may be potential therapeutic targets. 
The clinical usefulness of adhesion molecules is debatable at present. There is 
evidence that they may not yield any additional information in CV risk above and 
beyond that which traditional risk factors already provide (18). 
 
 
Cytokines in RA and CVD: 
 
A number of pro-inflammatory cytokines are particularly involved in RA 
pathogenesis, these include TNFα, IL1 and IL6. They are all found in abundance in 
the synovium and serum of RA patients and correlate with disease activity. They are 
in a position to alter function at distant tissues, including the vascular endothelium 
and as a result they are capable of generating a variety of pro-atherogenic changes 
including endothelial dysfunction, prothrombotic effects, pro-oxidative stress and 
dyslipidaemia (19). 
Over the last 2 decades, multiple therapies for RA have been developed to target 
these cytokines and their effects have revolutionised the treatment and prognosis of 
RA (20).  
 
TNFα also plays a pivotal role in the pathogenesis of CV disease. Advanced 
glycation end-products (AGEs), receptor for AGEs (RAGE) and NF-κB signalling 
play key roles in increasing both circulating and local vascular TNFα production. 
The resulting increase in TNFα expression induces the production of reactive oxygen 
species and this triggers the onset of endothelial dysfunction, now recognized as the 
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earliest stage of atherosclerosis (21). In animal studies, TNFα gene knockout mice 
have less endothelial activation (22) and a decrease in the extent of atherosclerosis 
(23). 
Coupled with TNFα’s effect on inflammatory and endothelial cells, it also induces 
insulin resistance, dyslipidaemia and a prothrombotic state (24). 
Investigation of IL-6 associations with CVD has been less extensive, as its effects 
may be more difficult to determine. This is due to its short half-life of 2 hours and 
large within-person variability. It is a proximal mediator in the inflammatory cascade 
compared to the further downstream CRP and fibrinogen. Jenny et al reported that 
increases in IL-6 were associated with increased risk of cardiovascular events in 
healthy elderly patients (25). In 2008 Danesh et al published a population based long 
term study (part of the Reykjavik and British Regional Heart Studies) which found 
that long-term IL-6 concentrations were associated with CHD, with risk comparable 
to some major established risk factors but causality was not proven (26). They 
reported an adjusted odds ratio for CHD in the combined studies of 1.46 (CI95%), 
(1.29, 1.65) for each 2 standard deviation increase in baseline IL-6 levels.  
 
Interleukin-6 has also been shown to correlate with markers of sub-clinical 
atherosclerosis in the general population. Szklo M et al found higher IL-6 
concentrations in healthy controls with carotid atherosclerosis. However they did not 
find the same association in RA patients (27).  
In a large follow-up study of 3035 adults in the Framingham Heart Study, Benjamin 
EJ et al found that both TNFα and IL-6 concentrations were related to cardiovascular 
mortality (28). 
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Interleulin-1 is one of the primary pro-inflammatory cytokines in RA and stimulates 
synovial cell synthesis of IL-6 (29). It is also one of the main cytokines involved in 
the pathogenesis of atherosclerosis and has many atherogenic effects. These include 
enhanced expression of cell surface adhesion molecules and selectins on endothelial 
cells, smooth muscle cells and marcophages. It is also involved in the production of 
reactive oxygen species and inducing cell proliferation (30).. 
 
Van Tassel et al recently reported that the expression of IL-1α and IL-1β appear to 
correlate with the progression of atherosclerotic plaques, with minimal expression in 
healthy coronary arteries and high expression in complicated plaques (31). IL-1β is 
difficult to measure in plasma so there are few studies showing an increased level in 
patients with a greater atherosclerotic burden (32, 33). 
Anti-IL-1 therapy in cardiovascular disease is still in its infancy but preliminary data 
suggests a beneficial role in atherosclerosis and atherothrombosis (34, 35). 
 
 
Markers of thrombosis in RA and CVD: 
 
The plasminogen activator / plasmin system is an endogenous defence mechanism 
against intravascular thrombosis (36). The most important inhibitor of this system is 
plasminogen activator inhibitor-1 (37). It has been classified as an acute phase 
reactant and inflammatory cytokines such as TNFα have been shown to trigger its 
production (38). Inflammation can initiate clotting mechanisms and reduce the 
body’s natural anticoagulant mechanisms (39).  
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There is a significant amount of evidence that inhibitors of the fibrinolytic system, 
including PAI-1 (40-42) are associated with an increased CVD risk in the general 
population. PAI-1 activity is heightened in people post-myocardial infarction who go 
on to develop a further MI (43). 
 
More recently, there is also evidence of abnormalities in the coagulation system 
correlating with CVD in RA populations. George Kitas et al examined a panel of 
coagulation markers in 141 RA patients and 50 controls and found that coagulation 
factors were higher in RA patients and having a diagnosis of RA predicting 
increased levels of tPA, PAI-1 and fibrinogen, independent of age and sex (44). 
Some earlier studies of coagulation in RA found similar results (45, 46). 
This link between abnormal coagulation and inflammation may be one of the 
mechanisms by which CVD risk is increased in RA. 
 
 
Urinary protein as a marker of vascular disease in general and RA: 
 
 
Endothelial dysfunction is involved in the development of microalbuminuria. 
Structural changes in the glomerulus over time results in microalbuminuria 
transitioning from a reversible to a fixed entity (47). It is a marker of 
microvasculopathy and has been shown to be associated with an increased risk of 
stroke and cardiovascular outcomes (48).  
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The connection between markers of inflammation, endothelial function and 
coagulation in RA has not been studied in detail in an Irish population. Therefore, we 
examined our RA group with respect to the above and tried to identify if RA patients 
were more prone to disorders of endothelial function and coagulation than OA 
controls. 
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Aims: 
 
 To compare ESR, CRP, serum urate, as markers of inflammation and 
cardiovascular disease in RA and OA.  
 To compare serum concentrations of adhesion molecules and inflammatory 
cytokines in RA and OA patients. 
 To examine both groups for any association between concentrations of 
adhesion molecules and cytokines and cardiovascular disease risks and pre-
clinical markers of atherosclerosis.  
 To investigate if markers of thrombosis; plasminogen activator -1 and 
fibrinogen were different in RA and OA patients or were associated with 
cardiovascular risks in either group.  
 To investigate urinary measures of protein in RA and OA patients and to 
assess their use as potential CV markers.  
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Methods: 
 
Blood was drawn for ESR, CRP, urate, fibrinogen, PAI-1 activity, PAI-antigen, 
serum cytokine and adhesion molecule concentrations.  
ESR and fibrinogen samples were analysed by the haematology laboratory in CUH 
in the usual manner. CRP and serum urate were analysed in the usual manner by the 
biochemistry department in CUH. 
 
 
Cytokine and Adhesion Molecule Analysis: 
 
The cytokine profile of each serum sample was analysed quantitatively using a 
multiplex chemi-luminescent array (Randox), a high fidelity system capable of 
determining the concentration of IL-1α, -1β, -2, -4, -6, -8, -10, TNFα, IFNγ, VEGF, 
EGF and MCP-1. The protocol followed the manufacturer’s instructions and entailed 
the incubation of 100 µl of un-diluted sample, calibrator or control on a biochip pre-
coated with immobilized capture antibody, to which 200 µl of assay diluents had 
been added. Following a 1 hour incubation at 37°C on a thermoshaker (370 rpm) 
each well was washed twice with wash buffer (Tris buffered saline) and 300 µl of 
conjugate (HRP-labelled detection antibodies) was added. This was incubated for a 
further hour at 37 °C on the thermoshaker (370 rpm) prior to 2 further washes. At 
this time 250 µl of a 1:1 combination of luminal and peroxide was added and 
incubated in the dark for 2 minutes. Samples were then analysed using the 
EVIDENCE Investigator platform. EVIDENCE software was then used to determine 
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the intercalated x-values from the resultant standard curve, the results expressed as 
pg/ml. 
The same multiplex chemi-luminescent immunoassay (Randox) was used to analyse 
the adhesion molecule profile. The Randox adhesion molecule biochip array 
simultaneously and quantitatively measured E-selectin, L-selectin, P-selectin, 
intracellular adhesion molecue-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1). 
 
PAI-1  analysis: 
 
A blood sample was taken and collected in a plastic tube containing sodium citrate to 
measure PAI-1 activity and PAI-1 antigen levels. Blood samples were centrifuged at 
5000 rpm for 20 minutes at 4 degrees Celsius. The upper 2/3’s of plasma was 
extracted from the sample and this was re-centrifuged for a further 20 minutes to 
remove any platelets. Again the upper 2/3’s was removed and divided into aliquots. 
Three 500 μl aliquots were collected for each patient. Aliquots were transferred on 
ice for storage in a minus 80 degree Celsius freezer and stored for analysis at a later 
stage.  
When samples were collected for all the study recruits, the aliquots of frozen plasma 
were transported on dry ice to Professor Nuala Booth, Department of Molecular and 
Cell Biology, University of Aberdeen, Institute of Medical Sciences. PAI-1 antigen 
level was measured by quantitative ELISA and a specific activity assay was utilized 
to measure PAI-1 activity levels according to the manufacturer’s instructions. 
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Urine for albuminuria measurement: 
 
An early morning urine sample of at least 20mls was collected from each patient for 
measurement of urinary protein-creatinine ratio and microalbuminuria by 
standardised methods in the biochemistry department of CUH. 
 
Statistical Methods: 
 
Means and standard deviations were calculated for normally distributed data and 
compared using a student t-test. Medians and interquartile ranges were calculated for 
non-normally distributed data and compared using a Mann Whitney U test. Bivariate 
correlations were calculated for continuous variables. Logistic regression analysis 
was performed to analyse the relationship between the presence of subclinical 
carotid atherosclerosis, peripheral vascular disease, ultrasound evidence of 
endothelial dysfunction and diastolic dysfunction and haematological markers of 
inflammation, endothelial dysfunction and thrombosis in Rheumatoid Arthritis and 
osteoarthritis. Odds ratios and 95% confidence intervals were computed. A p-value 
of <0.05 was considered significant.
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Results for Routine Inflammatory Markers: 
 
 
Comparison of ESR, CRP and Urate in RA and OA: 
 
 Neither ESR nor CRP was normally distributed in the study group so median values 
are quoted and nonparametric tests used for comparisons. Median ESR in the RA 
group was 18 mm/hr (7 – 25) compared with 7 mm/hr (5 – 11) in the OA group, p 
<0.000. CRP was significantly higher in patients with RA compared to those with 
OA, 6.2 mg/l (5 – 16.05) compared with 5 mg/l (2 – 6), p=0.000. 
Serum urate was similar in RA and OA patients, 281 Umol/l (SD 79) compared with 
278 Umol/l (SD 61), p=0.782. Males had a significantly higher serum urate than 
females in both groups, p=0.000. Six RA patients and 3 OA patients had 
hyperuricaemia, this difference was not significant, p = 0.728, Fisher’s exact test.  
 
 
ESR, CRP and Urate Levels and RA Serological Markers and Anti-Rheumatic 
Medications: 
 
Median ESR was significantly higher in RA patients not on a DMARD at the time of 
the study, p=0.010 (table 4.1). CRP was significantly lower in RA patients on a 
biologic treatment compared to those not taking a biologic, 5 mg/l (5 – 11.6) versus 
11.6 mg/l (5.3 – 18.9), p=0.007. RA patients on steroids had a significantly higher 
CRP than those not on steroids, 11.6 mg/l (5 – 25.7) compared with 5 mg/l (5 – 
 181 
 
11.6), p=0.041. RA patients on DMARDS, biologic agents, steroids or NSAIDs had 
similar serum urate levels to those not taking the above medications. 
 
ESR, CRP and serum urate levels were similar in sero-positive and sero-negative RA 
patients. 
 
 
 
  ESR, mm/hr (IQR) p 
DMARD Yes 13 (7 – 23) 0.010* 
No 25 (20 – 35) 
Biologic agent Yes 16 (5 -26) 0.798 
No 18 (8 – 25) 
NSAID Yes 18 (7 – 25) 0.720 
No 14 (6 – 28) 
Steroid Yes 18 (8 – 32) 0.326 
No 16 (5 – 25) 
 
 
Table 4.1: comparison of ESR level across the different treatment categories in the 
RA group 
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ESR, CRP and Urate levels and Markers of Cardiovascular Disease in RA: 
 
 
Serum urate concentrations were significantly higher in overweight RA patients 
compared with their normal weight counterparts (table 4.2). There was a significant 
correlation between waist circumference and serum urate in the RA group, r =0.603, 
p=0.000 (figure 4.1). RA patients with abdominal obesity, as defined by an elevated 
waist hip ratio, had a significantly higher serum urate than RA patients with a normal 
waist hip ratio (table 4.2). We found no associations between ESR, CRP and 
anthropometric variables.  
Fasting glucose and lipid profile correlated significantly with serum urate in the RA 
group (table 4.3). There was no significant correlation between ESR, CRP and 
fasting blood profile.  
ESR and CRP correlated significantly with fibrinogen levels in the RA group, r = 
0.454, p < 0.000 and r = 0.455, p < 0.000. RA patients with an elevated PAI-1 
antigen level had a significantly higher CRP and serum urate than those with a PAI-1 
in the normal reference range, 14 mg/l (12 – 22.45) compared with 5 mg/l (5 – 
13.15), p=0.007 for CRP and 329 Umol/l (SD 41) compared with 266 Umol/l (SD 
84), p = 0.002 for urate.  
 
RA patients with endothelial dysfunction, abnormal carotid intima media thickness 
or diastolic dysfunction did not have significantly different ESR or CRP readings to 
those RA patients without evidence of endothelial dysfunction, carotid 
atherosclerosis or diastolic dysfunction,  p=0.867, p=0.480, p=0.495 for ESR and p 
=0.440, p=0.263, p=0.622 for CRP.  
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Using logistic regression analysis, the presence of diastolic dysfunction, subclinical 
carotid atherosclerosis, abnormal ankle brachial index and endothelial dysfunction in 
the RA group, were not found to be associated with ESR, CRP or serum urate (table 
4.4). 
 
 
  Serum Urate 
Umol/l (SD) 
p 
RA High BMI 307 (81) 0.005* 
Normal BMI 250 (64) 
RA High waist hip ratio 315 (62) 0.001* 
Normal waist hip ratio 245 (80) 
 
 
 
Table 4.2: Comparison of serum urate in RA patients with normal and high BMI and 
normal and high waist hip ratio. SD, standard deviation; p, significance level; BMI, 
body mass index (kg/m
2
) 
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Figure 4.1: Correlation between waist circumference and serum urate in RA patients 
 
 
 
 
 
 
 
R = 0.603 
P <0.000 
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 Correlation with serum urate, r P 
Fasting glucose 0.294 0.027* 
Fasting cholesterol 0.138 0.306 
Serum LDL 0.295 0.034* 
Serum HDL -0.337 0.014* 
Serum triglycerides 0.377 0.005* 
 
 
Table 4.3: Association between serum urate and fasting glucose and lipid profile in 
RA patients 
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Table 4.4: Association of cardiovascular disease markers with ESR , CRP and serum 
urate in the RA group, using logistic regression; OR, odds ratio; CI, confidence 
interval 
 
 
 
 
 
 
 
 
 ESR 
OR (95%CI) 
p CRP 
OR (95%CI) 
p Urate 
OR (95%CI) 
p 
Diastolic  
Dysfunction 
1.01  
(0.97, 1.06) 
0.64
7 
0.99 
 (0.95, 1.05) 
0.925 1.01  
(0.99, 1.02) 
0.084 
Subclinical  
carotid atherosclerosis 
0.93  
(0.86, 1.02) 
0.13
6 
1.07  
(0.99, 1.14) 
0.056 1.00 
 (0.99, 1.01) 
0.648 
Peripheral vascular  
disease 
1.03  
(0.99, 1.06) 
0.15
5 
1.01 
 (0.96, 1.07) 
0.653 0.99  
(0.98, 1.0) 
0.145 
Endothelial  
dysfunction 
1.00  
(0.96, 1.05) 
0.68
7 
1.00  
(0.96, 1.05) 
0.858 1.00 
 (0.99, 1.01) 
0.520 
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ESR, CRP and Urate in OA: 
 
 
Using logistic regression analysis, the presence of diastolic dysfunction, subclinical 
carotid atherosclerosis, abnormal ankle brachial index and endothelial dysfunction in 
the OA group, were not found to be associated with ESR, CRP or serum urate (table 
4.5). 
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 Table 4.5: Association of cardiovascular disease markers with ESR ,CRP and urate 
in the OA group, using logistic regression; OR, odds ratio; CI, confidence interval.  
 
 
 
 
 
 ESR 
OR (95%CI) 
p CRP 
OR 
(95%CI) 
p Urate 
OR (95%CI) 
p 
Diastolic  
Dysfunction 
0.96  
(0.86, 1.07) 
0.478 1.01  
(0.82, 
1.25) 
0.923 1.01 
(0.99, 1.02) 
0.197 
Subclinical 
carotid  
atherosclerosis 
0.82  
(0.63, 1.07) 
0.150 1.08  
(0.82, 
1.43) 
0.590 1.01  
(0.99, 1.02) 
 
0.403 
Peripheral 
vascular  
disease 
0.91 
 (0.67, 1.24) 
0.547 0.89  
(0.49, 
1.59) 
0.683 0.97 
(0.94, 1.01) 
0.151 
Endothelial  
dysfunction 
0.93  
(0.80, 1.02) 
0.344 0.98 
 (0.74, 
1.30) 
0.882 1.00 
(0.99, 1.02) 
0.531 
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Adhesion molecules Results: 
 
Comparison of Adhesion Molecule Concentrations in RA and OA: 
 
 
Serum samples were collected for 5 adhesion molecules; VCAM, ICAM, E-selectin, 
P-selectin, L-selectin. Mean values in the RA and OA groups were compared using 
an independent t-test (table 4.6).  RA patients had significantly higher concentrations 
of VCAM and P- selectin compared to OA patients. RA patients had significantly 
lower concentrations of L-selectin than OA patients. The concentrations of adhesion 
molecules were similar in males and females.  
 
 
 
Table 4.6: Comparison of adhesion molecule concentrations in RA and OA patients 
 
Adhesion molecules RA  
 
OA 
  
 P value 
Mean VCAM, ng/ml (SD) 704.74 (329.98) 559.77 (182.10) 0.004 * 
Mean ICAM, ng/ml (SD) 292.26 (155.84) 268.19 (91.79) 0.325 
E – selectin, ng/ml (SD) 17.97 (7.47) 15.82 (5.82) 0.267 
P – selectin,  ng/ml (SD) 172.71 (79.15) 144.75 (52.40) 0.029 * 
L – selectin,  ng/ml (SD) 1089.54 (365.08) 1213.89 (280.25) 0.047* 
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Adhesion Molecule Concentrations and RA Serological Markers and Anti-
Rheumatic Medications: 
 
 
RA patients on biologic agents, DMARDS, NSAIDS and steroids were compared to 
those not on the above treatments and no difference was found with respect to serum 
levels of VCAM or ICAM. Current dose of prednisolone did correlate with serum 
VCAM levels, r = -0.286, p=0.024. RA patients who were on steroids at the time of 
the study also had a significantly lower serum L-selectin than RA patients not on 
steroids, 974.41 ng/ml (SD 310.60) versus 1184.36 ng/ml (SD 383.31), p = 0.020. 
Current steroid dose correlated significantly with serum L-selectin level, r = -0.361, 
p = 0.004. Otherwise, we found no difference in serum levels of the selectins with 
respect to anti-rheumatic medication.  
 
Serum VCAM was found to be significantly higher in RA patients who were anti-
CCP antibody and rheumatoid factor positive compared to those were antibody 
negative and serum ICAM was significantly higher in patients with a positive 
rheumatoid factor (table 4.7).  Rheumatoid factor level correlated significantly with 
serum levels of VCAM and ICAM, r=0.358, p=0.004 and r = 0.382, p = 0.003, 
respectively. Serum E-selectin significantly correlated with CRP and rheumatoid 
factor, r = 0.253, p=0.047 and r =0.341, p=0.007, respectively. 
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  Mean VCAM 
Ng/ml (SD) 
p Mean ICAM 
Ng/ml (SD) 
P 
RA Anti-CCP positive 748.82 (351.58) 0.017* 299.60 (111.92) 0.666 
Anti-CCP negative 566.63 (203.33) 268.68 (102.22) 
RA Rheumatoid factor positive 739.46 (346.07) 0.027* 312.31 (164.33) 0.001* 
Rheumatoid factor 
negative 
560.10 (205.02) 204.78 (59.91) 
 
 
 
Table 4.7: Comparison of serum VCAM and ICAM levels in sero-negative and sero-
positive RA patients.  
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Adhesion Molecule Concentrations and Cardiovascular Markers in RA: 
 
 
ICAM concentration in the RA group correlated significantly with smoking pack 
years, r = 0.307, p = 0.018. P-selectin was found to be elevated in RA smokers 
compared with RA non-smokers, 189.97ng/ml (SD89.64) versus 151.76ng/ml 
(SD59.19), p=0.049 and levels also correlated with smoking pack years, r=0.264, 
p=0.038. 
Both E- and P- selectin were associated with systolic blood pressure (table 4.8). 
Body mass index and waist circumference were significantly associated with serum 
L-selectin level in the RA group, r = - 0.382, p = 0.002 and r = -0.332, p = 0.008. 
This association was not seen in the OA group.  
Total cholesterol and serum urate were also associated with low levels of L-selectin 
in the RA group, r = - 0.276, p = 0.030 and r = -0.311 p = 0.018 (table 4.9). 
 
 
 
 
 
 
 
 
 
 
 
 193 
 
 
 
Correlation with systolic BP  Correlation coefficient, r p 
RA E-selectin  0.292 0.037* 
P-selectin 0.290 0.039* 
 
Table 4.8: Association between systolic blood pressure and E- and P- selectin in RA 
patients 
 
 
 
 
Correlation with L-selectin Correlation coefficient, r p 
Body mass index (kg/m
2
) - 0.382 0.002* 
Waist circumference (cm) - 0.332 0.008* 
Total cholesterol (mmol/l) - 0.276 0.030* 
Serum urate (umol/l) - 0.311 0.018* 
 
Table 4.9: Association between serum L-selectin and markers of obesity, total 
cholesterol and serum urate in RA patients 
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L-selectin was significantly higher in RA patients with no evidence of endothelial 
dysfunction on FMD and in those with a normal common carotid IMT, compared to 
those with an abnormal FMD or abnormal cIMT, p=0.017 and p=0.014, respectively 
(table 4.10).  
Urinary protein creatine ratio correlated significantly with serum VCAM in the RA 
group, r = 0.284, p = 0.042.  
 
On transthoracic echocardiogram, e’, a marker of diastolic dysfunction, was 
associated with serum ICAM levels in RA, r =-0.359, p=0.014. E-selectin was 
significantly associated with a number of markers of diastolic dysfunction in the RA 
group (table 4.11). Those RA patients with a BNP level above 125pg/ml had a 
significantly lower L-selectin than RA patients with BNP in the normal range, p = 
0.026.  
Using logistic regression analysis, the presence of endothelial dysfunction, 
subclinical atherosclerosis or diastolic dysfunction were not found to be associated 
with serum levels of VCAM. ICAM, E-, P- or L-selectin.  
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  L-selectin 
Ng/ml (SD) 
P 
RA FMD < 5%  
(ie endothelial dysfunction) 
917.95 (168.93) 0.017* 
FMD >5% 1100.11 (353.94) 
RA cIMT >0.9mm 
(ie subclinical atherosclerosis) 
927.39 (137.56) 0.014* 
cIMT <0.9mm 1127.38 (403.11) 
RA BNP > 125pg/ml 832.50 (75.66) 0.026* 
BNP <125pg/ml 1103.24 (381.91) 
 
 
 
Table 4.10: Comparison of L-selectin levels in RA patients with and without markers 
of endothelial dysfunction, subclinical atherosclerosis and diastolic dysfunction 
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 E-selectin correlation with diastolic dysfunction  
Correlation coefficient = r 
p 
E wave velocity -0.329 0.011* 
A wave velocity -0.289 0.026* 
E/A ratio -0.402 0.002* 
e’ lateral -0.484 0.000* 
e’septal -0.415 0.003 
 
 
 
Table 4.11: Correlation between E-selectin concentration and markers of diastolic 
dysfunction in RA 
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Osteoarthritis and Adhesion Molecule Concentrations: 
 
 
We did not find any significant associations between adhesion molecule 
concentrations and cardiovascular markers in the OA group. 
However, serum VCAM levels were significantly associated with a number of 
general health status measures, including HAQ (health assessment questionnaire), 
WOMAC total score and physical function score and both the physician and patient 
visual analogue scale for pain and disease activity (table 4.12). 
 
 
 
VCAM Correlation coefficient, r p 
HAQ 0.445 0.002* 
WOMAC total 0.382 0.008* 
WOMAC physical 0.453 0.001* 
Physician VAS of disease activity 0.305 0.037* 
Patient VAS for pain 0.288 0.050* 
Patient VAS of disease activity 0.445 0.002* 
 
Table 4.12: Correlation between serum VCAM and measures of general health in 
OA group. 
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Cytokine Results: 
 
Comparison of Cytokine Concentrations in RA and OA: 
 
12 different cytokines were measured in both groups. These included interleukin – 
1a and 1b, Il 2, 4, 6, 8, 10, interferon gamma, TNFα, MCP1, EGF and VEGF. Serum 
levels of cytokines were not normally distributed so median values are reported and 
nonparametric tests used for analysis. All cytokine concentrations, other than VEGF 
and MCP-1 were significantly higher in our RA group (table 4.13). Serum 
concentrations of cytokines were similar in males and females. 
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 RA  
 
OA 
 
P value 
Cytokines    
Il 1α, pg/ml (IQR) 1.41 (0.93 – 4.13) 0.56 ( 0.48 – 0.88) 0.008* 
Il 1β, pg/ml (IQR) 4.23 (2.01 – 12.51) 0.00 (0 – 0) 0.000* 
Il 2, pg/ml (IQR) 22.39 (15.82 -61.89) 4.99 (0 - 15.26) 0.000 * 
Il 4, pg/ml (IQR) 5.65 (4.30 - 12.57) 3.47 (2.76 – 4.63) 0.000* 
Il 6, pg/ml (IQR) 12.62 (4.20 – 27.44) 2.88 (1.79 – 5.22) 0.000 * 
Il 8, pg/ml (IQR) 21.98 (12.00 – 47.17) 13.69 (8.33 – 27.39) 0.014* 
Il 10, pg/ml (IQR) 5.10 (2.98 – 18.60) 0.00 ( 0 – 0) 0.000 * 
VEGF, pg/ml (IQR) 180.42 (87.62 – 219.25) 119.88 (68.47 – 216.33) 0.200 
IFNγ, pg/ml (IQR) 5.76 (2.98 – 18.60) 1.55 (0 – 3.44) 0.000 * 
TNFα, pg/ml (IQR) 13.29 (6.77 – 24.98) 4.83 (3.03 – 6.70) 0.000 * 
MCP1, pg/ml (IQR) 228.27 (154.87 – 355.90) 215.33 (175.81 – 359.80) 0.910 
EGF, pg/ml (IQR) 38.00 (12.98 – 89.42) 4.20 (0 – 39.13) 0.000* 
 
 
Table 4.13: comparison of cytokine concentrations between RA and OA patients  
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Cytokine Concentrations and RA Serological Markers and Anti-Rheumatic 
Medications: 
  
 RA patients on synthetic or biologic DMARDS or NSAIDS had similar serum 
concentrations of cytokines to those not taking DMARDS or NSAIDS. Monocyte 
chemotactic protein type 1 was significantly higher in RA patients not on a biologic 
agent, 277.10 pg/ml (191.43 – 415.33) compared with 215.12 pg/ml (153.32 – 
271.40) in RA patients taking a biologic agent, p = 0.045. 
 
RA patients who were on steroid treatment at the time of the study had a 
significantly higher Il-6 serum concentration than RA patients not on steroids, 20.82 
pg/ml (7.13 – 40.18) versus 8.72 pg/ml (3.21-16.22), p =0.018. There was a 
significant correlation between serum Il6 concentration and current steroid dose, r = 
0.319, p = 0.015.  
 
Anti-CCP antibody positive RA patients had significantly higher serum 
concentrations of the majority of cytokines tested, than anti-CCP negative patients 
(table 4.14). This was also the case for RA patients who tested positive for 
rheumatoid factor (table 4.15). Serum concentrations of cytokines correlated with 
anti-CCP antibody and rheumatoid factor levels (table 4.16 and figure 4.2). 
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RA patients with low disease activity, as characterised by a DAS28ESR less than 
3.2, had significantly lower concentrations of VEGF and TNFα than RA patients 
with moderate or high disease activity (table 4.17). Those with a low DAS28CRP of 
less than 3.2, also had a lower serum concentration of TNFα than RA patients with a 
DAS28CRP greater than 3.2, p=0.042. DAS28ESR and DAS28CRP correlated 
significantly with a number of different cytokines (table 4.18). The numbers of 
tender and swollen joint counts were significantly associated with serum Il1α and Il8 
concentrations (table 4.19). 
 
 
RA patients with a family history of RA had higher concentrations of a number of 
pro-inflammatory cytokines compared to those with no family history of RA (table 
4.20).  
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Cytokines, 
pg/ml 
Anti-CCP antibody 
positive 
Anti-CCP antibody 
negative 
p 
Il1α (IQR) 1.95 (1.13 – 5.75) 0.66 (0.49 – 1.04) 0.000 
Il1β (IQR) 5.86 3.36 – 14.75) 0.00  (0.00 – 0.00) 0.000 
Il2 (IQR) 29.16 (17.78 – 73.86) 17.76 (6.02 – 22.39) 0.024* 
Il4 (IQR) 6.95 (4.63 – 16.56) 4.47 (3.47 – 5.14) 0.003* 
Il6 (IQR) 14.62 (6.34 – 33.99) 3.63 (1.05 – 13.19) 0.003* 
Il8 (IQR) 26.27 (18.36 – 52.90) 12.12 (8.35 – 15.86) 0.006* 
Il10 (IQR) 7.03 (3.67 – 19.20) 0.00 (0.00 – 0.00) 0.004* 
VEGF (IQR) 188.95 (101.15 – 261.18)  111.14 (48.57 – 192.35) 0.028* 
TNFα (IQR) 13.99 (7.74 – 26.10) 8.30 (5.52 – 18.44) 0.114 
MCP1 (IQR) 240.76 (170.77 – 374.04) 174.71 (153.44 – 254.86) 0.173 
EGF (IQR) 37.99 (16.64 – 88.21) 46.98 (4.40 – 94.96) 0.586 
IFN  (IQR) 6.89  (3.34 – 19.24)  0.00  (0.00 – 9.99) 0.012* 
 
 
Table 4.14: Comparison of serum concentrations of cytokines in anti-CCP positive 
and negative RA patients 
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Cytokines, 
pg/ml 
Rheumatoid factor 
positive 
Rheumatoid factor 
negative 
P 
Il1α (IQR) 1.96(1.13 – 5.75) 0.67 (0.52 – 1.02) 0.000 
Il1β (IQR) 5.93(3.36 – 14.75) 0.00  (0.00 – 1.81) 0.000 
Il2 (IQR) 29.16(17.78 – 73.86) 15.82 (10.92 – 19.97) 0.007* 
Il4 (IQR) 6.86 (4.55 – 15.53) 4.63 (4.13 – 5.14) 0.015* 
Il6 (IQR) 14.35(5.90 – 33.42) 3.25 (0.53 – 9.62) 0.006* 
Il8 (IQR) 28.52(18.36 – 52.90) 12.23 (11.09 – 15.30) 0.005* 
Il10 (IQR) 6.70 (3.67 – 19.51) 0.00 (0.00 – 0.34) 0.001* 
VEGF (IQR) 188.95 (101.15 – 232.48)  96.98 (56.08 – 163.67) 0.037* 
TNFα (IQR) 13.71 (7.74 – 26.10) 8.57 (5.11 – 14.89) 0.110 
MCP1 (IQR) 235.84(160.20 – 374.04) 192.80 (155.52 – 276.76) 0.445 
EGF (IQR) 34.83 (15.59 – 86.86) 63.82 (5.99 – 114.21) 0.820 
IFN  (IQR) 7.26  (3.41 – 19.24)  0.00  (0.00 – 1.49) 0.002* 
 
Table 4.15: Comparison of serum cytokine concentrations rheumatoid factor positive 
and negative RA patients 
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 Correlation with anti-CCP 
antibody level, r 
p Correlation with 
rheumatoid factor level, r 
p 
Il1α 0.431 0.001* 0.627 0.000* 
Il1β 0.515 0.000* 0.698 0.000* 
Il2 0.346 0.008* 0.570 0.000* 
Il4 0.468 0.000* 0.560 0.000* 
Il6 0.408 0.001* 0.476 0.000* 
Il8 0.355 0.006* 0.528 0.000* 
Il10 0.511 0.000* 0.626 0.000* 
VEGF 0.321 0.014* 0.336 0.010* 
TNFα 0.255 0.053 0.485 0.000* 
IFNγ 0.396 0.002* 0.602 0.000* 
MCP 0.164 0.219 0.121 0.364 
EGF 0.067 0.618 -0.183 0.170 
 
 
Table 4.16: Association between serum cytokine concentrations and RA antibodies 
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Figure 4.2: Correlation between serum Il1β concentration and rheumatoid factor 
level in RA patients 
 
 
 
 DAS28ESR <3.2 DAS28ESR >3.2 p 
VEGF pg/ml (IQR) 101.61 (55.64 – 195.56) 190.65 (110.34 – 237.05) 0.024* 
TNFα pg/ml (IQR) 7.74 (5.73 – 14.62) 14.40 (9.41 – 26.10) 0.027* 
 
Table 4.17: Comparison of serum VEGF and TNFα concentrations in RA patients 
with low and high disease activity 
R = 0.515 
P <0.000 
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 Correlation with 
DAS28ESR, r  
p Correlation with 
DAS28CRP, r 
p 
Il1α 0.408 0.001* 0.337 0.010* 
Il1β 0.331 0.011* 0.257 0.051 
Il2 0.183 0.169 0.161 0.226 
Il4 0.280 0.033* 0.217 0.103 
Il6 0.317 0.015* 0.253 0.055 
Il8 0.377 0.003* 0.281 0.033* 
Il10 0.286 0.029* 0.208 0.117 
VEGF 0.321 0.014* 0.268 0.042* 
TNFα 0.361 0.005* 0.276 0.036* 
IFNγ 0.292 0.026* 0.194 0.144 
MCP 0.228 0.085 0.142 0.288 
EGF -0.031 0.819 0.060 0.652 
 
Table 4.18: correlation between disease activity scores and serum cytokine 
concentrations in RA patients 
 
 
 
 
 
 
 
 207 
 
 Correlation with tender joint 
count 
p Correlation with swollen 
joint count 
p 
Il1α R = 0.355 0.006* R = 0.300 0.022* 
Il1β R = 0.253 0.055 R = 0.259 0.049* 
Il2 R = 0.207 0.118 R = 0.123 0.359 
Il4 R = 0.256 0.053 R = 0.235 0.075 
Il6 R = 0.178 0.181 R = 0.202 0.128 
Il8 R = 0.316 0.016* R = 0.327 0.012* 
Il10 R = 0.234 0.077 R = 0.271 0.040* 
 
Table 4.19: Correlations between tender and swollen joint counts and serum cytokine 
concentrations in RA patients 
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 Positive family history of 
RA 
No family history of 
RA 
p 
Il2, pg/ml (IQR) 34.19 (20.24 – 105.17) 20.78 (15.82 – 34.69) 0.039* 
Il1α, pg/ml 
(IQR) 
2.89 (1.35 – 7.10) 1.13 (0.88 – 2.88) 0.035* 
Il1β, pg/ml (IQR) 11.47 (3.21 – 26.38) 3.44 (1.93 – 6.55) 0.027* 
 
 
Table 4.20: Comparison of cytokine concentrations in RA patients with and without 
a family history of RA 
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Cytokine Concentrations and Cardiovascular Markers in RA: 
 
11 of the 12 cytokines were significantly higher in RA patients who smoked 
compared with RA non-smokers (table 4.21). Furthermore, smoking pack years was 
significantly associated with serum cytokine concentrations (table 4.22). 
Serum cytokine concentrations did not correlate with fasting glucose or lipid profile 
in RA patients.  
RA patients with evidence of abnormal common carotid IMT, low ABI, abnormal 
FMD and diastolic dysfunction were compared to RA patients with cIMT, ABI, 
FMD and diastolic marker values in the normal ranges. No differences in serum 
cytokine concentrations were found between the different groups, except for serum 
IL1α concentrations in the group of RA patients with evidence of endothelial 
dysfunction, as documented by abnormal FMD. Those with ultrasound proven 
endothelial dysfunction had a significantly higher concentration of IL1α, p=0.031. 
 
 
Using logistic regression analysis, the presence of diastolic dysfunction, subclinical 
carotid atherosclerosis, abnormal ankle brachial index and endothelial dysfunction in 
the RA group, were not found to be associated with serum cytokine concentrations, 
OR (95%), 1.02 (0.95, 1.08), 1.09 (0.97, 1.23), 1.03 (0.92, 1.15) and 1.02 (0.98, 
1.05), p=0.602, p=0.159, p=0.601, p=0.411, respectively. 
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Cytokines, pg/ml Smoker Non-Smoker P 
Il1α (IQR) 4.62 (1.50 – 13.37) 1.13 (0.66 – 2.98) 0.001* 
Il1β (IQR) 14.38 (3.68 – 29.69) 3.21 (1.89 – 6.82) 0.001* 
Il2 (IQR) 61.89 (22.39 – 96.40) 20.24 (15.82 – 30.94) 0.004* 
Il4 (IQR) 13.86 (7.22 – 27.40) 4.63 (4.13 – 6.86) 0.000* 
Il6 (IQR) 61.89 (12.69 – 41.57) 6.54 (3.30 – 17.73) 0.004* 
Il8 (IQR) 46.50 (23.33 – 70.03) 18.36 (10.75 – 29.08) 0.005* 
Il10 (IQR) 18.70 (7.43 – 31.32) 3.60 (0.00 – 5.90) 0.000* 
VEGF (IQR) 207.54 ( 171.29 – 349.77) 125.29 (68.96 - -191.93) 0.001* 
TNFα (IQR) 20.39 (12.04 – 49.41) 9.68 (6.28 – 16.98) 0.004* 
MCP1 (IQR) 254.31 (221.11 – 414.57) 215.52 (149.98 – 306.87) 0.031* 
EGF (IQR) 33.08 (24.48 – 83.56) 55.71 (11.48 – 97.71) 0.980 
IFNγ (IQR) 18.60 (5.76 – 48.08) 3.41 (0.00 – 8.32) 0.000* 
 
Table 4.21: Comparison of serum cytokine concentrations in RA smokers and non-
smokers 
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Correlation between smoking pack years and serum 
cytokine concentrations (pg/ml) 
Correlation 
coefficient, r 
p 
Il1α 0.427 0.001* 
Il1β 0.402 0.002* 
Il2 0.307 0.019* 
Il4 0.390 0.002* 
Il6 0.351 0.007* 
Il8 0.267 0.043* 
Il10 0.505 0.000* 
VEGF 0.512 0.000* 
TNFα 0.317 0.015* 
Interferon γ 0.430 0.001* 
MCP-1 0.325 0.013* 
EGF 0/081 0.547 
 
 
Table 4.22: Correlation between smoking pack years and serum cytokine 
concentrations in RA patients 
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Osteoarthritis and Cytokine Concentrations: 
 
Within the OA group, we found significant correlations between disease duration 
and multiple serum cytokine concentrations (table 4.23). OA patients with a family 
history of MI had a significantly higher serum Il8 concentration than OA patients 
with no family history of MI, 20.17pg/ml (12 – 42.46) versus 9.65pg/ml (6.93 – 
18.52), p=0.005.  
Serum concentrations of Il10 in the OA group were found to have a negative 
correlation with mean common carotid IMT, r = -0.394, p=0.008. E/A ratio in the 
OA group correlated negatively with serum Il2 and Il6 concentrations, r = -0.416, 
p=0.004 and r = -0.304, p=0.038, respectively.  
Using logistic regression analysis, the presence of diastolic dysfunction, subclinical 
carotid atherosclerosis, abnormal ankle brachial index and endothelial dysfunction in 
the OA group, were not found to be associated with serum cytokine concentrations, 
OR(95%), 1.09 (0.99, 1.19). 1.04 (0.92, 1.17), 1.09 (0.80, 1.49), 0.98 (0.88, 1.09), 
p=0.071, p=0.530, p=0.588, p=0.699, respectively.  
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Correlation between disease duration 
and serum cytokine concentrations 
(pg/ml) 
Correlation coefficient, r p 
Il1β  0.384 0.008* 
Il4 0.387 0.007* 
Il6 0.301 0.040* 
Il8 0.295 0.044* 
 
 
Table 4.23: Association between serum cytokine concentrations and length of 
diagnosis in OA patients 
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Results for Markers of Thrombosis: 
 
Comparison of Thrombotic Markers in RA and OA: 
 
Fibrinogen levels where compared in RA and OA patients, mean values were higher 
in the RA group and this approached significance, 3.29g/l (SD 0.69) compared with 
3.05g/l (SD0.49) in the OA group, p=0.051. 
 
Plasminogen activator inhibitor-1 (PAI-1) antigen and activity levels were measured. 
PAI -1 was not normally distributed in the study population so medians and 
nonparametric tests were used for analysis. There was no significant difference in 
median PAI-1 antigen and activity levels between RA and OA patients (table 4.24). 
In both the OA and RA groups, males had higher PAI-1 activity and PAI-1 antigen 
levels than females (table 4.25). This difference was significant in the RA group.  
 
Using logistic regression analysis, a diagnosis of RA was not found to be associated 
with either PAI-1 activity or antigen level more so than a diagnosis of OA, OR (95% 
CI), 0.413 (0.036, 4.716), p=0.477 and 3.58 (0.93, 13.75), p=0.063.  
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 RA OA p 
Median PAI-1 antigen (IQR) 24.48ng/ml  
(15.78-35.51) 
23.52ng/ml  
(13.43-36.12) 
0.446 
Median PAI-1 activity (IQR) 21.48U/ml   
(17.80-27.31) 
23.60U/ml  
(19.63-30.72) 
0.195 
 
 
Table 4.24: comparison of PAI-1 antigen and activity levels in RA and OA patients 
 
  Median PAI-1 activity 
U/ml (IQR) 
p Median PAI-1 antigen 
Ng.ml (IQR) 
p 
RA Males 24.46 (20.34-31.10) 0.006* 34.98 (26.62-62.77) 0.000* 
Females 20.01 (15.51-24.09) 21.02 (11.38-27.96) 
OA Males 32.12 (20.94-34.59) 0.128 28.89 (22.04- 33.62) 0.298 
Females 22.67 (18.13-26.92) 22.60 ( 11.82-36.96) 
 
 
Table 4.25: Comparison of PAI-1 activity and antigen levels in male and female 
patients with RA and OA. 
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Markers of Thrombosis and RA Serological Markers and Anti-Rheumatic 
Medications: 
 
Within the RA group, fibrinogen levels were significantly higher in patients not on a 
biologic DMARD, p=0.007. Otherwise, we found no difference in fibrinogen levels 
when different medications were compared.  
RA patients who were taking a biologic agent at the time of the study, had a 
significantly lower PAI-1 activity level compared to those not on a biologic agent, 
19.81 U/ml (17.36-22.51) versus 24.15 U/ml (19.28-30.80), p = 0.05. PAI-1 antigen 
levels were similar in the 2 groups. Those patients on DMARDs, NSAIDs or steroids 
did not have a significantly different PAI-1 activity level to those patients not on the 
above treatments.  
 
There was no significant difference in PAI-1 activity and antigen levels when RA 
patients with active disease were compared to those with low disease activity or 
remission, p = 0.365 and p = 0.177. RA patients with a low disease activity had a 
significantly lower fibrinogen level compared with those with more active disease, 
2.99 g/l (SD 0.79) versus 3.43 g/l (SD 0.61), p = 0.048.  
 
Within the RA group, PAI-1 activity correlated significantly with CRP, anti -CCP 
antibody, rheumatoid factor, fibrinogen and urate levels (table 4.26). PAI-1 antigen 
also correlated with urate in the RA group, r=0.546, p=0.000. There was no 
association found between PAI-1 and urate in the OA group.  
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PAI-1 activity Correlation with PAI-1 activity,  
R = correlation coefficient 
p 
CRP 0.359 0.008* 
Anti-CCP antibody 0.335 0.013* 
Rheumatoid factor 0.281 0.040* 
Fibrinogen 0.370 0.007* 
Urate 0.303 0.035* 
 
 
Table 4.26: Correlation between PAI-1 activity and markers of inflammation and 
seropositivity in RA patients, p, significance level; r, correlation coefficient. 
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Markers of Thrombosis and Cardiovascular Markers in RA: 
 
PAI-1 activity level was higher in RA smokers compared to non-smokers but this did 
not achieve statistical significance. RA patients who drank more than 14 units of 
alcohol per week has a significantly higher PAI-1 activity level compared with those 
who consumed less than 14 units per week, 27.95U/ml (24.69-43.95) compared with 
21.11U/ml (17.45-26.04), p=0.036. 
There was no significant difference in PAI-1 antigen levels between smokers and 
non-smokers or between those who consumed greater than 14 units of alcohol per 
week and those who consumed less.  
 
RA patients who were overweight or obese had a significantly higher PAI-1 activity 
level and PAI-1 antigen compared to those RA patients with a normal BMI, p=0.016 
and p=0.040, respectively. This difference was not seen across the categories of BMI 
in the OA group. RA patients with evidence of abdominal obesity, as defined by the 
WHO, as a waist-hip ratio of greater than 0.85 in females and greater than 0.9 in 
males, had  significantly higher levels of PAI-1 activity and antigen than RA patients 
with normal waist-hip ratio, p=0.014 and p=0.001 (table 4.27). PAI-1 activity and 
antigen level correlated positively with waist hip ratio in RA patients, r=0.482, 
p=0.000 and r=0.629, p=0.000, respectively (figure 4.3). 
 
 
Systolic and diastolic blood pressure were significantly associated with both PAI-1 
activity and antigen in the RA group, but not in the OA group, r =0.417 p=0.003 and 
r=0.329, p=0.022, respectively.  
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We examined the RA group to see if there was a difference in PAI-1 activity or 
antigen levels in those with and without evidence of preclinical atherosclerosis or 
diastolic dysfunction. There was no difference in PAI-1 concentrations when those 
with abnormal IMT, abnormal ABI, low FMD or evidence of diastolic dysfunction 
were compared to those RA patients who had no evidence of preclinical 
atherosclerosis or diastolic dysfunction. However, mean common carotid IMT was 
found to correlate significantly with PAI-1 activity in the RA group, r = 0.294, p = 
0.013. 
 
RA patients with abnormal cIMT, ABI, FMD or evidence of diastolic dysfunction 
did not have a higher fibrinogen than those with normal IMT, ABI, FMD and 
diastolic function. 
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  Median PAI-1 activity 
U/ml (IQR) 
 
p Median PAI-1 antigen 
Ng/ml (IQR) 
p 
RA Normal BMI 20.37 (15.13-22.49) 0.016* 22.38 (11.67-29.78) 0.04* 
High BMI 24.01 (18.48-31.23) 26.62 (19.04-53.90) 
RA Normal waist-
hip ratio 
18.70 (15.09-24.62) 0.014* 16.79 (10.72026.78) 0.001* 
Abdominal 
obesity 
23.24 (19.38-30.80) 33.03 (22.60-48.03) 
 
 
Table 4.27: Comparison of PAI-1 activity and antigen levels in RA patients with 
normal and high BMI and also in RA patients with normal or high waist hip ratios.  
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Figure 4.3: Correlation between PAI activity and waist hip ratio in RA 
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Osteoarthritis and Markers of Thrombosis: 
 
Within the OA group, fibrinogen level correlated with weight, waist circumference 
and BMI, r=0.322, r=0.454, r=0.468, p=0.046, p=0.004, p=0.003, respectively.  
OA patients who were current or former smokers had a higher PAI-1 activity level 
than OA non-smokers, 25.92U/ml (22.87-32.81) compared with 20.68U/ml (17.45-
22.67), p=0.008. Smoking pack years correlated significantly with PAI-1 activity, 
r=0.431, p=0.003.  
 
 
 
Results for Urinary Protein-Creatinine Ratio and Microalbuminuria: 
 
Median values are quoted as these variables were not normally distributed. Median 
protein-creatinine ratio (PCR) was significantly higher in the RA group (table 4.28). 
Levels of microalbuminuria were similar between the 2 groups.  
Urinary PCR was significantly lower in RA patients currently taking a DMARD, 
compared to RA patients not on a DMARD at the time of the study, 5.54 (4.29 – 
7.21) versus 7.61 (5.50 – 10.07), p=0.027. There was no significant difference in 
PCR between RA patients on a biologic agent currently and those not on one, 
p=0.733. 
PCR was associated with serum levels of VCAM and L-selectin in the RA group, r  
= 0.284, p =0.042 and r =0.281, p=0.043. 
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We found a significant correlation between microalbuminuria and E/e’, a marker of 
diastolic dysfunction, r = 0.402, p =0.009. 
 
 
 
Table 4.28: Protein creatinine ratio and microalbuminuria in RA and OA patients. 
IQR, interquartile range; p, significance level. 
 
 
 
 
 
 
 
 
 RA OA p 
Median PCR (IQR) 5.85  
(4.41 – 7.96) 
4.86  
(2.89 – 7.03) 
0.023* 
Median microalbuminuria, 
mg/mmol (IQR) 
0.55  
(0.34 – 0.92) 
0.42  
(0.33 – 0.57) 
0.094 
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Discussion: 
 
Comparison of ESR, CRP and Urate in RA and OA: 
 
As expected, both ESR and CRP were significantly higher in the RA group. Also, 
not surprisingly, RA patients on synthetic and biologic DMARDS had significantly 
lower inflammatory markers. We found similar levels of inflammatory markers in 
sero- positive and sero-negative RA patients.  
CRP was found to be significantly associated with markers of thrombosis; fibrinogen 
and PAI-1 antigen in RA patients. Kitas et al, also found significant correlations 
between CRP and coagulation factors in RA patients (44). Whether these 
associations are due to inflammation or are markers of cardiovascular dysfunction 
has not yet been fully elucidated.  
A large prospective study of incident CVD events in RA was published in 2013 and 
reported that CRP level was associated with higher CVD risk in RA patients under 
65 years and reductions in CRP were associated with a decreased CVD risk in RA 
patients over 65 years (49). This validates the importance of early control of 
inflammation in RA to reduce CVD risk.  
 
Serum urate was similar in RA and OA patients. We did find significant associations 
between serum urate levels and a number of anthropometric variables in our RA 
group. There is mounting evidence that serum uric acid plays a role in the 
development of cardiovascular diseases (50). Levels of serum urate have been shown 
to correlate significantly with blood pressure and carotid intima-media thickness 
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(51). Earlier studies have reported a strong association between obesity and 
hyperuricaemia (52). A recent large study by Ohya et al, found a significantly higher 
prevalence of metabolic syndrome in patients with baseline hyperuricaemia and that 
hyperuricaemia was an independent predictor of metabolic syndrome (53).  
A recent review by van Holten et al, of multiple meta-analyses of biomarkers that 
predict cardiovascular disease risk, found that the highest risk for cardiovascular 
disease is reported for elevated CRP (RR 2.43 (95%CI), (2.10-2.83) ), followed by 
fibrinogen and lipids. Uric acid, together with fibrinogen, were the strongest risk 
markers for primary stroke  (54).  
 
 
 
Comparison of Adhesion Molecules in RA and OA: 
 
The serum concentrations of 2 pro-inflammatory adhesion molecules, VCAM and P-
selectin were significantly higher in our RA group compared to our OA group. These 
adhesion molecules are biomarkers of endothelial dysfunction. Increased expression 
and upregulation of adhesion molecules in conjunction with pro-inflammatory 
cytokines, is one of the earliest processes in damage to the endothelial cell layer (55). 
Leucocyte adhesion to endothelial cells is mediated by the above adhesion 
molecules. During this process selectins facilitate leucocyte “tethering” and 
“rolling”, while members of the immunoglobulin superfamily: VCAM and ICAM, 
are responsible for migration and adhesion of leucocytes (56).  
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Dessein et al also reported significantly higher concentrations of circulating adhesion 
molecules in 74 RA patients compared to controls (57) and found that VCAM 
concentrations were associated with common carotid atherosclerosis in their RA 
group. These findings have also been reported in earlier studies (45).  
 
These findings are important because elevated levels of adhesion molecules have 
been shown to be associated with CV risk factors and future CV events (58, 59). 
There is also evidence that in RA patients, these biomarkers may be more important 
than traditional CV risk factors in cardiovascular disease (60). Also of interest, is a 
study in 2006 by Gonzalez-Gay et al that reported a reduction in multiple adhesion 
molecules post-infliximab infusion (61). Foster et al also found a reduction in 
VCAM and E-selectin concentrations in RA patients measured 1 week after anti-
TNF therapy (62). 
 
 
L-selectin concentrations were lower in the RA group. There is very little recent 
literature on the concentration of L-selectin in RA patients and the results from 
earlier studies are controversial. In 2004, Ates et al, reported a lower L-selectin level 
in RA patients compared to controls (63). Sfikakis et al found no difference in L-
selectin concentrations between RA patients and controls (64). In contrast, Littler et 
al found significantly higher L-selectin concentrations in RA patients compared to 
controls (65).  
L-selectin is expressed on leucocytes and is rapidly shed during leucocyte activation 
and transmigration across the endothelial cell lining, therefore one would expect 
increased levels of L-selectin in activated leucocytes (66). However, one theory for 
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the lower concentrations of L-selectin in RA, is a downregulation of L-selectin 
expression as a protective mechanism to stop further leucocyte migration (67) and 
use of some anti-rheumatic medications, in particular, methotrexate and 
corticosteroids have also been shown to reduce L-selectin expression (68). 
 
 
Adhesion Molecule Concentrations and RA Serological Markers and Anti-
Rheumatic Medications: 
 
Within our RA group, serum concentrations of adhesion molecules were similar for 
those on synthetic and biologic DMARDs to those RA patients not on a DMARD at 
the time of the study. We did find a correlation between glucocorticoid dose and 
concentrations of both VCAM and L-selectin. Glucocorticoids have previously been 
shown to suppress serum concentrations of VCAM and ICAM in RA patients (69). 
Although glucocorticoids have may negative effects on metabolic and cardiovascular 
risks, they may, via their effect on pro-inflammatory cytokines and adhesion 
molecules, attenuate atherogenesis in RA.  
 
Seropositivity in our RA group was associated with higher concentrations of VCAM, 
ICAM and E-selectin. E-selectin also correlated with CRP. A review of 10 studies by 
J Giles in 2006 found that sero-positivity and CRP together with a host of other RA 
markers, were implicated in the development of RA-associated accelerated 
atherosclerosis (70). In 2011, Agewall S et al found that the presence of anti-CCP 
antibodies and rheumatoid factor IgM in RA patients was associated with endothelial 
dysfunction independent of other CV risk factors (71). Szekanecz et al also reported 
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that sero-positive RA patients had more pronounced endothelial dysfunction and 
carotid atherosclerosis than RA patients who were anti-CCP antibody and 
rheumatoid factor negative (72). Our findings are consistent with published work. 
 
 
Adhesion Molecule Concentrations and Cardiovascular Markers in RA: 
 
 
With regard to traditional CV risks, smoking in our RA group was significantly 
associated with serum ICAM and P-selectin concentrations. Smoking has been 
shown to be associated with elevated serum ICAM and smoking cessation improves 
ICAM concentrations (73). This may be one of the mechanisms by which smoking 
increases cardiovascular risk.  
Systolic blood pressure in our RA group was also associated with E- and P- selectin 
levels. A study by Sanada H et al found that patients with hypertension had elevated 
levels of the selectins and that treatment of the hypertension resulted in improvement 
of selectin concentrations (74). 
 
 
With regard to markers of subclinical vascular disease, we found that RA patients 
with evidence of an abnormal carotid IMT and those with endothelial dysfunction on 
brachial artery ultrasound had significantly lower concentrations of L-selectin. Also, 
lower concentrations of L-selectin were found to correlate with total cholesterol and 
serum urate levels RA patients. L-selectin was also negatively correlated with body 
mass index and waist circumference.  
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We have found that L-selectin appears to have significant negative associations with 
a number of markers of pre-clinical atherosclerosis and also with elements of the 
metabolic syndrome. L-selectin is down regulated in chronic inflammation. A lower 
level is associated with CVD in the general population (75). 
 It appears from our dataset, that elevated levels of L-selectin may be linked to anti-
atherogenic properties in RA patients and perhaps has a protective role, but this 
needs to be examined further with larger study numbers and in a prospective manner. 
Sodergren et al had similar findings with respect to L-selectin and markers of 
atherosclerosis in RA (76). They reported that reduced levels of L-selectin were 
strongly related to low FMD and increased IMT. 
 
 
 
A number of markers of diastolic dysfunction, including e’, E/A ratio and NT-
proBNP, were associated with higher concentrations of pro-inflammatory adhesion 
molecules but lower concentrations of L-selectin. In particular, E-selectin, a serum 
biomarker of endothelial dysfunction, had a negative association with markers of 
diastolic dysfunction. Masiha S et al recently reported similar associations between 
E-selectin and diastolic dysfunction in a population study of elderly patients. This 
was the first study demonstrating the association. The mechanisms are still unclear 
but it does appear from their research that biomarkers of endothelial dysfunction play 
a role in myocardial remodelling (77). 
 
Finally, urinary protein-creatinine ratio, a marker of vascular disease, was 
significantly correlated with serum VCAM concentrations in our RA patients. 
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This is a significant and novel finding and has not been previously reported in the 
RA literature. Lin J et al previously reported that serum VCAM concentrations 
were significantly higher in type II diabetic patients with low GFR. They 
concluded that elevation of serum biomarkers of endothelial dysfunction may be 
the link between renal insufficiency and cardiovascular risk in diabetic patients 
(78).  
This simple urine measurement appears to be a surrogate marker of early 
microvasculopathy in RA and can easily be checked in clinic. 
. 
 
 
Osteoarthritis and Adhesion Molecule Concentrations: 
 
There was no association between adhesion molecule concentrations and markers of 
cardiovascular disease in our OA group. A recent study by Lia Pulsatelli et al found 
significantly higher concentrations of serum VCAM in patients with erosive hand 
OA compared to healthy controls (79). VCAM has been found to be expressed in 
OA joints and has been suggested as a marker of OA disease severity (80). None of 
our OA patients had obvious clinical features of synovitis and only 1 had evidence of 
OA changes in the hands. Perhaps our OA group were of a different phenotype and 
this may explain the difference in results of adhesion molecules.  
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Serum VCAM concentrations correlated significantly with measures of general 
health, disability and disease activity scores in OA patients. This is interesting 
because health related quality of life scores for other chronic diseases have been 
shown to be associated with serum VCAM concentrations. In a study of CHF 
outpatients, a poor score on the Kansas City Cardiomyopathy Questionnaire, that 
assesses physical function and quality of life in heart failure, was associated with 
high concentrations of serum VCAM and was also associated with a shorter event- 
free survival (81). This emphasises the usefulness of self-administered 
questionnaires.  
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Comparison of Cytokine Concentrations in RA and OA: 
 
 
As expected, the majority of serum cytokine concentrations were higher in RA than 
OA patients. IL4 and IL10, both of which have anti-inflammatory properties, were 
also higher in RA patients. Although serum concentrations of VEGF and MCP1 
were not significantly different between the 2 groups, both were still higher in the 
RA group. This is in keeping with the inflammatory nature of RA, which is driven in 
particular by TNFα, IL6 and IL1. However, there is emerging evidence that these 
pro-inflammatory cytokines also play a role in articular cartilage degradation and 
OA development and OA associated pain (82). 
 
 
 
Cytokine Concentrations and RA Serological Markers and Anti-Rheumatic 
Medications: 
 
Patients on biologic or synthetic DMARDS or NSAIDS had similar concentrations 
of serum cytokines to those not on DMARDS or NSAIDS.  
One would expect to demonstrate lower levels of circulating cytokines in patients 
whose disease was controlled with biologic DMARDs. Perhaps our RA treatment 
subgroups were too small to detect a significant difference.  
MCP1 was the only cytokine which was lower in RA patients on a biologic agent 
compared to those not on one at the time of the study. MCP-1 is a potent 
atherosclerotic and RA factor. Levels have been associated with the incidence of 
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coronary artery disease in the general population and with the clinical symptoms of 
RA (83). It is interesting that this chemokine, which plays a role in the pathogenesis 
of both conditions, was suppressed in patients taking biologic DMARDs and this 
finding supports the evidence that treatment with biologic DMARDs not only 
improves RA disease scores and function but also has beneficial effects on CV risk. 
Barnabe et al reported that TNF suppression in RA patients was associated with 
reduced risk of all heart disease events (84). 
Naredo et al reported a lower level of carotid sub-clinical atherosclerosis in RA 
patients on a biologic DMARD compared to those on a synthetic DMARD (85). 
These findings of better CV risk profile in patients treated with TNF inhibitors 
substantiate the link in cytokine pathways between the 2 diseases.  
 
 
Patients with a flare of disease activity are often treated with short courses of 
corticosteroids to control synovitis and relieve symptoms. IL6 is one of the main 
pro-inflammatory cytokines responsible for driving the inflammatory burden of RA. 
It is therefore not surprising that we found higher IL6 concentrations in RA patients 
on corticosteroids and the steroid dose was found to correlate significantly with IL6 
concentration.  
With regard to disease activity, as expected, the serum concentrations of TNFα were 
significantly lower in those RA patients who had low disease activity or were in 
remission compared to those with moderate or high disease activity.  
 
Sero-positive RA patients had significantly higher concentrations of serum cytokines 
than RA patients who tested negative for anti-CCP antibody and Rheumatoid factor 
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IgM. The titres of anti-bodies also correlated with cytokine concentrations. This 
reflects the fact that those with anti-CCP antibody and Rheumatoid factor IgM 
positivity have more aggressive disease. This is well documented in the literature. 
Cortina et al reported that sero-positive patients had higher DAS scores and more 
radiological damage than sero-negative RA patients (86). In 2010, a study of RA 
patients with active disease found that anti-citrullinated peptide antibodies were 
markers independently associated with impaired left ventricular relaxation (87). 
They may exert a pro-atherogenic effect via common inflammatory cytokines but 
this remains to be investigated. 
 
 
Cytokine levels were also higher in those with a first degree relative of RA in our 
study. There appears be a familial clustering of serum cytokine levels within families 
with RA. Fritzler et al found that people with a first degree relative with RA had 
higher serum concentrations of cytokines than those with no such family history 
(88). 
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Cytokine Concentrations and Cardiovascular Markers in RA: 
 
 
A history of smoking was associated with increased levels of serum cytokines in our 
RA group. Smoking has been shown to stimulate a low-grade inflammatory response 
and elevated levels of CRP, IL6 and TNFα have been reported in smokers. It is felt 
that these abnormalities, in conjunction with effects on the coagulation and 
fibrinolytic systems, may be some of the mechanisms by which smoking increases 
cardiovascular risk (89). Smoking is the main environmental risk factor for the 
development of RA and it predisposes to seropositive RA. The risk of developing 
RA is twice as high in male smokers compared to males who do not smoke and for 
female smokers the risk is 1.3 times greater than non-smokers (90). 
The molecular mechanisms connecting smoking and the development of RA have 
not been identified in detail yet, however, they are most likely connected to the effect 
of smoking on inflammatory cytokines.  
 
Cytokine concentrations were similar in patients with and without evidence of 
peripheral vascular disease, subclinical carotid atherosclerosis, endothelial 
dysfunction and diastolic dysfunction. However, serum IL1α concentrations were 
higher in RA patients with endothelial dysfunction.  
 IL-1 is one of the primary pro-inflammatory cytokines in RA and one of its many 
functions is to induce adhesion molecule expression, V-CAM and I-CAM on 
endothelial cells (91) which explains why we found the above association.  
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OA and Cytokine Concentrations: 
 
Disease duration was associated with multiple serum cytokines in our OA group 
(table 23).  
Synovial inflammation is now known to play a role in the pathogenesis of OA and 
levels of inflammation correlate with the degree of cartilage pathology (92). It is 
plausible that as cartilage disease progresses over time, synovitis, as reflected by 
increased inflammation cytokines would also be associated with disease duration. 
 
E/A ratio, a marker of diastolic dysfunction was associated with levels of IL2 and 
IL6 in our OA patients. Collier et al reported increased levels of Il6 and other pro-
inflammatory cytokines in heart failure patients with preserved ejection fraction (93). 
Based on this report, it makes sense that we might see an association between pre-
clinical diastolic heart failure and inflammatory cytokines in our cohort, particularly 
as there is emerging evidence of a causal role for IL6 in coronary heart disease (94). 
 
 
Comparison of Thrombotic Markers in RA and OA: 
 
In our study, RA patients had a higher mean fibrinogen than OA controls. 
For more than half a century, fibrinogen has been found to be associated with acute 
thrombosis (95). In 1984, the Gothenburg Heart Study was the first prospective 
study to report an association between fibrinogen levels and future cardiovascular 
events (96).  
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Fibrinogen is an acute phase reactant and may be elevated along with CRP and 
ESR in active RA. It is also an important marker for predicting cardiovascular 
disease and stroke in populations without pre-existing cardiovascular disease (54). 
However, whether elevated fibrinogen levels are just an association or have an 
actual causal role in cardiovascular disease is still unclear. Danesh J et al reported 
that after adjustment for traditional cardiovascular risks, the hazard ratio for CHD 
in patients with no prior history of cardiovascular disease was 1.8 per 1g/L 
increase in fibrinogen level (40). 
 
Given that the risk of cerebrovascular disease in RA is double that of the general 
population (97), fibrinogen may be a useful screening tool to identify those at risk 
RA patients, particularly those with low disease activity whose elevated fibrinogen 
level would be less likely to be related to RA disease activity.  
 
We did not find a difference in PAI-1 activity or antigen levels between RA and 
OA patients. This is in contrast to a recent study of 141 RA patients and 50 
controls by Kitas et al, where the RA group had significantly higher PAI-1 levels. 
The differences between the studies with respect to PAI-1 levels may be explained 
by the fact that in the study by Kitas, the RA patients were significantly older than 
controls and the control group were healthy volunteers. Also of note, in the above 
study 20% of the RA group were on an anti-platelet agent and over 40% were 
taking anti-hypertensives which suggest they had a greater baseline CV risk 
profile than our RA group.  
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In contrast to Kitas’s work, a study comparing 125 RA patients and 132 controls 
found a lower PAI-1 in the RA group compared to controls (98). 
 
 
 
Markers of Thrombosis and RA Serological Markers and Anti-Rheumatic 
Medications: 
 
We reported a significantly higher fibrinogen level in RA patients not on a biologic 
DMARD compared to those on a biologic DMARD. This finding is in keeping with 
a study by Sandoo et al, which reported a significant improvement in fibrinogen 
levels in RA patients started on anti-TNF therapy (99).  
 
We found that RA patients on a biologic DMARD had a significantly lower PAI-1 
activity than those not on a biologic agent. In 2006, Agirbasli et al reported a 
reduction in inflammatory markers and PAI-1 in RA patients treated with infliximab 
(100). 
 
We detected a significant association between PAI-1 activity and CRP, urate, anti-
CCP antibody and rheumatoid factor IgM.  A number of small studies have reported 
abnormalities in coagulation in RA patients and correlation of these abnormalities 
with disease activity and inflammation (45, 101). 
Similar to our findings, Kitas et al demonstrated several coagulation abnormalities in 
RA patients, including derangement of fibrinogen, PAI-1 and tissue plasminogen 
activator and also reported an association with inflammation factors including ESR, 
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CRP and DAS scores (44). These results provide further evidence for the 
relationship between inflammation and fibrinolytic abnormalities in RA. 
 
 
 
Markers of Thrombosis and Cardiovascular Markers in RA: 
 
Our RA patients with high body mass index and abdominal obesity had significantly 
higher levels of PAI-1 activity and antigen.  
Increased risk of CVD in the general population has been shown to be associated 
with elevated levels of PAI-1. An increase in PAI-1 and other coagulation 
biomarkers leads to a pro-thrombotic state. An early study by Wallbery-Jonsson et 
al, found that baseline levels of PAI-1 in RA patients were significantly elevated in 
those who developed a cardiovascular event in the 2-year follow-up period (102). 
 
This evidence, combined with the fact that our RA patients with a more pro-
atherogenic body habitus had higher levels of PAI-1 reinforces the connection 
between RA and CV risk. 
 
Blood pressure and carotid subclinical atherosclerosis were also associated with PAI-
1 activity in the RA group. Wallberg-Jonsson et al, found a significant association 
between cIMT and tissue plasminogen activator and they also found an association 
between carotid atherosclerotic plaque and PAI-1 in RA patients (103). 
In 2010, Sodergren et al also found significant associations between PAI-1 and 
systolic blood pressure and between tPA mass and carotid IMT in RA patients 
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(76).Therefore, PAI-1 appears to be linked to increased CV risk and pre-clinical 
markers of atherosclerosis in RA patients.  
RA patients with evidence of subclinical atherosclerosis or diastolic dysfunction 
were not found to have higher fibrinogen levels than those with no evidence of 
subclinical atherosclerosis or diastolic dysfunction.  
 
 
 
Osteoarthritis and Markers of Thrombosis: 
 
We reported a significant correlation between a number of anthropometric 
measurements associated with the metabolic syndrome and fibrinogen level in OA 
patients. Fibrinogen levels have been shown to correlate with components of the 
metabolic syndrome (104). Given the recent research into the links between OA and 
the metabolic syndrome, our findings are not that surprising. OA is now known to be 
associated with hypertension, dyslipidaemia, hyperglycaemia and obesity (105) and 
has been linked to the metabolic syndrome as a whole. The NHANES III study, 
analysing more than 7000 adults, found that the metabolic syndrome was more 
prevalent in people with OA (106).  
Smoking status was associated with PAI- activity in OA patients. This is in keeping 
with other research showing that smokers in general have higher levels of PAI-1 (89, 
107). 
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Urinary Protein Measures in RA and OA: 
 
We found that protein-creatinine ratio (PCR) was higher in RA patients compared to 
OA patients and that RA patients on a DMARD had a better PCR than those not on a 
DMARD. PCR correlated significantly with serum biomarkers of endothelial 
dysfunction and microalbuminuria correlated with diastolic dysfunction. 
Microalbuminuria is a recognised index of vascular disease and excess 
cardiovascular mortality (108). There are also reports that it may be useful in IHD, 
stroke and peripheral arterial disease prognosis (109).  It is a marker of endothelial 
dysfunction and is thought to be due to endothelial dysfunction of the glomerulus 
(110). 
A higher prevalence of microalbuminuria has been reported in RA patients compared 
to controls and one early study found rates of 27.7% in RA patients compared with 
7.8% in controls (111).  
Albuminuria is increased in patients with heart failure and elevated levels have been 
shown to predict future hospitalization for heart failure in patients without heart 
failure (112). 
Our findings of an association with diastolic dysfunction are supported by recent 
research by Katz et al. They studied the relationship between urine albumin-
creatinine ratio (UACR) to cardiac mechanics in 1894 adults in the general 
population and reported an independent association between UACR and E/e’ ratio, a 
marker of increased LV filling pressures (113). 
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Conclusions: 
 
CRP is a useful and readily available marker in RA. Its functions appear to be two-
fold; persistently elevated levels identify RA patients with on-going inflammation 
that needs to be addressed to reduce future CV risk and elevated CRP levels correlate 
with other cardiovascular markers such as PAI-1 and fibrinogen and may help to 
identify patients who should be evaluated for CV risk more meticulously. 
Serum urate is emerging as another potential marker of CVD. However, in RA 
patients with active inflammation it may be difficult to tease out whether elevated 
levels are due to an acute phase reaction or predict those at increased CV risk.  
Our findings of an association between serum urate and BMI, waist hip ratio and 
waist circumference are in keeping with previous research that reports an association 
with the metabolic syndrome. If serum urate is in fact a marker of CVD in RA, 
targeting weight control in these patients may reduce its concentration and 
subsequent CV risk.  
 
Similar to other research in this area, we found that serum concentrations of adhesion 
molecules were significantly higher in our RA group. Because both of our study 
groups had very similar rates of traditional risk factors, this supports the growing 
body of evidence that factors other than traditional CV risks are driving the increased 
rate of CV disease in RA patients.  
Based on our findings of higher concentrations of adhesion molecules in RA patients 
who were anti-CCP antibody and rheumatoid factor IgM positive and on the 
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association between CV risk and RA sero-positivity in multiple other studies, 
rheumatologist should be extra vigilant in screening for CV risks and disease in these 
patients.  
The fact that smoking is quite prevalent in rheumatoid populations, with a possible 
causal link to the development of RA, combined with our findings of  an association 
with endothelial biomarkers of atherosclerosis, emphasises the importance of 
targeting traditional CV risks aggressively in these patients.  
 
Our findings in relation to serum biomarkers and diastolic dysfunction in RA 
demonstrate a link between endothelial dysfunction and cardiac remodelling in this 
group. 
Of interest, from the analysis of our OA group, self-administered health related 
questionnaires correlated with a marker of endothelial dysfunction and this displays 
how relevant these questionnaires may be in the general assessment of RA patients. 
 
As we expected, serum cytokine concentrations were higher in RA patients. 
Interestingly, MCP-1, a common chemokine in both RA and CVD pathways was 
lower in those on a biologic DMARD, suggesting an anti-atherogenic effect of 
biologic agents in addition to their role in RA disease. This may be a useful future 
therapeutic target to treat both diseases simultaneously. 
 
The association between smoking and inflammatory cytokines, fits with the known 
effects of smoking on TNFα, IL6 and CRP. Given that smoking is a significant 
common environmental risk factor for both RA and CVD and is preventable, 
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emphasis should be placed on smoking cessation at the rheumatology clinic and not 
left to the cardiologist.  
 
Although previously thought to be a degenerative condition, there is now evidence 
that OA also has an inflammatory component at the level of the synovium and we 
have found that the degree of inflammatory burden in these patients correlated with 
disease duration.  
 
In our RA patients, fibrinogen levels are higher than in OA. Fibrinogen 
measurements may be useful in screening for future cardiovascular and 
cerebrovascular events in RA patients. However, due to the multitude of assays 
available to measure fibrinogen and the great variation in results between 
laboratories, standardization of this assay is required before using it in the clinical 
setting. 
Higher fibrinogen levels in our OA patients with an elevated BMI and the known 
link between fibrinogen and the metabolic syndrome, adds weight to growing 
evidence that OA is closely associated with the metabolic syndrome. 
 
The association between PAI-1 activity and multiple markers of disease activity in 
our RA group supports previous research identifying a link between inflammation 
and coagulation abnormalities. PAI-1 was also linked to subclinical atherosclerosis 
in our RA patients, which suggests that abnormal coagulation may be one of the 
mechanisms by which CVD is increased in RA. 
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Urinary protein-creatinine ratio is higher in RA patients and correlates with diastolic 
dysfunction. Our findings suggest a pathophysiological link between endothelial 
dysfunction and diastolic dysfunction in RA that needs to be investigated further. 
This suggests that measurement of albuminuria in RA patients may help to detect 
those at risk of diastolic dysfunction who would benefit from transthoracic 
echocardiogram. This is the first known study showing such a correlation in RA. 
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Chapter 5 
Macrovascular Endothelial Function in RA  
 
 
Background: 
 
Endothelial cells are a single lining layer of all blood vessels and traditionally were 
considered to primarily provide a barrier to diffusion of molecules from the vessel 
lumen into the interstitial space (1). It is now known that the endothelial lining is 
much less inert than previously thought. It is involved in platelet activation, 
leukocyte adhesion, modulation of thrombosis and regulation of vasomotor tone by 
nitric oxide, endothelin, prostacyclin and angiotensinogen (2). Endothelial 
dysfunction is accepted as one of the earliest stages of atherosclerosis and has been 
identified even in early childhood (3). It can predict cardiovascular events even in 
patients with normal appearing coronary arteries on angiography (4). The Working 
Group on Endothelin and Endothelial Factors of the European Society of 
Hypertension define endothelial dysfunction as an imbalance between vasodilating 
and vasocontricting substances produced by or acting on endothelial cells (5). 
Reactive oxygen species are felt to contribute considerably to this phenomenon.  
The gold standard for diagnosis of endothelial dysfunction is via intracoronary 
infusion of acetylcholine. This is a highly invasive and costly procedure. Therefore, 
a number of less invasive methods of assessing endothelial function have been 
developed. These include macrovascular assessment via flow-mediated dilatation of 
 265 
 
the brachial artery, forearm plethysmography, finger-pulse plethysmography and 
pulse curve analysis and microvascular assessment via laser Doppler skin flowmetry. 
 
Flow-mediated dilatation is the dilatation of a blood vessel in response to “shear 
stress”. The precise mechanism for a blood vessels ability to detect shear forces and 
modulate vasomotor tone in response are not fully understood. 
Non-invasive ultrasound FMD of the brachial artery is the most widely used method 
in research studies (6). The brachial artery is measured before and after an increase 
in shear stress that is induced by reactive hyperaemia.  
FMD is usually reported as the change in post-ischaemic diameter as a percentage of 
the baseline diameter (7). It is important to be aware that the baseline brachial artery 
diameter influences the percentage FMD in 2 ways. First, a larger baseline diameter 
results in a smaller percentage change, because the absolute change in diameter will 
be less, and secondly, smaller arteries appear to dilate more than larger arteries do. 
Therefore it is important to report the absolute change in diameter from baseline to 
post-ischaemic diameter in addition to the percentage change. There have been a 
number of recommendations from 3 different working groups with regard to what 
FMD variables should be reported as markers of endothelial function. The 
International Brachial Artery Reactivity Task Force published guidelines for 
reporting of FMD and recommended that the artery diameter 60 seconds post-cuff 
deflation be used to calculate FMD (8). The American Society of Echocardiography 
Noninvasive Vascular Ultrasound Report recommended also measuring the arterial 
diameter 60 seconds post–cuff deflation to calculate FMD (9). However, the 
European Society of Hypertension Working Group on Endothelin and Endothelial 
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Factors advised using the maximum diameter post-cuff deflation rather than FMD at 
a particular time post-deflation. They reported that using only the diameter at 
60seconds to calculate FMD will miss significant dilatation in up to 70% of cases (5)  
There is no consensus on what the normal range for flow mediated dilatation is, 
however an FMD of less than 5% is considered as impaired endothelial function 
(10). There is a wide variation in mean FMD values across populations and between 
gender and race. Females have a higher brachial FMD% than males and Caucasians 
have higher values than blacks (11). Bots et al reported that some of the variability in 
absolute values is due to the technical aspects of FMD measurement, including 
length of time of cuff inflation and cuff position (12). 
The effect of endothelium-independent vasodilatation is assessed by administration 
of sublingual glyceryl trinitrate (GTN). This is typically performed after FMD. 
Nitroglycerin mediated dilatation (NMD) is a measure of smooth muscle function 
and not a marker of endothelial function (8). The degree of brachial artery dilatation 
and its duration are typically greater post GTN administration compared to what 
occurs with FMD. The maximum obtainable vasodilator response is seen after GTN 
is administered. It is typically quoted as 15-20%, however there is no normal 
reference range (13). If NMD is impaired, it indicates the probability of smooth 
muscle cell dysfunction of the arterial wall owing to structural changes in vascular 
tissues (14). It has been postulated that reduced vasodilator response may be due to 
changes in baseline vasomotor tone in the presence of atherosclerosis (15). 
Flow mediated dilatation has demonstrated endothelial dysfunction early in the 
course of rheumatoid arthritis and before any symptoms of cardiovascular disease 
are present (16). FMD has also been found to be associated with markers of 
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inflammation in RA patients (17-19). A number of trials have shown a benefit of 
statin therapy on endothelial function in RA patients (20, 21).  There is also evidence 
that anti-rheumatic medications, used to control RA disease activity, have a 
beneficial effect on FMD but it is still a matter of debate whether these effects are 
transient or prolonged (22, 23). In 2012, Sandoo et al found that cardiovascular risks 
in RA patients more so than RA disease activity markers were associated with 
endothelial dysfunction (24). Endothelial dysfunction in RA, as assessed by FMD 
has not been compared to controls in an Irish population and there is no current data 
on the effects of RA disease activity and treatment and Irish RA patients.  
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Aims: 
 
Our primary aim was to compare flow mediated dilatation and nitroglycerin 
mediated dilatation as markers of macrovascular endothelial dysfunction in RA and 
OA patients without clinical evidence of cardiovascular disease. Secondary aims 
were to investigate if markers of inflammation, anti-rheumatic medications and 
cardiovascular risks were associated with macrovascular endothelial dysfunction in 
either group. 
 
Methods: 
 
Brachial artery ultrasound to assess flow mediated and nitroglycerin mediated 
dilatation are discussed in detail in chapter 2. 
 
Briefly, the brachial artery was imaged above the antecubital fossa in the 
longitudinal plane and a blood pressure cuff was placed below the antecubital fossa 
on the mid-forearm. A baseline, resting 2D ultrasound image is then acquired for 2-5 
minutes. Following this, the blood pressure cuff is inflated to 50mm Hg above the 
recorded stable systolic blood pressure for complete occlusion of arterial forearm 
inflow for 5 minutes. This forearm ischaemia produces dilation of downstream 
resistance vessels via auto-regulatory mechanisms. On release of the cuff, a brief 
hyper-perfusion state through the brachial artery is induced to accommodate the 
dilated resistance vessels. The resulting increase in shear stress in the brachial artery 
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causes the brachial artery to dilate and the longitudinal image of the artery is 
recorded continuously for the next 2 minutes.  
 
The FMD, defined as the percentage increase in mean diameter over a 10 second 
interval, 60 seconds after tourniquet deflation, is automatically averaged and 
calculated by the software from diastolic vessel diameters, using the following 
formula: 
                              Maximum diameter – baseline diameter 
                                   baseline diameter X 100%  
 
 
Endothelium-Independent vasodilatation with nitroglycerin was then assessed after a 
rest period of 10 minutes to allow return of brachial artery diameter to resting, steady 
state perfusion. An exogenous NO donor is then administered in the form of a single 
dose of sublingual nitroglycerin spray (0.4 mg). This is given to determine the 
maximum obtainable vasodilator response, and to serve as a measure of 
endothelium-independent vasodilation which indicates vascular smooth muscle 
function. Peak vasodilation occurs 3-4 minutes after nitroglycerin administration and 
the brachial artery image was continuously captured during this time period. 
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Statistical Methods: 
 
Means and standard deviations were calculated for normally distributed data and 
compared using a student t-test. Medians and interquartile ranges were calculated for 
non-normally distributed data and compared using a Mann Whitney U test. Bivariate 
correlations were calculated for continuous variables. Logistic regression analysis 
was performed to analyse the relationship between the presence of endothelial 
dysfunction, as defined by an FMD of less than 5% and a diagnosis of Rheumatoid 
Arthritis. Odds ratios and 95% confidence intervals were computed. A p-value of 
<0.05 was considered significant. SPSS 20 was used for all statistical analysis. 
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Results: 
 
Comparison of FMD and NMD in RA and OA patients: 
 
Forty-one patients with OA and 51 with RA attended for the investigation. The mean 
brachial artery diameter at baseline for the total group was 3.85mm (SD+/- 0.82). In 
the RA group, mean baseline diameter was 3.91mm (SD+/- 0.84), compared with 
3.78mm (SD+/- 0.79) in the OA group, p = 0.442. Mean values for FMD % and 
absolute FMD were similar in RA and OA patients. Peak FMD values were also 
similar in the 2 groups. Nitroglycerin mediated dilatation was also assessed and 
mean values were similar between the RA and OA groups (table 5.1). Age was not 
found to correlate with FMD or NMD in either the RA or OA group. 
For the purpose of logistic regression analysis, an FMD value of less than 5% at 60 
seconds post cuff deflation was taken as a marker of abnormal endothelial function. 
We also examined peak FMD post cuff deflation as a second marker of endothelial 
function. Using logistic regression analysis, neither FMD at 60 seconds nor peak 
FMD were found to be associated with a diagnosis of RA more so than OA; OR 
(95%CI), 1.69 (0.677, 4.223), p = 0.261 and OR (95%CI), 1.60 (0.538, 4.787), p = 
0.397, respectively.  Using logistic regression analysis, nitroglycerin mediated 
dilatation was not found to be associated with a diagnosis of RA more so than a 
diagnosis of OA; OR (95%), 0.826 (0.329, 2.076), p=0.685. Nitroglycerin mediated 
dilatation was found to be associated with baseline brachial artery diameter in both 
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RA and OA patients; OR (95%CI), 2.46 (1.028, 5.867), p =0.043 and 5.65 (1.578, 
20.194), p =0.008. 
 
 RA 
Mean (SD) 
OA 
Mean (SD) 
p 
Diameter at 60 seconds (mm) 4.20 (0.89) 4.08 (0.83) 0.534 
FMD % at 60 seconds 7.33 (3.28) 8.14 (3.49) 0.262 
Absolute FMD at 60 seconds(mm) 0.28 (0.14) 0.30 (0.12) 0.481 
Peak FMD % 8.47 ( 3.59) 8.94 (3.55) 0.531 
Absolute peak FMD (mm) 0.33 (0.15) 0.33 (0.12) 0.930 
NMD% at 4 minutes  15.60 (6.66) 15.72 (7.35) 0.941 
Absolute NMD at 4 minutes (mm) 0.59 (0.23) 0.56 (0.22) 0.605 
Peak NMD % 18.12 (7.54) 16.37 (7.19) 0.315 
Absolute peak NMD (mm) 0.68 (0.26) 0.59 (0.22) 0.100 
 
Table 5.1: Comparison of FMD and NMD in RA and OA groups. RA, rheumatoid 
arthritis; OA, osteoarthritis; SD, standard deviation; mm, millimetres; FMD, flow 
mediated dilatation; NMD, nitroglycerin mediated dilatation.  
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Ten OA patients (24%) had an abnormal FMD compared with 18 RA patients 
(35.3%). Using a chi2 test to compare the groups, no difference was found, p=0.259.  
Twenty-one (51%) of the OA group had a NMD of less than 15% compared with 19 
(37%) of the RA group, p=0.684.  
When we examined the RA group with an abnormal FMD more closely, we found 
2/3 of them were overweight or obese and 2/3 had moderate or high disease activity, 
as defined by a DAS28ESR and DAS28CRP of greater than 3.2 (table 5.2). 
 
 RA patients with abnormal FMD 
N (%) 
Males 6/18 (33.3%) 
Smokers 7/18 (39%) 
Overweight 12/18 (67%) 
DAS28ESR > 3.2 12/18 (67%) 
High CRP 6/18 (33.3%) 
High ESR 9/18 (50%) 
On synthetic DMARD 13/18 (72%) 
On Biologic DMARD 12/18 (67%) 
On NSAID 10/18 (56%) 
On glucocorticoid 9/18 (50%) 
On statin 5/18 (28%) 
 
Table 5.2: Summary of baseline parameters for RA patients with an abnormal FMD 
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Comparison of FMD and NMD in Males and Females: 
 
Using an independent t-test, we found that males had a significantly larger baseline 
diameter then females, 4.72mm (SD+/- 0.53) versus 3.48mm (SD+/- 0.60), p <0.001. 
There was no significant difference between males with OA and RA, p = 0.545. The 
same was true when females with RA and OA were compared, p = 0.807. When 
males and females were compared, males with OA had a significantly lower FMD 
and NMD than females with OA. However, the opposite was found in the RA group 
with respect to FMD, both at 60 seconds and peak FMD (table 5.3). 
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 RA males 
(SD) 
RA females 
(SD) 
p OA males 
(SD) 
OA females 
(SD) 
p 
FMD% at 60 seconds 8.02 (3.72) 6.93 (2.98) 0.284 6.38 (2.47) 8.63 (3.61) 0.044* 
Absolute FMD at 60 
seconds (mm) 
0.37 (0.16) 0.23 (0.09) 0.002* 0.31 (0.12) 0.30 (0.12) 0.931 
Peak FMD % 8.61 (4.11) 8.38 (3.33) 0.839 6.54 (2.41`) 9.61 (3.55) 0.007* 
Absolute peak FMD (mm) 0.40 (0.18) 0.28 (0.10) 0.019* 0.31 (0.13) 0.33 (0.12) 0.706 
NMD% at 4 minutes 14.27 (6.74) 16.50 (6.60) 0.295 11.11 
(4.65) 
17.01 (7.51) 0.022* 
Absolute NMD at 4 
minutes (mm) 
0.64 (0.26) 0.55 (0.21) 0.257 0.52 (0.21) 0.57 (0.23) 0.624 
Peak NMD% 16.86 (8.67) 18.93 (6.78) 0.425 12.06 
(4.47) 
17.58 (7.41) 0.026* 
Absolute peak NMD 
(mm) 
0.76 (0.31) 0.63 (0.21) 0.149 0.57 (0.21) 0.59 (0.23) 0.840 
 
 
Table 5.3: Comparison of FMD and NMD percentage and absolute values between 
males and females in both the OA and RA groups. RA, rheumatoid arthritis; OA, 
osteoarthritis, SD, standard deviation; mm, millimetres; FMD, flow mediated 
dilatation; NMD, nitroglycerin mediated dilatation; p significance level.  
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RA Disease Activity and Macrovascular Endothelial Function: 
 
We examined the effect of treatment and disease activity in the RA group on FMD. 
Within the RA group, mean baseline brachial artery diameter was similar regardless 
of whether patients were, or were not, currently on NSAIDS, steroids, DMARDS or 
biologic agents. RA patients on DMARDS, biologic agents, NSAIDs or steroids, had 
a similar degree of FMD to RA patients not on the above treatments. However, RA 
patients on a biologic agent were found to have a larger NMD response than those 
not on a biologic agent at the time of scanning, p =0.037*.  
The diameter of the brachial artery after cuff deflation was significantly correlated 
with ESR in the RA group, r = -0.324, p=0.021. Peak diameter post ischaemia was 
also associated with ESR, r=-0.281, p=0.046.  Actual FMD was significantly 
associated with the number of swollen joints in RA patients, r = -0.339, p = 0.015. 
Actual peak FMD was associated with number of swollen joints in the RA group, r = 
- 0.280, p = 0.047. Anti-CCP antibody and rheumatoid factor status did not have an 
effect on FMD. 
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Assessment of Relationship Between Macrovascular Endothelial Function and 
Markers of Cardiovascular Disease in RA: 
 
When we explored the cardiovascular risk factors and subclinical markers of 
atherosclerosis in the RA group, we found a number of correlations with FMD.   
RA patients with a family history of stroke had a significantly worse FMD than 
those with no family history of stroke. FMD% was 5.37 (SD 1.79) in the patients 
with a first degree relative with a history of stroke, compared with 7.70 (SD 3.38) in 
those without a family history, p=0.01. Absolute values for FMD were also lower in 
the RA patients with family history of stroke, 0.20 mm (SD 0.07) versus 0.30 mm 
(SD 0.14), p = 0.011. 
Within the RA group current smoking status did not have an effect on FMD. There 
was no difference in baseline artery diameter when smokers and non-smokers were 
compared, p = 0.385.   
NMD % at 4 minutes correlated with BMI, waist circumference, waist-hip ratio, r = -
0.382, p=0.013, r = -0.411, p=0.007, r =-0.399, p=0.009.  The actual NMD at 4 
minutes correlated with BMI, r = - 0.320, p=0.039. The peak NMD% correlated 
significantly with weight, waist circumference, waist hip ratio, r= -0.356, p=0.022, r 
=-0.38, p=0.014, r = -0.375, p=0.016.   
Statin use at the time of the study was not associated with a difference in baseline 
diameter in either the RA or OA groups, p = 0.802 and p = 0.394.  RA patients on a 
statin had a significantly lower FMD, both at 60 seconds post cuff deflation and peak 
dilatation, compared with those RA patients not taking a statin at the time of 
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scanning (table 5.5). This difference with respect to use of statin therapy was not 
seen in the OA group. Within the RA group, the presence of endothelial dysfunction 
as determined by peak FMD, was significantly associated with current use of statin 
therapy, OR (95%CI), 10.28 (1.932, 54.662), p=0.006. This remained the case after 
simultaneous adjustment for current serum total cholesterol and LDL levels, OR 
(CI), 9.33 (1.459, 59.611), p=0.018. This association was not seen in OA patients on 
statins.  
 
There was no significant difference in FMD between RA patients with an elevated 
serum cholesterol level at the time of scanning compared to those with a total 
cholesterol level in the normal reference range, p = 0.344. The diameter of the 
brachial artery after cuff deflation was significantly correlated with total cholesterol 
in the RA group, r = -0.287, p = 0.041. Peak diameter post ischaemia was also 
associated with total cholesterol, r = -0.288, p = 0.040. Total cholesterol levels 
correlated with the brachial artery diameter post GTN, r = - 0.32, p=0.039. The peak 
NMD% correlated significantly with fasting glucose, r = -0.446, p=0.011. 
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 Current statin No current statin p 
FMD% at 60 seconds 5.25 (2.39) 7.72 (3.30) 0.027* 
Absolute FMD at 60 seconds (mm) 0.19 (0.08) 0.29 (0.14) 0.008* 
Peak FMD% 6.02 (3.47) 8.93 (3.47) 0.055* 
Absolute peak FMD (mm) 0.22 (0.10) 0.34 (0.15) 0.015* 
 
 
Table 5.5: FMD in RA patients on a statin compared with those not taking the 
medication. RA, rheumatoid arthritis; OA, osteoarthritis, SD, standard deviation; 
mm, millimetres; FMD, flow mediated dilatation; NMD, nitroglycerin mediated 
dilatation; p significance level.  
 
RA patients with abnormal ABI and cIMT had similar FMD to those with ABI and 
cIMT in the normal ranges, p=0.137 and p=0.399, respectively. Baseline brachial 
artery diameter in the RA group correlated significantly with mean common carotid 
IMT, r = 0.307, p=0.040. NMD % at 4 minutes correlated with mean ABI, r =0.344, 
p=0.026. 
Baseline brachial artery diameter in the RA group also had significant correlations 
with some of the echocardiographic markers of diastolic dysfunction, including left 
ventricular mass and posterior wall size (table 5.6).  Absolute FMD values were 
worse in RA patients with an elevated BNP, 0.14mm (SD 0.04), compared with 
0.29mm (SD 0.14), p=0.019. FMD percentage and absolute FMD at 60 seconds post 
deflation were significantly correlated with serum BNP level, r = - 0.295, p = 0.046 
and r = -0.336, p=0.023.  
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 LA size 
(cm) 
LVDD 
(cm) 
PW thickness 
(cm) 
LV mass 
(g) 
Baseline brachial artery 
diameter (mm) 
R=0.388 R=0.492 R= 0.350 R= 0.496 
P value 0.005* 0.000* 0.012* 0.000* 
 
 
Table 5.6: Correlation between baseline brachial artery diameter and markers of 
diastolic function, mm millimetres; LA left atrial; LVDD left ventricular diastolic 
diameter; PW posterior wall; LV left ventricular; cm centimetres; g grams R 
correlation coefficient, p significance level. 
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Assessment of FMD and NMD in OA patients: 
 
Within the OA group, the number of years since diagnosis correlated significantly 
with size of brachial artery after cuff deflation, r = 0.346, p = 0.027. Peak diameter 
post ischaemia and diameter post sublingual GTN were both associated with 
numbers of years of diagnosis, r = -0.352, p=0.024 and r =-0.417, p=0.018.  
OA patients who smoked had a significantly worse FMD% than OA non-smokers, 
6.08% (SD 3.02) compared with 8.72% (SD 3.44), p=0.044. Patients with a prior 
diagnosis of hypertension or hypercholesterolaemia had similar baseline diameters to 
those without such diagnoses. NMD % and absolute NMD at 4 minutes were found 
to correlate with fasting glucose, r = -0.469, p=0.007 and r =-0.429, p=0.014. 
Within the OA group, the brachial artery diameter after cuff deflation and peak 
diameter post ischaemia both correlated significantly with a number of inflammatory 
cytokines: IL4, r = -0.476, p = 0.002 and r = -0.352, p = 0.024; IL8, r =-0.349, p= 
0.025 and r = -0.520, p=0.000; TNFα, r = -0.382, p = 0.014 and r = -0.376, p=0.015.  
 FMD% and peak FMD% in the OA group were both significantly correlated with 
serum IL10 levels, r =-0.400, p = 0.010, r = -0.376, p = 0.015.  Absolute FMD was 
associated with serum IL4 levels, r = -0.319, p = 0.042. The brachial artery diameter 
post-GTN correlated with serum IL4 and IL8 levels, r = -0.47, p=0.007, r = -0.437, 
p=0.012.  
We did not find any associations between inflammatory cytokine and FMD in our 
RA group.  
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Discussion: 
 
Macrovascular function in RA and OA patients: 
 
Our primary aim in this study was to compare RA patients and OA patients with 
respect to measures of flow mediated (FMD) and nitroglycerin mediated dilatation 
(NMD). We did not find a significant difference in percentage or absolute values for 
FMD or NMD between the 2 groups. However, we did discover that 35.3 % of the 
RA group and 24% of the OA group had evidence of endothelial dysfunction, as 
documented with abnormal FMD. Also, a significant proportion of both groups 
demonstrated lower NMD than normal. 
A number of studies support our findings. In 2010, Foster et al found no difference 
in FMD measurements between RA patients and community controls (25). The same 
researchers studied FMD in patients with early inflammatory arthritis in 2011 and 
found that FMD was again similar to controls (26).  Van Doornum et al also report 
similar results for macrovascular function as assessed by FMD in 25 RA patients and 
25 controls. Both groups were free of cardiovascular risk factors (27). Södergren A 
et al studied 79 patients with early RA and found no significant difference in FMD 
compared to controls, but did find that FMD in the RA group was related to serum 
biomarkers of endothelial dysfunction to a greater extent than FMD in the control 
group (28).  
Contrary to our results, a study of 20 RA patients in 2009 found significantly worse 
FMD and NMD measurements compared to controls. However, their control group 
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were made up of normal healthy individuals, as opposed to OA patients and their 
study numbers were significantly smaller than ours (16). Kerekes et al, reported a 
lower FMD but a similar NMD in RA patients compared to healthy controls (18). 
Vaudo et al, compared RA and OA patients with respect to endothelial dysfunction 
and reported a significantly worse FMD in the RA group (17). The patients with RA 
in this study had a longer disease duration than our RA patients and had a 
significantly higher total cholesterol than the OA control group. There was no 
significant difference in traditional CV risks between our OA and RA group. Vaudo 
et al also excluded patients with a family history of CAD, whereas we did not. Also, 
as mentioned in chapter 3, our OA group had a significantly higher rate of MI 
compared with our RA group. These differences may explain why we did not find a 
better FMD in our OA group.  
 
Comparison of FMA and NMD in males and females: 
 
We compared FMD and NMD variables in males and females in our study because 
previous research has shown had females tend to have a higher FMD than males 
(11). In keeping with this, our male OA group had a significantly lower FMD than 
female OA patients, but interestingly, RA females had a worse FMD than males with 
RA.   
Baseline brachial artery diameter tends to be larger in males in general and it has 
been postulated that this larger baseline diameter is the reason for a smaller 
percentage FMD that is often reported in males compared to females and some 
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researchers have suggested than FMD% can only be compared objectively between 
patients with the same brachial artery size (29). In our RA group, baseline brachial 
artery diameter was larger in males than in females, as expected. Therefore, one 
would expect that RA males would have a worse FMD than RA females, based on 
the theory above. We examined a number of other parameters that could have 
potentially been linked to a worse FMD in females; including age, disease duration, 
disease activity markers, smoking status and serum lipid levels (described in chapter 
3). However, these were all similar in males and females. We also compared pre- 
and post- menopausal females with respect to brachial artery diameter and FMD, in 
case the higher levels of circulating oestrogens associated with a pre-menopausal 
state were driving the difference between the sexes, but no difference was found 
between pre- and post-menopausal females. 
 
RA Disease Measures and Endothelial Function: 
 
Flow mediated dilatation in RA patients on DMARDS (synthetic and biologic), 
NSAIDS and/ or glucocorticoids did not differ from RA patients not taking the 
above anti-rheumatic medications. However, nitroglycerin mediated dilatation was 
better in RA patients on a biologic DMARD compared to those not prescribed a 
biologic DMARD.  
A number of studies have found that endothelial function improves with biologic 
DMARD use, in particular anti-TNF therapy (30, 31). Mazzaccoli et al reported a 
significant improvement in FMD immediately after first dose of etanercept and 
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infliximab, however they did not find a difference in FMD at 12 weeks when 
compared with pre- TNF inhibitor FMD measurements. In 2010, Tikiz et al reported 
a significant improvement in FMD after 12 weeks of Etanercept therapy. In contrast 
to our results, neither of the above studies found a better NMD in those treated with 
biologic DMARDS. The reasons for this may be differences in the study designs. 
Our cross-sectional study gives a snapshot of NMD in patients on a biologic agent at 
a particular point in time whereas the other 2 studies were prospective but had 
smaller numbers.  
With respect to RA disease activity in our study, ESR correlated negatively with the 
post-ischaemic artery diameter and swollen joint count correlated negatively with 
absolute FMD. When we examined the RA patients with evidence of abnormal 
FMD, we found that 2/3’s of them had either moderate or high disease activity. 
We did not find an association between endothelial dysfunction and RA auto-
antibody positivity.  
In 2009, Hannawi et al, reported results similar to ours, when they found a 
significant correlation between markers of RA disease activity and both FMD and 
NMD (16). This suggests that the inflammatory burden of RA is linked to both 
dysfunction at the level of the endothelium and to vascular smooth muscle damage. 
In contrast to our study, a cross-sectional study of 99 RA patients in 2012, did not 
find an association between markers of RA activity and macrovascular endothelium-
dependent function. ESR measurements were similar in the 2 studies; however, mean 
disease duration was shorter in our study, 7 yrs, compared with 11 years in the above 
study. Research has previously shown that the inflammatory burden of RA is often 
highest earlier in the course of the disease (32) and perhaps this may explain why we 
found significant correlations between ESR and endothelial dysfunction. 
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Interestingly, the above group did find that global cardiovascular risk, as assessed by 
Framingham and Reynolds risk scores, correlated significantly with nitroglycerin-
mediated dilatation. (24). They hypothesised from this study that CVD risk more so 
than RA disease related markers, may influence endothelial function.  
From the above studies, we can conclude that treatment with a biologic agent 
improves endothelial function, although it may be short-lived. We have also seen 
that inflammatory markers in RA are associated with the presence of both 
endothelial and vascular smooth muscle dysfunction. 
 
CVD risks and subclinical markers in RA patients and macrovascular 
endothelial function: 
 
We examined the RA group separately for associations between macrovascular 
endothelial function and CV traditional risks and subclinical markers of 
atherosclerosis. With regard to family history, RA patients with a first degree relative 
with a history of CVA had a significantly worse FMD than those with no family 
history of CVA. Smoking status did not appear to have an effect on FMD. 
Anthropometric measurements were associated with nitroglycerin mediated 
dilatation. In particular, BMI and waist-hip ratio were found to correlate negatively 
with peak NMD% and NMD% at 4 minutes post-GTN. Metsios et al recently 
reported the effects of an individualised exercise programme on endothelial function 
in RA (33). They have shown that nitroglycerin mediated dilatation significantly 
improved with a 6 month individualised resistance and aerobic training programme. 
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We can postulate from these results and the fact that exercise has a beneficial effect 
on anthropometric measurements in general, that improvements in BMI and waist-
hip ratio could be associated with improvements in endothelial function in RA.  
Using both bivariate correlation and logistic regression, we found that statin use at 
the time of brachial artery ultrasound was associated with a lower FMD in RA 
patients. However, FMD was similar in RA patients with an elevated serum total 
cholesterol and those with a total cholesterol in the normal range. Total cholesterol 
levels correlated with brachial artery diameter post-ischaemia.  
Two studies have shown that treatment with statin therapy improves both disease 
activity and endothelial dysfunction in RA patients. El-Barbary et al found that 
atorvastatin in combination with methotrexate significantly improved FMD and 
disease activity in 30 RA patients after 6 months of treatment (21). Wilkinson IB et 
al reported a significant improvement in FMD and disease activity scores in RA 
patients treated with either simvastatin or ezitimibe for 6 weeks (33). The fact that 
we found a worse FMD in RA patients on statin therapy compared with  those not on 
statin therapy, may be explained by the fact that those RA patients on a statin could 
have had a higher inflammatory burden or greater cardiovascular risk and by the 
cross-sectional nature of our work. 
With regard to markers of subclinical atherosclerosis, FMD did not differ between 
RA patients with abnormal ABI and cIMT and those with ABI and cIMT 
measurements in the normal range. NMD was found to correlate with mean ABI.  
We did not find any other study in the literature comparing ABI and FMD in RA 
patients, however, a prospective study of rosuvastatin therapy in systemic sclerosis, 
did report that, although FMD improved significantly after 6 months of therapy, no 
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change was seen in ABI measurements. This finding is perhaps due to differing 
effects of statin therapy on various vascular beds. 
Similar to our findings for cIMT and FMD, Sandoo et al did not find an association 
between FMD and cIMT in 200 RA patients. They postulated that vascular function 
as assessed by FMD and vascular morphology as assessed by carotid IMT reflect 
distinct phases and mechanisms in the process of atherosclerosis and are therefore 
not comparable (24). 
 
Both absolute and percentage FMD were negatively associated with serum BNP 
levels in RA patients. We have previously discussed in chapter 6, that serum NT-
proBNP levels were not associated with other markers of diastolic function in our 
RA group and this has been supported in other research (34). Our findings of an 
association between BNP and endothelial dysfunction may suggest that NT-proBNP 
is a marker of inflammation and disease activity rather than a marker of diastolic 
function in RA. Bruce IN et al reported that levels of NT-proBNP correlated with 
HAQ and CRP in inflammatory polyarthritis and predicted CVD mortality (35). 
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Macrovascular Endothelial Function in Osteoarthritis: 
 
We also examined the OA group separately and found that duration of disease was 
significantly associated with brachial artery diameter post ischaemic and post-GTN. 
Although we did not find a link between disease duration in RA and endothelial 
dysfunction, there are a number of studies that have reported an association (19, 22). 
As far as we are aware, there are no studies for comparison, examining the 
relationship between disease duration in OA and endothelial function. 
Fasting glucose in the OA group correlated with absolute and percentage NMD 
values. This is not surprising given the mounting evidence identifying OA as a 
metabolic disease with close association with the metabolic syndrome. It is now 
understood that obesity-related OA is one aspect of a group known as metabolic 
osteoarthritis, which includes OA related to hypertension, dyslipidaemia and 
diabetes mellitus (36). 
 
A number of pro- inflammatory cytokines, including IL8 and TNFα, were found to 
be significantly associated with a low FMD and NMD in OA patients. This finding 
was not seen in our RA group. Our RA group had significantly higher IL8 and TNF 
concentrations than the OA group. Perhaps there is a low grade level of 
inflammation in the OA group, which we did not detect with routine inflammatory 
markers that may explain the association between NMD and pro-inflammatory 
cytokines. There is emerging evidence that OA has a significant inflammatory 
component (37). In OA, pro-inflammatory cytokines stimulate release of cartilage-
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degrading proteinases by chondrocytes (38). Future research on the inflammatory 
burden of OA and its effect on vascular disease may change previous beliefs that OA 
was primarily a degenerative disease.  
 
Conclusions: 
 
No significant difference in flow-mediated and nitroglycerin-mediated dilatation was 
found between our RA and OAgroups. There seems to be conflicting evidence 
regarding the rate of macrovascular dysfunction in RA compared to the general 
population, as described above. This is no doubt in part due to the small sample sizes 
in the majority of studies so far. Large scale prospective studies are required to tease 
out further whether RA itself is a risk factor for endothelial dysfunction.  
Our finding of a significant correlation between markers of RA disease activity and 
endothelial dysfunction, demonstrate that RA remission induction would have 
beneficial effect not only on disability reduction in the long term but also on vascular 
function and supports the growing body of evidence that aggressive anti-rheumatic 
treatment will improve cardiovascular outcomes as well as RA disease specific 
outcomes.  
Associations between anthropometric measurements and NMD, together with 
knowledge that exercise improves NMD in RA patients, demonstrate the importance 
of exercise prescription in RA patients.  
Lack of an association between markers of subclinical atherosclerosis and 
endothelial dysfunction suggests that both are 2 distinct processes, perhaps occurring 
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at different time points in the progression of atherosclerosis in RA and are therefore 
not equivalent.  
Associations between endothelial dysfunction and glucose and pro-inflammatory 
cytokines in our OA group, support other recent research that OA is an inflammatory 
disease and is closely linked to the metabolic syndrome. 
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Chapter 6 
 Sub-Clinical Carotid Atherosclerosis in RA 
 
Introduction: 
 
Carotid intimal medial thickness reflects early atherosclerosis and is frequently used 
to assess excess cardiovascular risk. It is non-invasive for the patient and the carotid 
artery is easily accessible for ultrasound interrogation. It is a strong predictor for 
future vascular events in the general population (1).  
In 2001, the National Cholesterol Education Program Adult Treatment Panel III 
agreed that cIMT could be used as an adjunct in CHD risk assessment. It is 
recognized by the American Heart Association as a surrogate marker for coronary 
artery disease. The American Society of Echocardiography Carotid Intimal Medial 
Thickness Task Force recommend that measuring cIMT and identifying presence of 
carotid plaque can be useful for refining CVD risk assessment in patients at 
intermediate CVD risk (2).  
Carotid IMT has been found to be increased in RA patients with longstanding 
disease, but recently it has been shown that increased cIMT is evident in RA patients 
within 1 year of symptom onset (3). There have also been reports that cIMT 
progresses more rapidly in RA patients compared to controls and that it correlates 
with RA disease activity (4). Plaque, as well as IMT, is also more common in RA 
patients than controls (5).  
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Recently Corrales et al identified that carotid ultrasound is a more sensitive marker 
of subclinical atherosclerosis in RA patients than coronary artery calcification score 
(6). They categorised the CV risk of 95 RA patients using the EULAR modified 
Systemic Coronary Risk Evaluation tool (mSCORE) and found that carotid 
ultrasound examination had a higher sensitivity than coronary artery calcification 
scores for identifying patients with high mSCOREs. They also found that over 50% 
of RA patients with a coronary artery calcification score of 0 had evidence of carotid 
plaque on ultrasound. This study highlights the usefulness of carotid ultrasound for 
stratifying CV risk in RA patients. 
This evidence is further supported by a study of over 300 RA patients that found the 
addition of carotid ultrasound assessment to the EULAR modified SCORE tool 
increased the sensitivity of the mSCORE tool, particularly in patients with high CV 
risk. Severe carotid ultrasound abnormalities were found in 63% of RA patients with 
a moderate mSCORE (7).  
There is also research supporting this in the general population. The Multi-Ethnic 
Study of Atherosclerosis has found that increased cIMT readings are predictive of 
CVD events in adults with no evidence of coronary calcification (8).  
The assessment of cIMT and presence of plaque as markers of pre-clinical 
atherosclerosis in RA has not been extensively investigated in an Irish population.  
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Aims: 
 
Our primary aim was to compare carotid intima-medial thickness and degree of 
carotid plaque, as markers of sub-clinical atherosclerosis, in RA and OA patients 
without clinical evidence of cardiovascular disease. Secondary aims were to 
investigate if markers of inflammation, anti-rheumatic medications and 
cardiovascular risks were associated with sub-clinical atherosclerosis in either group. 
 
Methods: 
 
Patients attended the radiology department for carotid ultrasound examination. B 
mode ultrasound using a Toshiba Xario system and linear array 7mHz probe was 
used and scans were performed by a trained radiographer.  IMT (intima-media 
thickness) values were obtained at specific points for the right and left common 
carotid artery and for both the right and left internal carotid artery (RCCA, RICA, 
LCCA, LICA).  An average of three readings was taken for each variable and a 
composite value, expressed in mm was recorded.  Each of the 4 vessels was assessed 
for presence of plaque. Plaque was defined as a distinct protrusion > 1.5mm into the 
vessel lumen. This was recorded as either present or absent. If present, plaque size 
was recorded and expressed in mm. Both the radiographer performing the 
examination and the radiologist reading and interpreting the scans, were blinded to 
the identity of the study subjects and are unaware of whether they formed part of RA 
or OA group.  
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Based on recommendations from the American Society of Echocardiography (2) and 
the Mannheim Consensus document (9), carotid intimal medial thickness (cIMT) 
values were reported as a mean of the cIMT from the left and right common carotid 
arteries. A mean cIMT of greater than 0.9mm was considered abnormal (6). 
 
Statistical Methods: 
 
Means and standard deviations were calculated for normally distributed data and 
compared using a student t-test. Medians and interquartile ranges were calculated for 
non-normally distributed data and compared using a Mann Whitney U test. Bivariate 
correlations were calculated for continuous variables. Logistic regression analysis 
was performed to analyse the relationship between the presence of subclinical 
atherosclerosis, as defined by presence of carotid plaque and / or cIMT greater than 
0.9mm, and a diagnosis of Rheumatoid Arthritis. Odds ratios and 95% confidence 
intervals were computed. A p-value of < 0.05 was considered significant. SPSS 20 
was used for all statistical analysis.  
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Results: 
 
Comparison of Carotid Intima-Media Thickness in RA and OA groups: 
 
99 subjects from the study group attended for carotid ultrasound examination. 54 of 
these had a diagnosis of RA and 45 were patients with OA. A mean common carotid 
intimal medial thickness (cIMT) of 0.71mm (+/-SD 0.32) in the RA group and 
0.73mm (+/-SD 0.23) in the OA group was found. Using an independent t-test, no 
significant difference between the 2 groups was seen, p 0.614.  
Eight patients (14.8%) in the RA group had an abnormal cIMT, ie mean cIMT 
greater than 0.9mm. Seven patients (15.6%) in the OA group had abnormal cIMT 
readings.  
 
Carotid IMT and Characteristics of RA patients: 
 
In patients with RA, there was a significant positive correlation between age and 
mean common cIMT, Pearsons correlation, r= 0.425, p=0.001 (figure 6.1).  
Within the RA group, disease duration was longer in those with an abnormal cIMT 
compared to those RA patients whose cIMT fell within the normal range, 12.75 yrs 
(+/- SD 10.85yrs) versus 8.37 yrs (+/- SD 6.13yrs). However, this difference was not 
statistically significant, p=0.3. 
 304 
 
We also investigated whether there was a difference in cIMT between those on 
DMARDS, biologic agents, steroids and NSAIDS and those RA patients not on the 
above therapies (table 6.1). It is noteworthy that the mean cIMT was higher in RA 
patients not currently on a biologic agent compared with those on a biologic at time 
of ultrasound, 0.807 mm(SD 0.443 mm) versus 0.632 mm (SD 0.163 mm), p=0.048.  
We investigated this further to see if there was a higher rate of steroid and NSAID 
use in the biologic DMARD group, which may have been contributing to reduction 
of inflammation. There was no significant difference in current steroid dose between 
RA patients on a biologic agent and those not currently taking a biologic agent. 
NSAID use was higher in RA patients not currently on a biologic, p=0.008.  
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  Mean cIMT (mm) SD (+/-) P value 
Sex Male 0.740 0.248 0.525 
Female 0.687 0.361 
Current synthetic DMARD Yes 0.717 0.362 0.633 
No 0.680 0.192 
Current Biologic DMARD Yes 0.632 0.163 0.048* 
No 0.807 0.443 
Current steroid use Yes 0.746 0.438 0.465 
No 0.675 0.188 
Current NSAID use Yes 0.736 0.441 0.562 
No 0.681 0.168 
Current smoker Yes 0.629 0.149 0.137 
No 0.734 0.362 
Family history of any CVD Yes 0.714 0.416 0.903 
No 0.702 0.245 
 
Table 6.1: Mean cIMT in RA patients, comparing sex, current smoking status and 
current RA therapies, cIMT, carotid intimal medial thickness; mm, millimetres; SD, 
standard deviation; CVD, cardiovascular disease; p, significance at 0.05 level 
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Markers of CV disease and Carotid IMT measurements in RA: 
 
Within the RA group, we investigated whether there was a difference in cIMT 
measurements between those with and without CV risks. Bivariate correlations were 
used to look for associations between cIMT and CV risks (table 6.1 and table 6.2). 
Systolic blood pressure was found to have a clinically significant association with 
cIMT, r = 0.419, p = 0.004. Fasting glucose also correlated with cIMT 
measurements, r = 0.351, p = 0.012. On logistic regression analysis, fasting glucose 
was associated with an abnormal cIMT in patients with rheumatoid arthritis, OR 
(95%), 3.224 (1.161-8.954), p=0.025. 
A prior diagnosis of hypercholesterolaemia was found to be associated with an 
abnormal cIMT in the RA group, OR (95%CI), 6.667 (1.306-34.027), p=0.023. This 
association remained significant after simultaneous adjustment for traditional 
cardiovascular risk factors (table 6.3). To further investigate the significant 
association between a previous diagnosis of hypercholesterolaemia and presence of 
abnormal cIMT on ultrasound, logistic regression analysis was performed to assess 
for an association between current serum fasting cholesterol level and abnormal 
cIMT.  This did not reveal any significant association, OR (95%CI), 0.524 (0.108-
2.552), p=0.424. This lack of association can be explained by the fact that all but one 
of the patients with a prior diagnosis of hypercholesterolaemia were taking a statin at 
the time that blood was drawn for fasting cholesterol level.  
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Within the RA group, alcohol consumption was associated with the presence of an 
abnormal cIMT, OR (95%), 13.2 (1.761-98.926), p=0.012. This was still significant 
after adjustment for age, smoking status, presence of hypertension and 
hypercholesterolaemia, OR (95%CI), 14.523 (1.342-157.126), p=0.028. However, 
our wide confidence interval reflects the small sample size.  
Carotid IMT was not associated with smoking in the RA group, r = 0.024, p =0.836. 
 
Two measures from transthoracic echocardiogram; LV posterior wall thickness, a 
marker of diastolic dysfunction and LV mass, a marker of hypertension, were both 
found to significantly correlate with cIMT measurements in the RA group, r = 0.358, 
p = 0.009 and r = 0.359, p = 0.009, respectively.  
Also, PAI-1, a marker of thrombosis, was found to correlate significantly with cIMT 
in the RA group, an association which was not seen in the OA group, r = 0.294, p 
=0.045. 
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Correlation between mean cIMT and markers of CVD  
and metabolic syndrome  
Correlation 
coefficient, r 
p 
Age, yrs 0.425 0.001* 
Smoking Pack years 0.024 0.863 
Systolic Blood Pressure 0.419 0.004* 
Body Mass Index (kg/m
2
) 0.252 0.066 
Waist Hip Ratio 0.188 0.174 
LV posterior wall thickness 0.358 0.009* 
LV mass (g) 0.359 0.009* 
Total cholesterol (mmol/l) 0.056 0.687 
Fasting Glucose (mmol/l) 0.351 0.012* 
PAI activity 0.294 0.045* 
Fibrinogen 0.001 0.997 
 
 
Table 6.2: Correlations between cIMT and markers of CVD and the metabolic 
syndrome in the RA group. RA, rheumatoid arthritis; cIMT, carotid intimal medial 
thickness; r, correlation co-efficient; p, significance level 0.05 
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Figure 6.1: Scatter plot demonstrating the positive correlation between age and mean 
common carotid IMT in RA patients 
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cIMT in RA group OR 95%CI p Adjusted 
OR (a) 
Adjusted 
95%CI 
p 
Age 1.146 0.991- 
1.326 
0.067 1.115 0.920-
1.351 
0.269 
Sex 1.875 0.413- 
8.512 
0.415 1.786 0.213-
14.983 
0.593 
Family history of CVD 0.433 0.079- 
2.380 
0.336 0.127 0.010-
1.630 
0.113 
Prior diagnosis of 
Hypercholesterolaemia 
6.667 1.306-
34.027 
0.023* 14.467 1.461-
143.26 
0.022* 
Fasting glucose (mmol/l) 3.224 1.161- 
8.954 
0.025* 6.104 0.723-
32.169 
0.050* 
Total cholesterol 
(mmol/l) 
0.524 0.108- 
2.552 
0.424 1.241 0.426-
3.612 
0.692 
LDL (mmol/l) 0.590 0.140- 
2.457 
0.472 0.267 0.042- 
1.697 
0.162 
Smoking status 1.818 0.388- 
8.514 
0.448 3.160 0.374-
26.713 
0.291 
Alcohol consumption 13.2 1.761-
98.926 
0.012* 14.523 1.342-
157.126 
0.028* 
   a = OR after simultaneous adjustment for age, sex, smoking status, diagnosis of 
hypertension and family history of CVD 
Table 6.3: Summary of association between cIMT and CVD risks in the RA group 
analysed using logistic regression. RA, rheumatoid arthritis; OR, odds ratio; CI, 
confidence interval; p, 0.05 significance level 
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Results for Presence of Carotid Plaque: 
 
Carotid plaque was present in 12 of the 99 subjects who had a carotid ultrasound. 
Seven of the 12 were patients with RA. Using Chi squared testing, no significant 
difference in the number of RA patients and OA patients who had plaque visible on 
ultrasound was found, p=0.779. 
Of the 12 patients with evidence of plaque on ultrasound, 6 were smokers, 3 were 
already on a statin, 8 had a higher than normal BMI and waist-hip ratio.  
 
Carotid Plaque and Lipid Profile: 
 
Serum HDL was significantly higher in RA patients without presence of plaque 
compared to those with plaque burden on ultrasound, 1.65mmml/l (SD 0.46mmol/l) 
versus 1.33mmol/l (SD 0.31 mmol/l), p=0.04. LDL levels were higher in the RA 
patients who had evidence of plaque on ultrasound compared to RA patients with no 
plaque, 3.67 mmol/l (SD 0.49 mmol/l) versus 3.15 mmol/l (SD 0.54 mmol/l), p = 
0.033.  
Interestingly, serum LDL level was significantly associated with the presence of 
carotid plaque in RA patients on logistic regression, OR (CI 95%), 9.058 (1.178-
69.635) p = 0.034. This remained significant after simultaneous adjustment for 
traditional cardiovascular risk factors, p = 0.046. LDL level was not found to be 
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associated with the presence of carotid plaque in the OA group, OR (95%CI), 1.988, 
(0.619-6.383), p = 0.248 (table 4). 
 
Carotid Plaque and Diastolic Dysfunction: 
 
E/e’ lateral, a marker of diastolic dysfunction, was associated with presence of 
plaque in both the RA and OA groups, p=0.017 and p=0.007 respectively. E/e’ 
(average lateral and septal combined) was also associated with carotid plaque in both 
the RA and OA groups, p =0.031 and p=0.019 respectively (table 6.4). After 
simultaneous adjustment for age and hypertension, these associations were no longer 
significant in the RA group, p = 0.093. Significance remained in the OA group, but 
confidence intervals were very wide, p = 0.012. 
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Carotid Plaque in RA group Odds 
ratio 
95% CI p 
Male sex 1.320 (0.30, 9.25) 0.733 
Current biologic therapy 2.019 (0.42, 18.14) 0.428 
Current steroid use 1.800 (0.38, 10.99) 0.473 
Family History RA 2.455 (0.58, 20.01) 0.284 
Dx of HTN 4.286 (0.78, 23.43) 0.093 
Rheumatoid factor positive 2.057 (0.22, 18.87) 0.524 
Fasting Cholesterol 1.469 (0.50, 4.36) 0.488 
LDL 9.058 (1.18, 69.65) 0.034* 
E wave velocity 1.131 (1.03, 1.25) 0.014* 
E/A ratio <1 1.706 (0.31, 9.42) 0.540 
E/e’lateral 2.616 (1.19, 5.75) 0.017* 
E/e’average 2.189 (1.08, 4.46) 0.031* 
Diastolic dysfunction 8.700 (0.81, 93.49) 0.074 
 
Table 6.4: Summary of results for variables associated with carotid plaque in the RA 
group, using logistic regression analysis. HTN, hypertension; ABI, ankle brachial 
index; E wave, early diastolic filling velocity; E/A ratio, ratio of early to late 
diastolic filling velocity; e’, early diastolic mitral annular velocity; p, significance 
level 
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Carotid Disease in the OA group: 
 
As with the RA group, age also correlated with cIMT in the OA group, r = 0.487, 
p=0.001. A prior diagnosis of hypercholesterolaemia was found to be associated with 
an abnormal cIMT in the OA group, 9.375 (1.525-57.621), p=0.016.   
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Discussion: 
 
Comparison of Carotid Intima-Media Thickness in RA and OA groups: 
 
Carotid IMT did not differ between rheumatoid and osteoarthritis patients in our 
study. A number of studies have found that cIMT is increased in RA patients 
compared with healthy controls and they have postulated that this difference is due 
to the inflammatory burden of the disease (5, 10-12). The majority of these studies 
used healthy adults as their control group and this is one reason why we may have 
found conflicting results. 
However, similar to our findings, del Rincon et al did not find a difference in cIMT 
when they compared 204 RA patients with 102 healthy controls (13). 
Our control group were patients attending a rheumatology department with a 
diagnosis of osteoarthritis. There are a number of potential reasons why we did not 
find a difference in cIMT; OA patients attending a rheumatology clinic are at the 
more severe end of the disease spectrum and may be more likely to be exposed to 
NSAID use over time. Also, some traditional cardiovascular risk factors were 
significantly higher in the OA group, as previously discussed in chapter 3, a family 
history of myocardial infarction was significantly higher in the OA group (60% 
compared with 25% in the RA group), p= 0.001. Mean BMI was also significantly 
higher in the OA group, p=0.017. However, we have corrected for these differences 
in traditional risk factors, using logistic regression analysis.  
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Another factor to consider is that females with OA are more likely to have an 
inflammatory element to their disease during the perimenopausal period and this 
may be associated with an increased cardiovascular risk. There is also emerging 
evidence that OA is associated with an increased risk of CVD, especially IHD and 
CHF. Goldsmith et al found that older males and adult females with OA had a higher 
risk of CVD compared with non-OA controls (14). In the Rotterdam study, Hoeven 
et al conducted a large prospective study to investigate if atherosclerosis was 
associated with the presence and progression of OA. They found that atherosclerosis, 
as assessed by carotid IMT and presence of plaque was independently associated 
with hand and knee OA in women (15). 
 
 
Carotid IMT and Characteristics of RA patients: 
 
As expected, we found that increasing age correlated with mean cIMT. Age related 
increases in cIMT of about 0.010 mm per year in healthy males and 0.014 mm per 
year in healthy females have been reported (16). The progression rates of cIMT in 
patients with known coronary artery disease are up to 3 times that of healthy 
individuals (17).  
Although not statistically significant, we did find that RA patients with an abnormal 
cIMT had longer disease duration than those with cIMT in the normal range. A 
number of studies have found similar results (18-20). However, the literature appears 
to be contradictory in this area; numerous studies  have found evidence of 
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atherosclerotic disease, documented as abnormal cIMT, in RA patients with disease 
duration of 12 months or less (3, 11, 21). 
These conflicting results suggest that the degree of carotid atherosclerosis in RA may 
be linked to RA disease activity rather than disease duration.  
 
In this study, 29 of the 63 RA patients were on a biologic DMARD at the time of 
carotid ultrasound and they had a significantly more favourable cIMT than those not 
currently on a biologic DMARD. Concomitant medications such as steroid and 
NSAID use were not driving this difference. This is in keeping with results from 
other studies which have found anti-TNF agents to have a beneficial effect on cIMT 
over time (22-24). Giles et al followed 158 RA patients over 3 years and found that 
those taking tumour necrosis factor (TNF) inhibitors at baseline had a 37% lower 
adjusted rate of progression in cIMT compared with those not on anti-TNF therapy 
at baseline (25).  
These findings support evidence that TNF inhibitors appear to be associated with 
reduced risk of all heart disease events (26). 
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Markers of CV disease and Carotid IMT measurements in RA: 
 
A prior diagnosis of hypercholesterolaemia was associated with the presence of 
abnormal cIMT in the RA group. Our findings for this association are in keeping 
with multiple other studies that have found a link between serum levels of lipids and 
both cIMT and carotid plaque (20, 27, 28). Dessein et al recently reported that serum 
cholesterol / HDL ratio was significantly associated with cIMT and carotid plaque in 
RA patients (28). In 2011, Majdan M et al studied 74 RA patients without evidence 
of CVD and found that serum cholesterol was positively associated with cIMT (20). 
Oxidized LDL antibodies have also been shown to be independently associated with 
cIMT in RA patients (27).  
Our findings and those listed above indicate that abnormal lipid profiles are 
independently associated with subclinical atherosclerosis in patients with RA. 
 
We also found that fasting glucose correlated significantly with cIMT in RA 
patients. Del Rincon et al had similar findings (29). They looked at numbers of RA 
patients with carotid plaque who had diabetes mellitus, as opposed to a single fasting 
glucose measurement. They described a significant association between cIMT and 
presence of diabetes mellitus. Their RA patients with evidence of carotid plaque also 
had a significantly higher rate of diabetes mellitus than those with no plaque on 
ultrasound. A prospective study of 114 RA patients in Sweden found that a diagnosis 
of diabetes was significantly associated with carotid IMT at a 5 year follow-up (30).  
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With regard to the results of the transthoracic echocardiography, LV mass in the RA 
group was significantly correlated with carotid IMT. Left ventricular mass reflects 
hypertension and we also found that systolic blood pressure correlated significantly 
with cIMT in the RA group. These correlations were not seen with the OA control 
group. Patients with RA are at a higher risk of developing hypertension than the 
general population, due to frequent NSAID use over time and also steroid use, often 
in quiet high doses. The above association with a surrogate marker of atherosclerosis 
highlights the importance of close monitoring of blood pressure in RA and early 
intervention if required. Puato et al recently reported a higher cIMT in patients with 
psoriatic arthritis (PsA) and hypertension when compared to normotensive patients 
with PsA (31). Del Rincon et al found a significant association between hypertension 
and presence of carotid plaque in a large cohort of RA patients (29). In their study of 
631 RA patients they reported that those with presence of plaque on ultrasound had a 
significantly higher rate of hypertension. They also found that a diagnosis of 
hypertension was associated with cIMT.  
 
PAI-1, a marker of thrombosis, correlated significantly with cIMT in our RA patient 
group. This indicates that RA patients with abnormal cIMT also have altered 
haemostasis and links between these pathways may be responsible for the excess 
CVD seen in RA.  
Sodergren et al found that disease activity markers in RA patients were associated 
with higher concentrations of PAI-1 and other markers of thrombosis. They also 
reported a significant association between cIMT and some thrombotic markers (32). 
In an earlier study of 39 RA patients, Wallberg-Jonsson et al also described a 
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significant association between cIMT and PAI-1, along with other thrombotic 
markers and adhesion molecules (33).  
 
Although not a traditional marker of CV disease, it is interesting to note that alcohol 
consumption was associated with carotid IMT in RA patients, even after adjustment 
for traditional CV risk factors. As reflected in our wide confidence intervals, the 
numbers of RA patients consuming more than 14 units of alcohol per week was 
small and based on this it is not possible to conclude whether this lifestyle choice is a 
risk factor for cIMT in RA patients. We did not find any evidence of this in the 
literature. Studying cIMT and perhaps progression of cIMT over time in a larger 
cohort of RA patients who drink more than the recommended amount of alcohol 
would be interesting to investigate further.  
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Carotid Plaque and Lipid Profile: 
 
In our RA group, serum HLD was better in patients without evidence of carotid 
plaque. Also, serum LDL level was significantly associated with presence of plaque 
on carotid ultrasound in the RA group but not in the OA control group. This 
highlights the importance of screening for traditional cardiovascular risk factors in 
RA patients, as those with elevated LDL levels may be more prone to developing 
carotid disease. Identifying these patients early and treating promptly with statin 
therapy may help to reduce their atherosclerotic disease burden in the longer-term.  
 
Carotid Plaque and Diastolic Dysfunction: 
 
E/e’, a marker of diastolic dysfunction on tissue Doppler imaging, was significantly 
associated with presence of plaque in both the RA and OA group. However, after 
adjustment for age, this finding was no longer significant. As both of these 
parameters are known to deteriorate with increasing age, it makes sense that age, 
rather than diagnosis is the reason for this association.  
Ciftci et al examined diastolic function and carotid IMT in 30 RA patients with no 
evidence of CVD and found similar results. They examined coronary flow reserve 
and found that it correlated positively with E/A ratio and negatively with IMT (34).  
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Conclusions: 
 
Contrary to previous research, we did not find that RA patients had a greater degree 
of carotid IMT compared with OA controls. However, our OA control group are not 
comparable to normal healthy controls as there is emerging evidence that OA itself 
has an inflammatory component and is associated with increased CV risk.  
Whether or not RA disease duration is a risk factor for abnormal cIMT is a matter for 
debate. As mentioned above, abnormal cIMT has been reported in longstanding 
disease but also in patients who have a diagnosis of RA for less than 1 year. This 
demonstrates the importance of screening for CVD early in the course of RA, when 
the burden of inflammation is often high prior to control with anti-rheumatic 
medications. Traditionally, when rheumatologists think of CVD risk in RA patients, 
it tends to be those patients with a long disease duration and their focus early in the 
course of RA is often solely on disease activity control rather than CV risk 
assessment. 
Our findings of an association of serum lipid measurements with both cIMT and 
carotid plaque indicate that RA patients with an abnormal lipid profile would appear 
to be at a greater risk of developing future CV events. The fact that we have shown a 
link between lipid profile and subclinical atherosclerosis reinforces the importance of 
CV risk screening in this population. RA patients who have an abnormal lipid profile 
may benefit from carotid artery ultrasound to further stratify their CV risk and 
rheumatologists should have a low threshold for treatment with statin therapy.  
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PAI-1, a measure of haemostasis, correlates with sub-clinical atherosclerosis in RA 
patients. This highlights the fact that a number of mechanisms including altered 
coagulation and atheroma formation are involved in atherosclerosis and CV disease 
in this group.  
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Chapter 7 
Peripheral Vascular Disease in RA 
 
Introduction: 
 
Peripheral vascular disease is a chronic occlusive disease of the arteries in the lower 
extremities caused by atherosclerosis. Prevalence of PVD increases with age and 
worldwide figures range from 3 to 12 percent (1). It is more prevalent in older 
individuals and those with risk factors for cardiovascular disease. The risk of 
developing PVD is increased with smoking, hypertension, diabetes, hyperlipidaemia 
and the metabolic syndrome (2).  
PVD often coexists with other atherosclerotic diseases. Aronow et al studied 1,886 
people with a mean age of 81 years and found that 58% of the 468 people with PVD 
also had coexistent coronary artery disease (CAD) and 34% had a prior ischaemic 
stoke (3). People who suffer from PVD have an increased risk for cardiovascular and 
all-cause mortality (4).  
Coronary artery disease has been the primary focus of cardiovascular risk assessment 
in patients with rheumatoid arthritis (RA). Much less is known about the risk factors 
for PVD (5) in RA. One prospective study of 813 RA patients found no difference in 
rates of peripheral arterial events compared to non-RA controls (6).  In 2004, del 
Rincon et al, found that glucocorticoid use in RA patients was significantly 
associated with arterial incompressibility, as defined by an elevated ABI > 1.4. This 
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incompressibility is due to calcified arterial walls and it results in increased vascular 
stiffness. They did not report an association between steroid use and lower-limb 
artery obstruction. 
The prevalence of PVD in other inflammatory arthropathies has not been 
investigated thoroughly. One cross-sectional study in 2006, reported an overall risk 
of PVD in patients with psoriatic arthritis (PsA) of 1.6 (1.2-2.0) compared to non- 
PsA controls (7). 
Ankle brachial index is the standard non-invasive tool for the assessment of 
peripheral arterial disease. It is not only a marker of peripheral artery disease but also 
of generalized atherosclerosis. Lower measurements of the ABI have been associated 
with the presence of cardiovascular risk factors and with higher rates of coronary and 
cerebrovascular disease (8, 9). In 2008, a meta-analysis performed by the Ankle 
Brachial Index Collaboration, reported that ABI provided independent risk 
information compared with the Framingham risk score (FRS) and also, an ABI < 0.9 
in combination with FRS, approximately doubled the risk of all cause and 
cardiovascular mortality and major coronary events across all Framingham risk 
groups (10).  
Multiple studies, including the Strong Heart Study (11, 12) have found that the 
relationship between CVD and ABI is non-linear. High ABI values (>1.40) may be 
due to increased arterial stiffness resulting in poor compressibility, occuring in 
particular in diabetic patients. This may help to explain why those with a high ABI 
are at an increased CV risk. 
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In 2007, the Fourth Joint Task Force of the European Society of Cardiology 
suggested that ABI be considered for the purposes of cardiovascular risk assessment 
(13). 
PVD has not been studied in RA patients in an Irish population. 
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Aims: 
 
To compare ABI measurements, as a marker of PVD, in RA and OA patients 
To investigate if there was a relationship between ABI and other markers of 
subclinical atherosclerosis in RA.  
 
Methods: 
 
Ankle brachial index was performed in the usual manner. Blood pressure was 
recorded in both arms after a period of at least 15 minutes rest. The highest systolic 
reading of the 2 was used in the index calculation. For ankle pressure measurement, 
the cuff was placed around the calf and it was then inflated 20 mmHg above the 
upper limb systolic pressure.  
A Nicolet Elite handheld Doppler ultrasound with an 8 MHz probe was used to 
measure ABI. The ultrasound probe was placed over the dorsalis pedis artery and the 
blood pressure cuff slowly deflated. If the dorsalis pedis artery was not easily 
palpable, the posterior tibial artery was used instead. The pressure at which arterial 
pulsation was first heard, was recorded and used in the calculation. ABI for each leg 
was calculated as a ratio of ankle pressure to upper limb systolic pressure. A mean of 
both lower limb ABIs was then calculated. A value of 0.96 or greater was considered 
as a normal ankle brachial index measurement (14). 
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Statistical Methods: 
 
Means and standard deviations were calculated for normally distributed data and 
compared using a student t-test. Medians and interquartile ranges were calculated for 
non-normally distributed data and compared using a Mann Whitney U test. Bivariate 
correlations were calculated for continuous variables. Logistic regression analysis 
was performed to analyse the relationship between the presence of peripheral 
vascular disease and a diagnosis of Rheumatoid Arthritis. Odds ratios and 95% 
confidence intervals were computed. A p-value of <0.05 was considered significant. 
SPSS 20 was used for all statistical analysis. 
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Results: 
 
108 recruits had an ankle brachial index (ABI) measured as part of the study. Mean 
ABI for the total group was 1.035 (+/- 0.071). The mean ABI in the RA group was 
1.013 (+/- 0.073) compared with a mean ABI of 1.059 (+/- 0.063) in the OA group, 
see table 7.1. Using an independent t-test, this difference was found to be significant, 
p <0.001, see figure 7.1.  
Both male and female patients with rheumatoid arthritis had a significantly worse 
ABI than their OA counterparts, p=0.012 and p=0.043, respectively. Nine patients 
with rheumatoid arthritis had an abnormal ABI, while 3 of the OA group had an 
abnormal ABI. Using a Chi
2
 test, this was not a significant difference between the 
groups, p=0.150. No one in the study had a non-compressible ABI. 
Using logistic regression analysis, PVD was not found to be associated with markers 
of inflammation or disease activity scores in the RA group, OR (CI 95%), 1.03 (0.99, 
1.07) p=0.211 and OR (CI 95%), 2.18 (0.19, 25.23), p = 0.532, respectively. 
ABI was better in RA patients currently on a biologic DMARD, however this 
difference was not significant, p=0.076 (see table 7.2). E –selectin levels were also 
associated with ABI in the RA group, r= -0.265, p=0.043. There was no  significant 
correlation between other adhesion molecules (ICAM, VCAM, L-selectin, P-
selectin) and ABI, or between inflammatory cytokines and ABI.  
ABI was lower in those RA patients with a family history of rheumatoid arthritis, 
compared to RA patients who had no family member with RA, 0.988 (+/-0.059) 
versus 1.023 (+/- 0.076), p=0.063. 
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Four of the RA patients with abnormal ABI measurements were smokers. Four were 
less than 50 years old and 3 of these had never smoked. RA patients with a family 
history of peripheral vascular disease (PVD) had a lower ABI than RA patients with 
a negative family history for PVD, 0.997 (+/-0.063) versus 1.023 (+/- 0.078), 
p=0.051.  
Within the RA group, those who were taking a statin had a significantly lower ABI 
compared with those RA patients not taking a statin, 0.986 (+/-0.036) versus 
1.019(+/-0.078), p=0.046. RA patients with a prior diagnosis of 
hypercholesterolaemia had a worse ABI than those RA patients with no such prior 
diagnosis, 0.987 (+/-0.034) versus 1.019 (+/-0.079), p=0.039. Fasting glucose was 
associated with ABI in the RA group, r= -0.301, p=0.023.  
 
PAI activity levels were associated with ABI in the RA group, r= -0.280, p=0.04. 
GTN FMD at 4 and 6 minutes was significantly correlated with ABI in RA patients, 
r = 0.344, p = 0.026 and r = 0.324, p = 0.036 respectively. Common carotid IMT in 
the RA group was associated with ABI, r = - 0.297, p=0.033. E/E prime, a marker of 
diastolic dysfunction, also correlated with ABI in the RA group, r = -0.322, p=0.024.  
Using logistic regression analysis, the presence of carotid subclinical atherosclerosis, 
endothelial dysfunction or diastolic dysfunction in the RA and OA groups were not 
found to be associated with abnormal ankle brachial index (table 7.3).  
No associations were found between ankle brachial index and any of the pro-
inflammatory cytokines on linear correlation or logistic regression.  
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In the OA group, there was a significant correlation between smoking pack years and 
ABI, r= -0.305, p=0.035. This was not seen in the RA group. NT-proBNP level in 
the OA group also significantly correlated with ABI, r=-0.349, p=0.037. 
 
 
  Mean ABI SD P value 
Diagnosis RA 1.013 0.073 0.001 
OA 1.059 0.063 
Males RA 0.992 0.075 0.012 
OA 1.064 0.061 
Females RA 1.026 0.070 0.043 
OA 1.060 0.065 
 
 
Table 7.1: Comparison of mean ABI in RA and OA males and females 
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  Mean ABI (SD) P 
Synthetic DMARD Yes 1.018 (0.07) 0.436 
No 0.999 (0.09) 
Biologic DMARD Yes 1.028 (0.09) 0.076 
No 0.996 (0.04) 
Steroid use Yes 1.010 (0.07) 0.782 
No 1.016 (0.08) 
Statin use Yes 0.986 (0.04) 0.046* 
No 1.019 (0.08) 
Hypertension Yes 1.001 (0.09) 0.667 
No 1.015 (0.07) 
Hypercholesterolaemia Yes 0.987 (0.03) 0.039* 
No 1.019 (0.08) 
Smoker Yes 0.997 (0.07) 0.061 
No 1.033 (0.08) 
Family history of PVD Yes 0.997 (0.06) 0.051 
No 1.023 (0.08) 
Family history of RA Yes 0.988 (0.06) 0.063 
No 1.023 (0.07) 
 
Table 7.2: Comparison of mean ABI in RA patients with respect to medications 
used, CVD risks and family history. PVD, peripheral vascular disease; p, 
significance level; SD, standard deviation. 
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Figure 7.1: Boxplot comparing mean ABI measurements in RA and OA 
patients, ABI, ankle brachial index. 
P =0.001 
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 Abnormal ABI 
OR (CI 95%) 
p 
RA Endothelial dysfunction 0.329 (0.04, 3.06) 0.327 
Carotid atherosclerosis 1.76 (0.29, 10.58) 0.536 
Diastolic dysfunction 1.62 (0.32, 8.17) 0.567 
OA Endothelial dysfunction 7.5 (0.60, 93.59) 0.118 
Carotid atherosclerosis 1.30 (0.91, 8.02) 0.523 
Diastolic dysfunction 4.14 (0.35, 49.66) 0.262 
 
 
Table 7.3: Association between ABI and markers of CVD in RA and OA patients. 
OR, odds ratio, CI, confidence interval; p, significance level. 
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Discussion: 
 
Ankle brachial index was found to be significantly lower in the RA group compared 
to the OA group of patients. No association was seen between ABI and inflammatory 
markers or disease activity scores in RA patients on logistic regression analysis. 
Sixty-six percent of our RA patients were smokers compared with 33% of the OA 
group, which may explain the lower mean ABI in the RA group.  
In a similar study to ours, Belch et al investigated subclinical markers of 
atherosclerosis in RA patients and also found that RA patients had a significantly 
lower ABI than controls (15). In 2005, a study of lower limb arterial blood flow in 
234 RA patients found a greater frequency of arterial obstruction and 
incompressibility compared with controls and this was independent of age, sex, and 
cardiovascular risk factors (16). However, in contrast to our findings, Gabriel et al in 
2012, reported no significant difference in the cumulative incidence of peripheral 
vascular disease over 10 years in RA and non-RA subjects (6), 1.6 (SE 0.8) versus 
1.7 (SE 0.9), p=0.60. Smoking rates in the 2 groups were similar, which may explain 
the difference from our results. 
Abnormal ABI measurement was seen in 15% of the RA group and 6.25% of the OA 
group, none of whom has symptoms of peripheral vascular disease. The fact that our 
patients with evidence of PVD, as documented by a low ABI, did not report typical 
symptoms of PVD is not surprising. Fifty percent of elderly people with documented 
PVD have no symptoms. Often these people are unable to walk far or fast enough to 
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reproduce symptoms of intermittent claudication due to arthritis, pulmonary disease 
and other comorbidities (17). Ahmad et al recently compared ABI in 100 RA 
patients and 100 controls, all of whom were asymptomatic from a peripheral 
vascular point of view. They found a rate of 7% for abnormal ABI in the RA group 
and 5% in the control group (18). The higher rate of PVD in our RA group compared 
to the above study can be explained by the fact that the mean age in our patients was 
higher and an abnormal ABI was defined as < 0.96, compared with an ABI value of 
< 0.9 in Ahmad’s group. 
In 2013, Guellec et al reported a prevalence of 10% of PVD in RA patients, as 
defined by an ABI < 0.9. They found that those with a low ABI were older and more 
often had a history of coronary artery disease compared to those RA patients with a 
normal ABI. They also reported that 5% of the RA study group had incompressible 
arteries, as defined by an ABI > 1.3 and diabetes was more common in this group 
(19). 
Subclinical atherosclerosis of the femoral artery, as defined by intima-media 
thickness and presence of plaque, has been reported as being more advanced in RA 
patients compared with controls. The same group also found that femoral plaques 
were less frequent than carotid plaques in RA patients, but were independent of age 
in contrast to carotid plaque (5)  
Overall, the evidence would seem to suggest that RA patients have a higher rate of 
PVD compared with controls, however, large scale follow-up studies are required to 
delineate this further.  
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Inflammation in RA and ABI: 
 
The RA patients were studied with respect to treatment. A lower ABI was seen in 
those not on a biologic DMARD. This approached statistical significance. TNF 
inhibitors, the most commonly prescribed biologic DMARD in our study, have 
previously been shown to have beneficial effects on the progression of subclinical 
atherosclerosis in RA (20). Choice of anti-rheumatic treatment is an important 
consideration in RA patients with evidence of cardiovascular disease, as aggressive 
control of inflammation early in the disease process will also have a positive impact 
on future cardiovascular events (21). 
 
Levels of E-selectin in the RA group, a pro-inflammatory adhesion molecule, 
correlated significantly with ABI measurements. There was no significant correlation 
between other adhesion molecules (ICAM, VCAM, L-selectin, P-selectin) and ABI, 
or between inflammatory cytokines and ABI.  
E-selectin is a known inflammatory mediator in atherosclerosis and RA, so it is not 
surprising that it is elevated in our RA patients with low ABI. 
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ABI and Markers of subclinical CVD and traditional cardiovascular risks in 
RA patients: 
 
Four of our 9 RA patients with an abnormal ABI were non-smokers. Although 
smoking is the most well-known associated risk factor with PVD, non-smokers are 
not entirely protected. Lu L et al found that 3.2% of 4231 non-smokers had 
intermittent claudication and that second-hand smoke exposure was independently 
associated with intermittent claudication (22). 
In this study RA patients with a family history of peripheral vascular disease had a 
lower ABI than those with no PVD in their family (p=0.051). Valentine et al, found 
that a positive family history of PVD was a major determinant of occult PVD and 
that it was at least as important as other traditional vascular risks (23).  
RA patients in this study, with a prior diagnosis of hypercholesterolaemia had a 
lower ABI than those with a normal lipid profile. ABI was also found to correlate 
with fasting glucose levels in RA patients. Dyslipidaemia and diabetes are known 
risk factors that predispose to peripheral artery disease (24). Given the association of 
ABI with the above traditional CV risks in our study, rheumatologists need to be 
vigilant with respect to targeting traditional cardiovascular risks in RA patients to 
protect the arterial bed.  
A number of markers of subclinical atherosclerosis and diastolic dysfunction; 
nitroglycerin mediated dilatation (NMD) of the brachial artery, common carotid 
artery intima-media thickness (cIMT) and mitral annular velocity on transthoracic 
echocardiography, were all found to correlate with ABI in RA patients. 
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 On examination of the brachial artery, no association was found between endothelial 
dysfunction, as measured by flow mediated dilatation and ABI. However, abnormal 
nitroglycerin mediated dilatation; a measure of vascular smooth muscle dysfunction 
was significantly correlated with ABI. Exogenous nitroglycerin causes vasodilatation 
by direct action on the smooth muscle. Its effect is independent of the endothelium. 
Early studies of endothelial function have found that smooth muscle dysfunction 
occurs independently of endothelial –dependent dilatation in adults at risk of 
atherosclerosis (25). If NMD is impaired, it indicates the probability of smooth 
muscle cell dysfunction of the arterial wall owing to structural changes in vascular 
tissues. This phenomenon occurs in systemic sclerosis (26), however it is not 
typically reported in studies of endothelial dysfunction in RA patients. One small 
study of 18 patients with early arthritis did find a poorer nitroglycerin mediated 
response in disease subjects compared to controls (27). 
Our findings suggest that damage to the vasculature in RA patients may not be 
confined to just the endothelium and this warrants further studies to investigate the 
association further.  
Miszalski-Jamka et al recently found an association between cIMT and low ABI and 
also reported that together  they were associated with more extensive coronary artery 
disease and a higher coronary plaque burden , as seen on CT coronary angiography, 
than in patients with normal ABI and cIMT measurements  (28). As far as we are 
aware, our study is the first to show an association between abnormal ABI and cIMT 
in RA patients.  
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Yamasaki et al, examined 120 patients with an ABI <0.9 and found an elevated BNP 
in 30% and also reported a strong association with E/E prime, a marker of diastolic 
dysfunction (29). This is one of the first studies to identify a high prevalence of 
diastolic dysfunction in PVD.  
 
Further, activity levels of plasminogen activator inhibitor 1 (PAI-1), a potent 
inhibitor of fibrinolysis, correlated significantly with ABI in RA patients.  Markers 
of a hypercoagulable state, including PAI-1 are known to be associated with the 
presence of PVD and increased levels of PAI-1 may be linked to peripheral arterial 
disease severity (30).  Kitas et al have found that having RA predicts increased levels 
of PAI-1 and other markers of fibrinolysis, including fibrinogen, thrombomodulin 
and protein C. They also reported a link between metabolic factors such as 
hypertriglyceridaemia and insulin resistance and PAI-1 levels in RA (31).  
The association between PVD and coagulation in our RA patients suggests that 
factors such as an imbalance in coagulation and inflammation, in addition to 
atherosclerosis, are involved in the pathogenesis of cardiovascular disease in RA 
patients.   
Interestingly, we did not find correlations between ABI and the above markers of 
subclinical atherosclerosis in the OA group. 
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Conclusions: 
 
PVD is less well studied than coronary artery disease in RA patients. The limited 
data available suggests than there is an increased prevalence of peripheral arterial 
disease compared to controls. However, whether this difference is driven by the 
inflammatory burden of RA or excess traditional risk factors has not been fully 
identified.  
We have shown that ABI measurement would be useful to identify silent PVD in RA 
patients, highlighted by the fact that 15% of our RA group have abnormally low 
ABI. This cheap, easily performed screening tool for systemic and well as peripheral 
artery disease may be particularly helpful in RA patients who do not complain of the 
classical claudication symptoms due to their primary disease limiting exercise 
capacity.  
A link has been shown between ABI and other cardiovascular disease measures, 
such as carotid IMT and diastolic function, indicating that abnormal ABI in RA 
patients coexists with abnormalities in other vascular beds.  
Finally, although we cannot attribute a treatment benefit to biologic agents with 
respect to ABI in our group due to the cross-sectional nature of our study, it does 
support multiple other published studies, that have found a CV protective effect from 
aggressive anti-inflammatory therapy.  
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Chapter 8 
Diastolic function in Rheumatoid Arthritis 
 
Introduction: 
Diastolic dysfunction, an echocardiographic diagnosis, occurs due to increased 
stiffness of the left ventricular wall, which impairs diastolic blood flow from the left 
atrium to the left ventricle. Reports of the prevalence of diastolic dysfunction in the 
general population vary from 28% (1) to 65% (2). Clinical conditions responsible for 
primary diastolic dysfunction include hypertension, coronary artery disease, 
cardiomyopathy and obesity. It occurs frequently without clinical symptoms and is 
associated with an increase in mortality and incident congestive heart failure in the 
general population (1, 3).  
A number of studies have found an increased prevalence of diastolic dysfunction in 
RA compared to healthy controls (4-6). Crowson et al reported the prevalence of 
diastolic dysfunction in RA to be approximately 37% (4). The reasons for this 
increased rate in RA patients has not been fully elucidated, however; chronic 
inflammation, disease duration and disease activity have been postulated as potential 
mechanisms.  
 
The relative risk of congestive heart failure in patients with rheumatoid arthritis has 
been reported as 1.43 (95% CI 1.24-1.33) compared with osteoarthritis controls (7). 
In 2008, Gabriel et al compared the clinical presentation and management of heart 
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failure in RA patients and the general population. They found that RA patients were 
less likely to present with paroxysmal nocturnal dyspnoea, dyspnoea on exertion or 
orthopnoea than non-RA patients (8). Interestingly, RA patients were 33% less likely 
than non-RA patients to undergo  echocardiographic assessment for their symptoms, 
therefore highlighting that RA patients receive different evaluation and management 
compared to their non-RA counterparts. They postulated that this may have been due 
to differences in clinical presentations between the 2 groups. 
 
In 2009, the American Society of Echocardiography published recommendations for 
the evaluation of left ventricular diastolic function in the Journal of the American 
Society of Echocardiography (9). In these guidelines a practical approach to grading 
diastolic dysfunction is explained.  
Summarized as follows:  
Normal diastolic function is defined as:  septal e' ≥ 8 cm/sec, lateral e' ≥ 10 cm/sec, 
LA volume < 34 ml/m
2
 
Grade I diastolic dysfunction as:   septal e' < 8cm/sec, lateral e' < 10cm/sec, LA ≥ 34 
ml/m2, E/A < 0.8 and DT > 200 ms, E/e' average < 8. 
Grade II diastolic dysfunction as:  septal e' < 8cm/sec, lateral e' < 10cm/sec, LA ≥ 
34ml/m
2
, E/A 0.8-1.5, DT 160-200ms, E/e' average 9-12. 
Grade III diastolic dysfunction as:   septal e' < 8 cm/sec, lateral e' < 10 cm/sec, LA ≥ 
34 ml/m
2
, E/A > 2, DT < 160ms, E/e' average > 13. 
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NT-proBNP and BNP levels are recognised non-invasive markers of LV dysfunction 
(10). Recent studies have found that levels of NT-proBNP correlate with 
conventional Doppler and tissue Doppler imaging parameters used for the diagnosis 
of diastolic dysfunction on echocardiography (11-13). RA patients have been shown 
to have elevated levels of BNP, however BNP may not be as useful as a screening 
tool of LV diastolic dysfunction in RA patients as it is in the general population (4). 
To date, the presence of diastolic function in RA has not been studied extensively in 
the Irish population. 
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Aims: 
 
Our primary aim was to compare echocardiographic markers of diastolic function in 
RA and OA patients without clinical evidence of cardiovascular disease. Secondary 
aims were to examine systolic function on transthoracic echocardiogram and to 
investigate if markers of inflammation, anti-rheumatic medications and 
cardiovascular risks were associated with diastolic function in either group. 
 
Methods: 
 
Transthoracic Echocardiography: 
 
A transthoracic echocardiogram was performed on 51 RA patients and 46 OA 
patients, using a Vivid–I GE-Medical portable echocardiography machine with a 
2.5Hz probe. Using 2-D and M-mode echo, measurements were taken for ejection 
fraction, fractional shortening, left ventricular (LV) wall size and LV diameter. LV 
mass in grams was calculated based on Devereaux’s formula, a validated method and 
recommended by the ASE as part of the assessment of LV function. All 
measurements were made in accord with ASE guidelines. 
 Mitral inflow velocities were measured using pulsed wave Doppler to assess LV 
filling. These included peak early filling velocity, m/s (E wave), late diastolic filling 
velocity, m/s (A wave), E/A ratio and deceleration time (DT) of early filling velocity 
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in milliseconds.  Tissue Doppler imaging (TDI) was utilised to acquire lateral and 
septal mitral annular velocities including; systolic velocity (s), early diastolic 
velocity (e') and late diastolic velocity (a'). E/e' septal and E/e' lateral ratios and their 
average (E/e' average) were calculated.  
 
NT-proBNP analysis: 
At the time of the echocardiogram, blood was drawn for NT-proBNP. Samples were 
centrifuged and serum pipetted into aliquots. Serum was then stored at minus 80 
degrees and samples were analysed in batches. The Roche cobas proBNP II kit was 
used on an Elecsys 1010 analyzer in the department of biochemistry, in Cork 
University Hospital, to analyse all serum samples. Samples were analysed according 
to the manufacturers’ standard operating procedures.  
 
Statistical Methods: 
Means and standard deviations were calculated for normally distributed data and 
compared using a student t-test. Medians and interquartile ranges were calculated for 
non-normally distributed data and compared using a Mann Whitney U test. Logistic 
regression analysis was performed to analyse the relationship between the presence 
of diastolic dysfunction and a diagnosis of Rheumatoid Arthritis. Odds ratios and 
95% confidence intervals were computed. A p-value of <0.05 was considered 
significant. SPSS 20 was used for all statistical analysis. 
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Results: 
Systolic Function: 
 
96 of the 111 total study group attended for their outpatient echocardiogram 
appointment. Systolic function was measured as described in chapter 2.  Measures of 
systolic function are reported below as means (SD) and compared using an 
independent t-test. Mean aortic outlet size in the RA group was 2.59 cm (+/- 0.36) 
and 2.61 cm (+/- 0.34) in the OA group. The groups were compared using an 
independent t-test and no statistically significant difference was found (p= 0.890).  
Left atrial diameter was similar in the RA and OA groups, 3.30 cm (+/- 0.47) vs 3.35 
cm (+/- 0.42) respectively, p = 0.618. Overall, males had a greater left atrial size than 
females, 3.58 cm (+/- 0.47) vs 3.21 cm (+/- 0.38), p = 0.000.  
The ratio of left atrial diameter to aortic outlet diameter (LA/Ao) was similar in the 
RA and OA groups, 1.29 (+/- 0.19) vs 1.30 (+/- 0.21), p = 0.707.  
Left ventricular systolic diameter (LVSD) was similar in RA and OA patients. Mean 
LVSD in the RA group was 3.09 cm (+/- 0.49), compared with 3.06 cm (+/- 0.34) in 
the OA group, p = 0.754. LVSD was significantly larger in males compared with 
females, 3.25 cm (+/- 0.51) vs 3.01 cm (+/- 0.38), p = 0.018. This was also the case 
when the RA group was analysed separately, RA male LVSD 3.28 cm (+/-0.54) 
versus RA females LVSD 2.97 cm (+/- 0.42), p = 0.024. There was no significant 
difference in LVSD between OA males and OA females, p = 0. 418.  
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Left ventricular diastolic diameter (LVDD) was not different in RA patients and OA 
patients, 4.55 cm (+/-0.60) and 4.43 cm (+/- 0.42), p = 0.215. Males had a 
significantly larger LVDD compared with females, 4.83cm (+/-0.59) vs 4.36cm (+/- 
0.43), p = 0.000. Male RA patients had a mean LVDD of 4.94 cm (+/- 0.61) 
compared with 4.31 cm (+/- 0.45) for female RA patients, p < 0.000 (figure 8.1). 
There was no significant difference in LVDD between male and female OA patients, 
p = 0.443. When males were analysed separately, RA males were found to have a 
significantly larger LVDD compared with male OA patients, 4.94 cm (+/- 0.61) vs 
4.53 cm (+/- 0.43), p = 0.044. Female OA patients and female RA patients had 
similar LVDDs, p = 0.335.  
 
Mean septal wall thickness in the RA group was 0.93 cm (0+/- 0.12) and 0.93 cm 
(+/-0.13) for the OA group, p = 1.00. In the RA group, mean posterior wall thickness 
was 0.96cm (+/- 0.12) and it was 0.99 cm (+/-0.14) in the OA group, p = 0.225.  
 
Mean ejection fraction in the RA group was 61% (+/- 8.28) compared with 60% (+/- 
6.29) in the OA group, p = 0.426, (table 8.1). Ejection fraction was also similar in 
males and females. Looking at the RA group separately, there was no significant 
difference between ejection fractions in males and females, 63% (+/- 8.27) vs 60% 
(+/- 8.26), p = 0.272. Again using an independent t-test and looking at the OA group 
alone, there was no significant difference in ejection fractions in males and females, 
61% (+/- 7.10) vs 60% (+/- 6.17), p = 0.680.  
5 patients (3 with RA and 2 with OA) had an ejection fraction of less than 55%. 
Nobody had an EF of less than 45%. 
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Mean fractional shortening (%) in the RA group was 33% (+/- 5.98) compared with 
31% (+/- 4.42) in the OA group, p = 0.155. Using an independent t-test, the 
difference in fractional shortening between males and females approached statistical 
significance, p = 0.051.  
 
LV mass in grams was calculated based on Devereaux’s formula, a validated method 
and recommended by the ASE as part of the assessment of LV function. 
1.04[(LVDd + PW +SW)
3
- (LVDd)
3
] x 0.8 + 0.6g 
Mean LV mass in the RA group was 147 g (+/- 45.47) compared with 142 g (+/-
30.57) in the OA group, p = 0.467. As expected, the mean LV mass was significantly 
greater in males than females, 169.95 g (+/- 46.33) versus 134.47 g (+/- 30.94) 
respectively, p < 0.000.  
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Figure 8.1: Boxplots comparing LVDD (cm) in male and female RA patients 
P < 0.000 
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 RA 
N = 63 
OA 
N = 48 
P value 
LA (cm), mean (SD) 3.30 (0.47) 3.35 (0.42) 0.618 
LVSD (cm), mean (SD) 3.09 (0.49) 3.06 (0.34) 0.754 
LVDD (cm), mean (SD) 4.55 (0.60) 4.43 (0.42) 0.215 
Posterior Wall (cm) 0.96 (0.12) 0.99 (0.14) 0.225 
Septal Wall (cm) 0.93 (0.12) 0.93 (0.13) 1.000 
LV mass (grams), mean (SD) 147 (45.47) 142 (30.57) 0.467 
Ejection Fraction (%), mean (SD) 61 (8.28) 60 (6.29) 0.426 
Fractional Shortening (%), mean (SD) 33 (5.98) 31 (4.42) 0.155 
 
Table 8.1: 2D and M-mode echocardiographic results for RA and OA patients. 
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Diastolic Function: 
 
The mean E wave velocity was greater in the RA group compared with the OA 
group, p = 0.043, (table 8.2). E wave velocities were similar in males and females, 
0.63 m/sec (+/- 0.98) vs 0.64 m/sec (+/- 0.14), p = 0.601. Within the RA group, E 
wave velocities were similar for males and females. Similar velocities were also 
recorded for males and females in the OA group. Comparing females in the RA and 
OA groups, there was no statistically significant difference in mean E wave 
velocities, p = 0.121. However, male RA patients had a significantly greater E wave 
velocity compared with male OA patients, 0.65 m/sec (+/- 0.10) vs 0.58 m/sec (+/- 
0.06), p = 0.015. 
 
A wave velocities were similar in the RA and OA group, 0.60 m/sec (+/- 0.11) vs 
0.57 m/sec (+/- 0.15), p = 0.226. Males in the RA group had a significantly greater A 
wave velocity than male OA patients, p = 0.004.  
 
Mean E/A ratio in the RA group was 1.11 (+/- 0.27), compared with 1.11 (+/- 0.19), 
p = 0.915. E/A values were also very similar in male and females, 1.11 (+/- 0.18) vs 
1.11 (+/- 0.26), p = 0.973. This finding held through when the RA and OA groups 
were analysed separately 
Deceleration time was similar for RA and OA patients, 188.67 msec (SD 29.62) 
compared with 191.19 msec (SD36.71), p=0.701. 
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Mean values for e’ lateral readings were 12.25 cm/sec (+/- 3.45) in the RA group and 
11.70 cm/s (+/- 2.32) in the OA group, p = 0.347. Mean E prime septal was 
significantly higher in the RA group, 8.88 cm/sec (+/- 2.23) versus 7.74 cm/sec (+/-
1.73), p = 0.006, (table 3). 
 
Mean E/e’ lateral was similar in RA patients and OA patients, p = 0.264.  Mean E/e’ 
septal was 7.71 (+/- 2.19) in the RA group, compared with 8.21 (+/- 2.38) in the OA 
group, p = 0.293. When the values for E/e’ lateral and septal were combined, as 
recommended by the ASE, the results were similar in the RA and OA groups, p = 
0.830. 
Age in both the RA and OA groups was significantly correlated with E/e’, r= 0.283, 
p=0.049 and r=0.439, p=0.002. 
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 RA 
N = 63 
OA 
N = 48 
P value 
E wave (cm/sec), mean (SD) 66.33 (11.48) 61.33 (13.37) 0.043* 
A wave (cm/sec), mean (SD) 59.82 (10.81) 56.69 (14.93) 0.226 
E/A ratio, mean (SD) 1.11 (0.27) 1.11 (0.19) 0.915 
DT (msec), mean (SD) 188.67 (29.62) 191.19 (36.71) 0.701 
e’ lateral (cm/sec), mean (SD) 12.25 (3.45) 11.70 (2.32) 0.347 
e' septal (cm/sec), mean (SD) 8.88 (2.23) 7.74 (1.73) 0.006* 
E/e' lateral ratio, mean (SD) 5.56 (1.47) 5.34 (1.25) 0.264 
E/e' septal ratio, mean (SD) 7.71 (2.19) 8.21 (2.38) 0.293 
E/e' average ratio, mean (SD) 6.47 (1.53) 6.40 (1.46) 0.830 
 
 
 
Table 8.2: Mitral inflow velocities and tissue Doppler measurements for RA and OA 
patients 
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Two RA patients and 4 OA patients had an elevated BNP as defined as a value of 
greater than 125pg/ml. Median N-terminal pro-BNP in the RA group was 45.90 
pg/ml (33.00- 71.97) compared with 48.75 pg/ml (33.50- 68.48) in the OA group, p 
= 0.729. Using logistic regression analysis, elevated BNP was not associated with a 
diagnosis of RA, OR (95%), 0.29 (0.05, 1.68), p=0.167.  
Females had a significantly higher NTpro-BNP than males, 55.30 pg/ml (38.94- 
76.78) vs 33.62 pg/ml (15.90- 42.97), p < 0.000. When the RA group were analysed 
separately, the female group still had a significantly higher value for pro-BNP than 
male RAs, p <0.000.  
There was no significant correlation between echocardiographic markers of diastolic 
dysfunction and serum NT-proBNP in RA patients. However, we did find that ESR 
correlated with NT-proBNP in the RA group and this approached statistical 
significance, r = 0.244, p=0.067. 
N-terminal pro-BNP was similar in RA patients on DMARDS, biologics, NSAID 
and steroids compared to RA patients not on the above medications, p=0.885. 
NTpro-BNP was significantly higher in RA patients with an elevated waist hip ratio, 
ie abdominal obesity, 51pg/ml (37.00 – 66.15) versus 45.75pg/ml (33.50 – 62.78), 
p=0.032.  
OA patients with an elevated BNP had a significantly lower ejection fraction and 
fractional shortening than those with BNP of less than 125pg/mg (table 8.3). 
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Table 8.3: Comparison of ejection fraction and fractional shortening in OA patients 
with elevated and normal BNP levels. P, significance level, SD, standard deviation.  
 
 
 
 
 
 
 
 
 
 
 
 Elevated BNP Normal range BNP p 
Ejection fraction %, (SD) 57.00 (1.41) 60.28 (6.31) 0.021* 
Fractional shortening %, (SD) 29.25 (0.50) 31.69 (4.42) 0.005* 
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Based on the ASE criteria for a diagnosis of diastolic dysfunction, as described in the 
introduction, we identified 17 (33.3%) RA patients and 16 (34.8%) OA patients with 
diastolic dysfunction (table 8.4). There was no difference in the frequency of grade I 
or grade II diastolic dysfunction between the 2 groups. No one in the group had 
grade III diastolic dysfunction.  
Binary logistic regression analysis was used to analyse the relationship between 
diastolic dysfunction and a diagnosis of rheumatoid arthritis. Using logistic 
regression analysis and taking an E/A ratio of less than 1 as a marker of diastolic 
dysfunction, a diagnosis of Rheumatoid arthritis was not found to predict the 
presence of diastolic dysfunction, more so than a diagnosis of osteoarthritis, OR 
(95%CI), 1.22 (0.52,2.67), p 0.626. Following simultaneous adjustment for age, 
gender, smoking history, presence of hypertension or diabetes, level of BNP, TNF, 
Il6 and CRP, the odds of having diastolic dysfunction with Rheumatoid arthritis was 
not significantly higher than that for osteoarthritis, OR (95%CI), 1.27 (0.36,4.53), p 
0.710. Neither was a diagnosis of RA associated with an abnormal e’ lateral, OR (CI 
95%), 1.31 (0.47, 3.60), p=0.605 or an abnormal E/e’ average, OR (CI 95%), 1.60 
(0.48, 5.30), p = 0.442. Using the ASE criteria to diagnose diastolic dysfunction with 
a combination of echocardiographic measurements, as described in the methods 
section, a diagnosis of RA was not found to be associated with diastolic dysfunction, 
OR (CI 95%), 0.94 (0.40, 2.17), p = 0.880.  
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  RA 
n=51 
OA  
n=46 
Total  
n=97 
P 
value 
Normal Diastolic Function N 34 30 64  
% 66.7 65.2 66  
Grade I Diastolic Dysfunction N 9 10 19 0.612 
% 17.6 21.7 19.6  
Grade 2 Diastolic Dysfunction N 8 6 13 0.487 
% 15.7 10.9 13.4  
Grade 3 Diastolic Dysfunction N 0 0 0 N/A 
% 0 0 0  
Presence of any grade Diastolic 
Dysfunction 
N 17 16 33 0.880 
% 33.3 34.8 34  
 
Table 8.4: Numbers of RA and OA patients with diastolic dysfunction, using ASE 
diagnostic criteria 
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Disease activity, anti-rheumatic medications and diastolic function: 
 
RA patients with a high DAS28ESR and DAS28CRP of greater than 3.2 (ie 
moderate or high disease activity) were compared to those with low disease activity, 
defined by both a DAS28ESR and DAS28CRP of less than 3.2. There was no 
significant difference with respect to markers of diastolic function between the 2 
groups. However, E/A ratio was lower in RA patients with moderate or high disease 
activity, 1.06 (SD 0.24), compared with 1.21 (SD 0.30) in the RA group with low 
disease activity. This approached statistical significance, p=0.06.  
RA patients on a DMARD had a significantly higher E/A ratio, e’ lateral and e’ 
septal, compared with those RA patients not taking a DMARD, p=0.004, p=0.048, 
p=0.024, respectively (table 8.5). RA patients on a biologic agent had less features of 
diastolic dysfunction than those not on a biologic (table 8.6). The E/A was higher in 
those on a biologic agent, however this did not achieve statistical significance, 
p=0.668. 
Using logistic regression analysis, a diagnosis of diastolic dysfunction was not found 
to be associated with the use of synthetic or biologic DMARDS, OR (CI 95%), 0.38 
(0.09, 1.50), p=0.172 and OR (CI 95%), 0.91 (0.27, 3.10), p=0.885. 
 
RA patients on an NSAID has significantly lower fractional shortening, ejection 
fraction and E velocity compared to those RA patients not on NSAIDS, p=0.008, 
p=0.009, p=0.04 (table 8.7). There was no difference in markers of diastolic function 
between RA patients on steroids and those not taking steroids.  
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Left atrial size, although within the normal range, was significantly larger in OA 
patients who were taking an NSAID at the time of the study compared to those not 
taking NSAIDS, 3.55 cm (SD0.45) versus 3.25 cm (SD0.37), p=0.033. 
 
 
 
 
 
Table 8.5: Comparison of markers of diastolic function in RA patients on a DMARD 
with those not on a DMARD, p, significance level; SD, standard deviation 
 
 
 
 DMARD  No DMARD p 
E/A (SD) 1.41 (0.29) 1.02 (0.17) 0.044* 
e’ lateral, cm/s (SD) 12.74 (3.51) 10.67 (2.84) 0.048* 
e’ septal, cm/s (SD) 9.21 (2.29) 7.73 (1.62) 0.024* 
E/e’ (SD) 6.27 (1.44) 7.16 (1.71) 0.135 
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 Current biologic 
agent 
No biologic 
agent 
p 
Posterior wall thickness, cm 
(SD) 
0.92 (0.13) 0.99 (0.12) 0.016* 
Septal wall thickness, cm (SD) 0.89 (0.11) 0.94 (0.13) 0.035* 
E velocity, cm/s (SD) 68.22 (11.78) 62.38 (12.53) 0.024* 
E/A ratio (SD) 1.13 (0.29) 1.10 (0.21) 0.668 
E/e’ (SD) 6.58 (1.67) 6.39 (1.44) 0.640 
 
Table 8.6: comparison of markers of diastolic function between RA patients on a 
biologic agent and those not on a biologic agent. P, significance level; SD, standard 
deviation 
 
 Current NSAID No current NSAID p 
Fractional shortening % (SD) 30.90 (5.31) 34.93 (6.04) 0.008* 
Ejection fraction % (SD) 58.35 (7.74) 63.86 (8.00) 0.009* 
E velocity, cm/s (SD) 63.39 (10.42) 69.48 (11.89) 0.040* 
E/A ratio (SD) 1.08 (0.27) 1.13 (0.26) 0.465 
E/e’ (SD) 6.28 (1.45) 6.70 (1.63) 0.361 
 
Table 8.7: Comparison of markers of systolic and diastolic function in RA patients 
on an NSAID with RA patients not currently on an NSAID. P, significance level; SD 
standard deviation. 
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Cardiovascular risks and diastolic function: 
 
RA patients with a prior diagnosis of hypertension had a significantly greater E/e’ 
than those with normal blood pressure, 7.79 (SD1.63) versus 6.21 (SD1.39), 
p=0.029. Using logistic regression analysis, a diagnosis of diastolic dysfunction was 
associated with hypertension in the RA group, OR (95%), 8.73 (1.53, 49.76), 
p=0.015. However, following simultaneous adjustment for age, smoking and obesity, 
this association was no longer statistically significant, OR (95%), 5.70 (0.73, 44.46), 
p=0.097. 
 
A higher E/e’ was also seen in RA patients with an elevated serum cholesterol, 6.71 
(SD1.65) compared with 5.79 (0.89), p=0.017. As already discussed in the chapter 
on fasting lipid profile, RA patients with evidence of diastolic dysfunction on 
transthoracic echocardiogram had a less favourable lipid profile than RA patients 
with normal diastolic function (table 8.8). In both RA and OA patients, there was a 
significant correlation between lipid profile and E/e’, as a marker of diastolic 
dysfunction on echocardiography (table 8.9). 
 
Smoking status did not affect markers of diastolic function in either RA or OA 
patients. OA patients with a family history of myocardial infarction had a 
significantly lower ejection fraction than those with no such family history, 58.41% 
(SD 6.19) versus 62.16% (SD 5.89), p=0.041. 
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 Evidence of diastolic 
dysfunction 
Normal diastolic 
function 
p 
Total cholesterol, 
mmol/l (SD) 
5.79 (0.64) 5.37 (0.79) 0.048* 
Serum LDL, mmol/l 
(SD) 
3.55 (0.54) 3.14 (0.59) 0.025* 
 
 
Table 8.8: Comparison of lipid profile in RA patients with and without evidence of 
diastolic dysfunction 
 
 
 Correlation with E/e', r p 
RA Total cholesterol 0.255 0.077 
LDL 0.508 0.001* 
OA Total cholesterol 0.316 0.034* 
LDL 0.227 0.139 
 
Table 8.9: Correlation between E/e’ and lipid profile in RA and OA patients 
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Both RA and OA patients with presence of plaque on carotid ultrasound had 
significantly higher E/e’ ratios compared to those with no evidence of carotid plaque 
(table 8.10, figure 8.2 and 8.3). E/e’ correlated significantly with ABI in the RA 
group, r = -0.322, p=0.024 and also with microalbuminuria in the RA group, r = 
0.402, p=0.009. 
 
 
 
 
 E/E prime (SD) p 
RA Carotid plaque present 8.77 (0.16) 0.000* 
No carotid plaque present 6.31 (1.48) 
OA Carotid plaque present 9.00 (1.26) 0.005* 
No carotid plaque present 6.09 (1.10) 
 
 
Table 8.10: comparison of patients with and without carotid plaque with respect to 
E/E prime ratio. P, significance level; SD, standard deviation.  
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Figure 8.2: Boxplot comparing E/E prime in RA patients with and without carotid plaque 
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Figure 8.3: Boxplot comparing E/E prime in OA patients with and without carotid plaque 
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Discussion: 
 
The aims of this chapter were to compare diastolic function in RA and OA patients 
and also to investigate if an association between diastolic dysfunction and 
inflammatory markers, cardiovascular risks and anti- rheumatic medications exists in 
either group. 
Left atrial and ventricular sizes were assessed by measuring LA diameter and left 
ventricular systolic and diastolic diameters. LA size was similar in both groups in 
our study. A recent meta-analysis by Aslam et al, reported that a number of studies 
found that RA patients had a significantly larger mean left atrial size compared with 
controls (14). The left atrium reflects the burden of LV diastolic filling and is a 
marker of LV diastolic dysfunction. LA enlargement has been shown to be 
associated with an increased risk of atrial fibrillation (15) and cardiovascular events 
(16). Size and volume of the left atrium increases as diastolic dysfunction progresses 
(17). No one in the study group had atrial fibrillation or a history of prior 
cardiovascular events. Also, of the 33 patients in our group with echocardiographic 
evidence of diastolic dysfunction, no one had grade III diastolic dysfunction. 
Therefore, perhaps the patients with evidence of diastolic dysfunction have not had it 
long enough to cause significant atrial remodeling and enlargement as yet. 
Left ventricular diastolic diameter, a marker of systolic function, was significantly 
larger in males with RA compared to males with OA (table). However, this value 
was still well within the normal reference range for men, as recommended by the 
ASE (18). With regard to assessment of left ventricular systolic function, we 
measured ejection fraction and fractional shortening. These were similar in both 
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groups, with mean values in the accepted normal range (18). A number of studies 
have also found similar EF and FS readings between RA patients and controls (6, 19, 
20). Gabriel et al, reported a significantly lower EF in a large cohort of RA patients 
compared to controls, however, the mean age of their RA patients was 10 years older 
than ours and they also included patients with a prior history of CVD (21).  
Patients with diastolic heart failure often have normal ventricular wall thickness; 
however, they may have evidence of concentric hypertrophy or remodelling and on 
foot of this the American Society of Echocardiography recommend assessment of 
LV mass as part of the evaluation of diastolic function (9). We measured septal and 
posterior wall thickness to calculate LV mass. Both walls were of similar size in RA 
and OA patients. LV mass was also similar in RA and OA patients (table). A number 
of studies, whose patients had a mean age similar to ours, support this finding (5, 20) 
but there is also evidence of both an elevated LV mass in younger RA patients (22) 
and LV mass significantly lower than in controls, in studies involving older RA 
patients (21). Crowson and colleagues explain that LV mass in RA may go through 
sequential changes from myocardial hypertrophy to remodelling and wasting.  
 
As markers of diastolic function, we measured early diastolic LV filling (E wave), 
late diastolic filling (A wave), deceleration time and E/A ratio was calculated. Tissue 
Doppler imaging was used to record the mitral annular early diastolic velocity, e’, at 
the lateral and septal walls. E/e’ was then calculated. The American Society of 
echocardiography recommends using a combination of variables for the assessment 
of diastolic function, rather than relying on individual variables, which may be 
misleading (9). Based on their recommendations for the grading of diastolic 
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dysfunction, we used E prime septal and lateral, E/A ratio, deceleration time and E/e’ 
in combination to investigate if any of our study patient has evidence of diastolic 
dysfunction.  
 
It was found that RA patients had a higher E wave than OA patients and RA males 
had a higher E and A wave than OA males. Deceleration time, E/A ratio and E/e’ 
ratio were both similar in RA and OA patients (table). 33.3% of RA patients 34.8% 
of OA patients had evidence of diastolic dysfunction. 
Similar to our results, in 2011, Abdul Muizz et al reported no difference in diastolic 
function, using both pulsed wave Doppler and tissue Doppler imaging techniques, in 
RA patients and age matched controls (23). They also found no evidence of a 
correlation between disease activity or duration and markers of diastolic dysfunction.  
Tomas L et al recently reported that RA patients in their study had a significantly 
worse diastolic function compared to controls (24). They had similar patient numbers 
to our study; however, the mean duration of disease in their RA group was 11.8 
years compared to 7 years in our RA group. With regard to the cardiovascular risk 
profile in their study, the RA group had a significantly higher prevalence of 
hypertension and impaired glucose tolerance compared to the control group. 
Hypertension is one of the commonest causes of diastolic dysfunction and this may 
have been driving the increased rate of diastolic dysfunction that they found in the 
RA group. In our cohort, there was no difference in prevalence of hypertension or 
impaired glucose tolerance in RA and OA patients.  
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It is also important to note that Tomas et al used a low E/A ratio alone to define 
diastolic dysfunction. All other echocardiographic parameters were similar in their 
RA and control group and tissue Doppler imaging, which is a more sensitive tool for 
detecting diastolic dysfunction, was not employed.  
Contrary to our findings, Vizzardi E et al reported a significant difference in diastolic 
dysfunction on tissue Doppler imaging, in RA patients compared to controls (25). In 
2010, Sherine Gabriel’s group also described a higher prevalence of diastolic 
dysfunction in RA patients compared with controls, however, as mentioned above, 
this study enrolled RA patients with a history of CVD and the RA group also had a 
significantly higher rate of hypertension and significantly higher blood pressure 
readings during the study, compared with the control group. LV mass is their RA 
group was also lower than controls which may suggest that myocardial remodelling 
had already taken effect (21).  
It is noteworthy that the majority of other studies investigating diastolic dysfunction 
compared RA patients to healthy controls, while our control group had a diagnosis of 
osteoarthritis. There is now increasing evidence that OA has inflammatory 
components to its pathophysiology (26), especially in postmenopausal females. This 
may be responsible for diminishing the difference in results between the 2 groups.  
There is also more recent evidence of an increased risk of CVD in both younger and 
older females and in older males, compared to their non-OA counterparts (27). 
Rahman et al reported that females under 65 years had a 66% increased risk of IHD 
and a 29% increased risk of CHF. The risks were not as high in older females and 
males but were still statistically significant. If the rates of CHF are higher in OA 
patients than healthy controls, it seems plausible that a precursor of CHF, namely 
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diastolic dysfunction, would also be a more frequent finding in OA patients 
compared to non-OA controls.  
 
The rate of progression of diastolic dysfunction in RA is currently unknown; 
however a small 5 year follow-up study by Yazici et al, report that cardiac function 
was conserved without major deterioration when compared with baseline 
echocardiography (19). 
 
Based on a number of studies in the assessment of left ventricular dysfunction (28), a 
value of greater than 125 pg/ml was considered as abnormal for our patients N-
terminal pro-BNP natriuretic peptide measurements.  
 
The vast majority of RA (96.5%) and OA (89%) patients had a serum NT-proBNP in 
the normal range and there was no significant difference in values between the 2 
groups. Contrary to our results, a study in 2011 by Gabriel et al, found that RA 
patients had a significantly higher median BNP and that more RA patients had an 
abnormal BNP level, compared with non-RA controls (4). However, there was a 
significantly higher proportion of non-white patients in their RA group and more 
recently, Selim et al have reported that Asian and black patients have higher baseline 
BNP levels than white and Hispanic patients (29) Our study was made up entirely of 
Caucasians.  
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We did find a significantly higher NT-proBNP in RA females compared with RA 
males. This gender difference is well reported in the literature (30, 31). Higher 
oestrogen levels in females have been postulated as a potential reason for the higher 
levels of BNP and NT-proBNP (30) and conversely, testosterone may be responsible 
for lowering BNP levels (32). 
A higher NT-proBNP level was seen in RA patients with abdominal obesity 
compared to those with a normal waist hip ratio. However, we did not find a 
difference in NT-proBNP in obese patients compared to non-obese patients. A 
number of studies have previously found an association between obesity and low 
BNP levels and there have been suggestions that visceral fat aids clearance of 
natriuretic peptides via increased expression of clearance receptors on adipocytes 
(33, 34). 
 
Markers of systolic function, including ejection fraction and fractional shortening, 
were significantly worse in OA patients with an elevated NT-proBNP. This is in 
keeping with Luchner’s early study of BNP as a marker of left ventricular 
dysfunction, where they reported that reduced LV ejection fraction was significantly 
associated with increased circulating concentrations of BNP (35).  
 
No correlation was seen between serum NT-proBNP and echocardiographic markers 
of diastolic function in either RA or OA patients. Only 2 of the 16 OA patients with 
evidence of diastolic dysfunction had an elevated NT-proBNP at the time of 
echocardiography and none of the 17 RA patients with diastolic dysfunction had an 
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elevated NT-proBNP. Our results are supported by a similar study in 2011 by 
Sherine Gabriel et al (4). This group found that few of their RA cohort who had 
elevated BNP actually had evidence of diastolic dysfunction and that BNP in the 
normal range was less likely to out rule diastolic dysfunction in RA patients 
compared to non-RA patients. The fact that we did not identify a correlation between 
NT-proBNP and diastolic dysfunction may in part be due to the fact that the majority 
of our study group with diastolic dysfunction had grade I changes, with a smaller 
number having evidence of grade II diastolic dysfunction and no one with grade III 
diastolic dysfunction.  
 
We did note a correlation between ESR and NT-proBNP levels. In a large population 
– based inception cohort of RA patients, Crowson et al reported that in those patients 
who developed heart failure in the 15 year follow-up period, the proportion with an 
elevated ESR, was highest in the 6 months preceding onset of heart failure. They 
concluded from this that inflammatory stimuli may be involved in triggering heart 
failure in this group and that ESR may be a useful evaluation tool for heart failure in 
RA patients (36). 
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We further examined the RA group to see if markers of diastolic function were 
associated with disease activity and anti-rheumatic medications.  
RA patients with active disease, as determined by DAS28ESR and DAS28CRP, had 
a lower E/A ratio than those RA patients with low disease activity and those in 
remission. A study similar to ours also reported an association between E/A ratio and 
disease activity scores in RA patients (6). However, in contrast, Vizzzardi et al found 
no correlation between inflammatory disease parameters and diastolic function (25). 
These differences are probably in part due to small study sizes and patients with a 
wide range of disease activities being included.  
 
RA patients who were not taking a synthetic DMARD at the time of the transthoracic 
echocardiogram were found to have a significantly lower E/A ratio. Lateral and 
septal mitral annular velocities (e’) on tissue Doppler imaging were also significantly 
lower in the non-DMARD group. These findings demonstrate a poorer diastolic 
function in RA patients not on a DMARD. However, after correcting for potential 
confounders on logistic regression, we did not find a significant association between 
presence of diastolic dysfunction and use of a synthetic DMARD. 
Gabriel et al examined 244 RA subjects for evidence of diastolic dysfunction (21) 
and found that anti- rheumatic medication did not appear to impact on diastolic 
function. On initial analysis they found that RA patients prescribed methotrexate had 
a 2.1 odds ratio (CI 95%, 1.01,4.2) for an association with diastolic dysfunction. 
However, similar to our findings, after correcting for confounders, including CV 
risk, RA duration and inflammatory cytokine concentrations, this association was 
reduced and no longer statistically significant. 
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RA patients on a biologic DMARD had a higher E/A ratio compared with those not 
on a biologic agent (non-significant). The biologic group also had a significantly 
better E wave velocity, another marker of diastolic function. Posterior wall and 
septal wall thickness was greater in the non-biologic group. Again, these findings 
suggests that RA patients not on a biologic DMARD had evidence of worse diastolic 
function compared to those taking a biologic DMARD.  
There has been a lot of debate with regard to the effects of anti-TNF therapy on 
cardiac function, in particular with respect to heart failure. Two high profile clinical 
trials set up in the late 1990s to establish whether TNF inhibitors (etanercept and 
infliximab) would be of benefit in the treatment of patients with advanced congestive 
heart failure (CHF), yielded generally unfavourable results. New or worsening CHF 
was reported in 47 of approximately 300,000 patients treated with either infliximab 
or etanercept. 81% of these cases had no prior history of CHF (37, 38). Following 
these adverse events, anti-TNF medications were felt by many clinicians to be more 
detrimental than beneficial to cardiac function. Contrary to the above, a study 
published by Bernatsky et al in 2005, reported a 30% reduction in hospitalizations 
for new-onset CHF in RA patients on DMARDS, including TNF inhibitors (39).  
More recently, Senel et al found that etanercept was safe with respect to cardiac 
function and lipid profile in RA patients followed up for 6 months (40). They 
reported no significant change in diastolic function and ejection fraction during the 
follow-up period. Etanercept has also been shown to improve arterial stiffness in RA 
patients treated and followed up with serial measurements of augmentation index 
over a 4 month period (41).  
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These conflicting reports highlight that the direction of the impact of anti-TNF 
medication on CV risk in RA patients is still largely unknown.  
 
In our study there was no difference in diastolic function in RA patients on steroids 
and those not taking steroid medication. Patients in both the RA and OA groups who 
were on an NSAID at the time of the study had more features of systolic and 
diastolic dysfunction compared to those not taking an NSAID. This is in keeping 
with a large body of evidence that now exists that both coxibs and NSAIDS are 
associated with an increased risk of heart failure. A recent meta-analysis of NSAID 
trials has reported a risk of hospitalization due to heart failure in those treated with 
NSAIDS to be double that of placebo (42). 
 
RA patients with a prior diagnosis of hypertension had a significantly higher E/e’ 
ratio than normotensive RA patients. We found a significant unadjusted odds ratio of 
8.73 (1.53, 49.76) for a diagnosis of diastolic dysfunction in the RA hypertensive 
group. This ties in with hypertension in the general population being one of the 
commonest causes of diastolic dysfunction and heart failure with preserved ejection 
fraction (43). 
 
Also, RA patients in our study with a prior diagnosis of hypercholesterolaemia had a 
significantly higher E/e’ than RA patients without hypercholesterolaemia. The total 
serum cholesterol and LDL measurements were significantly higher in RA patients 
with evidence of diastolic dysfunction compared to RA patients with normal 
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diastolic function. Patients with hyperlipidaemia and other features of the metabolic 
syndrome have been shown to have evidence of diastolic dysfunction and are at an 
increased risk of diastolic heart failure (44, 45). 
 
Within the RA group, E/e’ was associated with a number of markers of subclinical 
vascular dysfunction, namely, carotid artery plaque, microalbuminuria and ankle 
brachial index. Chahal et al have previously reported the close relationship of carotid 
artery plaque to LV systolic and diastolic dysfunction and they advocate the use of 
carotid ultrasound as a screening tool for identifying patients who may be at risk of 
developing heart failure syndromes (46). The fact that we demonstrated a 
significantly higher E/e’ in patients with evidence of carotid plaque, suggests that 
any LV diastolic function abnormalities may be due to atherosclerosis rather than 
hypertensive disease.  
Microalbuminuria is a marker of endothelial dysfunction and has been shown to be 
associated with adverse cardiovascular outcomes in diabetes, hypertensives and the 
general population (47). Elevated urinary albumin-creatinine ratio in patients without 
evidence of heart failure, predicts future hospitalization for heart failure (48). We 
found that microalbuminuria correlated positively with E/e’, a marker of diastolic 
dysfunction. This is in keeping with the results of a recent large study examining the 
relationship between albuminuria and adverse cardiac mechanics (49) and suggests a 
link between endothelial dysfunction and subclinical diastolic dysfunction. 
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Ankle brachial index, a measure of peripheral vascular disease (PVD), correlated 
significantly with E/e’ in the RA group. Yamasaki et al have reported prevalence of 
high BNP and E/e’ as markers of diastolic dysfunction in patients with PVD, as 
defined by an ankle brachial index of less than 0.9 (50). PVD is associated with a 2-
fold increase in the prevalence of heart failure (51). Ankle brachial index 
measurement is cheap and easy to record rapidly in the out-patient setting and 
provides important information about vascular risk, allowing preventative measures 
to be introduced in a timely fashion if required. 
 
 
Conclusion: 
 
We report similar prevalence of diastolic dysfunction in RA and OA patients. The 
fact that our study group were naïve of any CV events and there was no significant 
difference in CV risk profile between our groups, may explain why our results are 
different to some of the recent published work that has found increased rates of 
diastolic dysfunction in rheumatoid patients compared to controls. Also, as 
mentioned above, our control group may have inflammatory components making it 
more similar to our RA group than healthy controls. We have found that a third of 
both the RA and OA groups have echocardiographic evidence of diastolic 
dysfunction, despite no symptoms of cardiac disease. This highlights the importance 
of diastolic function assessment at the time of echocardiography in these groups.  
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With regard to the direct effect of anti-rheumatic medication on diastolic function, it 
is difficult to attribute either harm or benefit to these treatments, due to the large 
number of factors at play, including RA disease activity, traditional CV risks, pro-
inflammatory cytokines, and immune dysregulation. 
The lack of an association between serum NT-proBNP and markers of diastolic 
dysfunction in our study group suggests that NT- proBNP may not be a useful 
screening tool for diastolic dysfunction in RA or OA patients. 
Based on our findings of a correlation with E/E prime, microalbuminuria would 
appear to be a useful, inexpensive screening tool for identifying RA patients who 
may be at risk of diastolic dysfunction and would benefit from early 
echocardiographic examination. Carotid ultrasound, to quantify plaque as well as 
IMT, also appears to provide information about those at risk of diastolic dysfunction. 
Finally, use of ankle brachial index measurements also appear to provide relevant 
information regarding diastolic dysfunction, in those with abnormal ABI scores. 
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Chapter 9 
Summary and Concluding Remarks 
 
Summary of our findings: 
To the best of our knowledge, this is the first study of its kind in RA patients in 
Ireland. We conducted a cross-sectional examination of markers of pre-clinical 
atherosclerosis and diastolic dysfunction is RA patients and OA controls. Our 
hypothesis was that patients with rheumatoid arthritis are more likely to display 
evidence of pre-clinical atherosclerosis compared to patients with osteoarthritis, due 
to the inflammatory effects of their disease on vascular function. 
 
Traditional CV risks and Markers of Inflammation: 
To investigate the relative contributions of both traditional cardiovascular risk 
factors and inflammation in RA as a non- traditional risk factor, to the development 
of CV events, we collected information on traditional CV risk profiles for both 
groups and also measured a number of markers of inflammation to identify if these 
were associated with pre-clinical CVD. 
We found that the prevalence of traditional CV risk factors were similar in RA and 
OA patients. We identified that 7 RA and 7 OA patients fitted the criteria for the 
metabolic syndrome. This diagnosis had not been previously documented. Over 
2/3’s of both the RA and OA groups had elevated levels of fasting serum cholesterol, 
however only 20% of these patients were taking a statin. 
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Markers of inflammation were compared between RA and OA groups. CRP was 
significantly higher in our RA group, which is not at all surprising. It was also higher 
in RA patients not on DMARD therapy. Levels correlated with markers of 
thrombosis in our RA group. Based on these finding and evidence that links CRP 
levels to future CVD events in RA patients, patients with a persistently elevated CRP 
should be evaluated appropriately for CV risk. 
 
Given the fact the hyperuricaemia is an independent predictor of the metabolic 
syndrome and that we found significant associations between serum urate level and 
BMI and waist-hip ratio in our RA patients, it would appear that measurement of this 
inflammatory marker may have a predictive value in RA patients with respect to 
their CV risk. 
 
We measured a number of pro-inflammatory cytokines in both groups and not 
surprisingly, concentrations were higher in RA patients. RA patients on a biologic 
DMARD had lower concentrations of MCP-1, a common chemokine in both RA and 
CVD pathways, suggesting an anti-atherogenic effect of biologic agents in addition 
to their role in controlling RA disease activity.  This may be an important future 
consideration as a potential therapeutic target to treat both diseases simultaneously. 
Smoking status, a risk factor for both CVD and RA, was associated with 
inflammatory cytokine concentrations in our RA group, supporting the theory that 
the pathological process of CVD in RA is due to the combined effects of traditional 
and inflammatory risks.  
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Fibrinogen, a marker of thrombosis, was significantly higher in the RA group. 
Markers of thrombosis correlated with measures of disease activity and subclinical 
atherosclerosis in our RA group, suggesting that abnormal haemostasis is one of the 
mechanisms linked with CVD development in RA. 
In support of the increasing body of evidence that OA has in fact an inflammatory 
component to it, is the correlation we reported between inflammatory cytokines and 
OA disease duration. This finding goes against the traditional theory that OA is 
merely a degenerative condition and suggests that our control group also had a 
degree of inflammation driving their condition.  
 
 
Subclinical Atherosclerosis: 
 
We did not find a difference in the prevalence of subclinical atherosclerosis between 
RA patients and OA controls. However, our OA control group are not comparable to 
normal healthy controls due to the inflammatory component to their disease and 
recent evidence of increased CV risk in OA patients.  
The importance of screening for traditional CV risks in RA patients, in particular, 
abnormal lipid profiles, was highlighted in our findings of an association of serum 
lipid measurements with both cIMT and carotid plaque. The fact that we have shown 
a link between the 2 reinforces the importance of CV risk screening in this 
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population. Carotid artery ultrasound may help to stratify RA patients according to 
CV risk. Rheumatologists should have a low threshold for treatment with statin 
therapy in this group. 
PAI-1 levels also correlated with sub-clinical atherosclerosis in RA patients. This 
highlights the fact that a number of mechanisms including altered haemostasis and 
atheroma formation are involved in the pathogenesis of CVD in this group.  
 
Ankle brachial index, a measure of peripheral vascular disease (PVD), was 
significantly lower in our RA group compared with the OA group. 15% of the RA 
group had abnormal ABI measurements, despite no symptoms of PVD.  This 
demonstrates that ABI is a useful tool for identifying silent disease in patients who 
may not be able to exercise sufficiently to generate symptoms of claudication, due to 
mobility restrictions. Also of interest is our finding that evidence of PVD in RA 
patients was associated with vascular disease at other sites, demonstrating the 
systemic nature of CVD in RA patients.  
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Endothelial Dysfunction: 
 
Serum concentrations of adhesion molecules, which are known biomarkers of 
endothelial dysfunction, were significantly higher in RA patients. They were also 
found in higher concentrations in those RA patients who tested positive for 
Rheumatoid factor and anti-CCP antibody compared to sero-negative RA patients. 
These results demonstrate that factors other than traditional CV risks are also 
responsible for the increased CVD risk in RA. 
A number of adhesion molecules had significantly higher concentrations in RA 
smokers than non-smokers, emphasising the important role that smoking plays in 
both atherosclerosis and RA. Given the causal link between smoking and RA and 
smoking and atherosclerosis, this preventable risk factor should to be top of the 
agenda for rheumatologists to target aggressively.  
Adhesion molecule concentrations also correlated with markers of diastolic 
dysfunction in RA patients, suggesting a link between endothelial dysfunction and 
cardiac function in these patients. Diastolic dysfunction also correlated with, urinary 
protein-creatinine ratio (PCR), another marker of endothelial dysfunction. Urinary 
PCR was higher in RA than OA patients. 
Our findings suggest a pathophysiological link between endothelial dysfunction and 
diastolic dysfunction in RA that needs to be investigated further. Measurement of 
albuminuria in RA patients may help to detect those at risk of diastolic dysfunction 
who would benefit from transthoracic echocardiogram. 
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Endothelial dysfunction was also assessed using flow mediated dilatation of the 
brachial artery. We did not identify a significant difference in flow-mediated and 
nitroglycerin-mediated dilatation between our RA and OA patients.  However, our 
finding of a significant correlation between markers of RA disease activity and 
endothelial dysfunction, demonstrate that RA remission induction would have 
beneficial effects on vascular function and supports the evidence for aggressive anti-
rheumatic treatment to improve cardiovascular outcomes in RA.  
Associations between endothelial dysfunction and glucose and pro-inflammatory 
cytokines in our OA group, support recent research that OA is an inflammatory 
disease and is closely linked to the metabolic syndrome. 
 
Diastolic dysfunction: 
 
RA and OA patients had similar prevalence of diastolic dysfunction. 
One third of both the RA and OA groups had echocardiographic evidence of 
diastolic dysfunction, despite no symptoms of cardiac disease. Diastolic dysfunction 
is silent until symptoms of heart failure appear. Assessment of diastolic function at 
the time of echocardiography in RA and OA patients should be incorporated into the 
examination. 
The lack of an association between serum NT-proBNP and markers of diastolic 
dysfunction in our study group suggests that NT- proBNP may not be a useful 
screening tool for diastolic dysfunction in RA or OA patients. 
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Salient points for the practicing clinician: 
 
1) Recognition and management of traditional cardiovascular risks by 
rheumatologists need to improve. This is evident from our findings that a large 
number of patients with elevated fasting serum cholesterol were not prescribed a 
statin and that a proportion of both RA and OA patients have the metabolic 
syndrome that has been unrecognised.  
2) Smoking, a modifiable CV and RA risk, was associated with increased expression 
of adhesion molecules in our RA group and correlated with serum cytokine 
concentrations. Its prevention and cessation should be targeted aggressively in the 
out-patient setting. 
3) A novel association between urinary protein creatinine ratio (PCR) and diastolic 
dysfunction in RA was found. Urinary PCR is a cheap and readily available marker 
of endothelial dysfunction. It should be used in the rheumatology clinic to identify 
RA patients at potential risk of diastolic dysfunction. 
4) Silent peripheral vascular disease is prevalent in RA patients and is detectable by 
ankle brachial index, a minimally invasive investigation. Identification of PVD 
should alert clinicians to the fact that atherosclerosis may be present in other 
vascular beds, as was the case in our RA patients and prompt further investigation.  
5) Osteoarthritis is associated with CV disease and markers of the metabolic 
syndrome. Traditional CV risks should be addressed in this group also. If 
inflammation is clinically apparent it should be treated as OA is no longer 
considered a natural aging process. 
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Recommendations for the Future: 
 
Coordination of care among rheumatologists, cardiologists and general practioners is 
crucial to improve detection and management of CV disease in RA patients. 
Increasing education and physician awareness that RA had a risk profile for 
developing CVD similar to the magnitude of the risk associated with diabetes 
mellitus will no doubt improve survival.  
A recent study of UK primary care practices by Monk et al, found that rates of 
screening for CVD were similar in RA and non-RA patients, but diabetic patients 
were 12 times more likely to receive screening (1).  
The COMORA study of comorbidities in RA also recently reported that 30-50% of 
RA patients do not have their CV risk factors optimally monitored or treated (2).  
Traditional cardiovascular risk factors need to be actively screened for in the 
rheumatology clinic. We advocate the use of modified cardiovascular risk screening 
tools, such as the mSCORE, as recommended by EULAR (3), as these tools may put 
the CV risk of RA patients in perspective for non-cardiologists. As described in this 
score, NSAIDs should be used with caution, the lowest possible does of 
corticosteroids should be prescribed and control of RA disease activity with anti-
rheumatic medications should be assessed regularly. 
 
It is difficult to disentangle the relationship between CV risk, inflammation and 
treatment effects in RA. Medication used to control RA has beneficial and 
detrimental effects on CV risk profile. Biologic and synthetic DMARDS, 
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particularly TNF inhibitiors and methotrexate are powerful agents for suppressing 
inflammation and also reduce CV risk. However, glucocorticoids are associated with 
increased CV risk due to their negative metabolic effects (4).   
One exciting clinical trial, The Cardiovascular Inflammation Trial (CIRT) is 
currently enrolling patients post- MI without a history of RA to receive either 
placebo or methotrexate, to assess if reducing inflammation will decrease future CV 
events (5). 
A second such trial, the Canakinumab anti-inflammatory thrombosis outcomes study 
(CANTOS), will address the effects of anti- Il1β inhibition on recurrent MI, stroke 
and rates of CV death in patients with stable coronary artery disease (5). Targeting 
common cytokine pathways, such as Il6 and Il1 as treatment options for both 
diseases may prove useful in controlling both diseases with a single agent. 
 
Communication between the specialities of cardiology and rheumatology is of 
paramount importance because control of CV risk and reduction of future CV events 
can be achieved not only by cardiac medications and interventions but also by RA 
disease control with anti-rheumatic medications, in particular biologic. 
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Study Limitations: 
 
Some limitations of our study merit mention. Our sample was drawn from a 
subspecialty referral centre, which makes our results most generalizable to the type 
of RA patient seen by rheumatologists rather than general practitioners. The cross-
sectional design of our study is a limitation. It was difficult to recruit large numbers 
of OA patients with a clean CV profile attending a tertiary referral centre. A larger 
sample size would allow for more detailed analysis with respect to causation.  
 
It is also important to mention that our OA group are different from “healthy” 
controls for a number of reasons. Because they attend a hospital based rheumatology 
clinic, they are more likely to have more severe OA than those attending their 
general practitioner. Also, increasing evidence of an inflammatory component to OA 
and its association with features of metabolic syndrome and increased cardiovascular 
risk, make this control group less representative of “healthy” adults than previously 
thought. 
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Future plans: 
 
In this cohort of RA and OA patients we are currently repeating the carotid 
ultrasound assessment of IMT and presence of plaque to assess the degree of 
progression, if any, of pre-clinical atherosclerosis over time. Ultrasound scanning is 
being performed 2 years after the baseline scan. In the preliminary analysis, 
comparison of interval scans in a subgroup of patients has not identified any 
progression of IMT over time. However, this will be re-analysed when the repeat 
carotid ultrasounds are completed for the whole cohort. Disease activity assessments 
2 years from baseline will also be analysed to examine for correlations with IMT. 
We are also following up both the RA and OA groups to identify patients who have 
developed cardiovascular events or died since recruitment. In 2012, 1 RA patient had 
suffered a cerebrovascular event since recruitment and 2 RA patients had died both 
from malignancy. There were no documented CV events or deaths in the OA group.  
Given the accumulating collection of evidence that OA is associated with increased 
CV risk, it would be interesting to compare our OA group to healthy controls in the 
community. 
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Appendix A 
 
Study Questionnaire 
 
COMBINED QUESTIONNAIRE AND CHART REVIEW FOR STUDY OF 
CARDIOVASCULAS DISEASE IN PATIENTS WITH RHEUMATOID 
ARHTRITIS 
 
 
Study number:                                               MRN: 
 
Name:                                                            DOB: 
 
Address: 
 
Telephone:                                                     Sex:  M/ F 
 
Date of diagnosis of RA:          /       / 
 
Diagnosed by whom: Consultant________________      
GP______________________ 
 
1987 ACR criteria: (need 4) 
 
EMS> 1 HOUR > 6/52 
Arthritis of at least 3 joints ( soft tissue swelling lasting .> 6/52 ) 
Arthritis of hand joints (wrists, MCPs , PIPs lasting >6/52 ) 
Symmetrical arthritis ( at least one area, lasting > 6/52 ) 
Nodules 
RF positive 
Radiographic changes ( erosions) 
 
Treatment history of RA: 
 
DMARD THERAPY 
 
 
 
DMARD 
START 
DATE 
STOP 
DATE 
MEAN 
DOSE 
REASON FOR 
STOPPING 
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USE OF BIOLOGICS 
 
DRUG 
START  
DATE 
FINISH  
DATE 
RESPONSE REASON FOR 
STOPPING 
 
 
    
 
 
    
 
 
    
 
Response? Is there a stanardised grading system available for this? 
 
Combination therapy with DMARD and biologic? 
 
Use of steroids since diagnosis?   Y/N                                 If  yes:        Duration: 
  
Current use?                                  Y/N                                                     Max. dose: 
Previous use?                                 Y/N                                                    Mean dose: 
 
 
Use of NSAIDS: 
 
 Current                                     Y/N 
 Previous                                   Y/N 
 
List:                                                Y/N                        Duration                    Dose 
 
Difene / Voltarol (Diclofenac) 
 
Brufen (Ibuprofen) 
 
Mobic ( Meloxicam) 
 
Feldene (Piroxicam) 
 
Celebrex (Celecoxib) 
 
Arcoxia (Etoricoxib) 
 
Vioxx 
 
Bextra 
 
Aulin (Nimesulid) 
 
Naprosyn 
Mefac (Mefanamic acid) 
 416 
 
 
 
 
 
 
 
Statins: 
 
Atorvastatin:          Y/N             Dose: 
 
Pravastatin:            Y/N             Dose: 
 
Simvastatin:           Y/N             Dose: 
 
Fluvastatin              Y/N            Dose: 
 
Other: 
 
 
Fibrates                  Y/N 
 
Ezetimibe:             Y/N 
 
Aspirin                   Y/N             Dose: 
 
ACEI                      Y/N            Dose: 
 
ARB                       Y/N   
 
Loop Diuretics       Y/N 
  
Thiazides                Y/N 
 
B-blocker                Y/N 
 
Ca blocker               Y/N 
 
PPI                          Y/N 
 
Bisphosphonate      Y/N 
 
 
 
 
                                                                   
 Allergies: 
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Family history of RA:                 Y/N     Who?         Age at presentation: 
 
Family history of  stroke             Y/N     Who?         Age at presentation: 
 
Family history of heart attack     Y/N     Who?         Age at presentation: 
 
Family history of cardiacstent    Y/N     Who?         Age at presentation: 
 
Family history of CABG            Y/N     Who?          Age at presentation: 
 
Family history of PVD ie. Claudication/ bypass/ angioplasty    Y/N       Who? 
Age at presentation: 
 
 
 
Social history: 
 Occupation:_______________________ 
 Currently working?                            Y/N        If not, is this due to disease?     
Y/N          
 Level of education?  Junior Cert        Y/N 
                                        Leaving Cert     Y/N 
                                        University         Y/N 
                                        
Smoker          Y/N                Exsmoker           Y/N              Pack years:  ________            
 
Units of C2H5OH/ wk: 
Past medical history: 
 
DM                   Y/N        When D(x) ? 
                                        Diet / Tabs / Insulin? 
Hypertension    Y/N                             
                                                                                                                                                   
Vitiligo          Y/N 
 
Hyperchol          Y/N                                                                     Alopecia        Y/N 
 
Raynauds            Y/N                                                                    Autoimmune Hep. 
Y/N 
 
Thyroid Dis.     Y/N    ( Goitre, hypo/hyperthyroid/ I 131)          SLE                Y/N 
 
Coeliac             Y/N                                                                       Felty’s syn     Y/N 
 
Sjogrens            Y/N      ( ask for dry eyes/ dry mouth)                Pulm. Fibrosis Y/N 
  
Systemic sclerosis      Y/N                                                            Osteoporosis    Y/N 
Atlanto-axial sublux.   Y/N                                                           Addison’s         Y/N 
Erosions on X-Ray      Y/N 
 
Other: 
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Any first degree relative with any of the above?        Y/N     If yes, who? 
 
 
Cardoivascular Symptoms: 
 
 SOB at rest                                                                                Y/N 
 SOB on exertion                                                                        Y/N 
 SOB lying flat/ how many pillows?                                          Y/N 
 Cough                                                                                        Y/N 
 Chest pain/ discomfort/ tightness on exertion                            Y/N 
 Chest pain/discomfort/tightness at rest                                       Y/N 
 Leg swelling/ Ankle swelling( ?bilat, ? worse at end of day)   Y/N 
 Palpitations                                                                                Y/N 
 Jaw pain/ Arm pain                                                                    Y/N 
 
 
Examination: 
 
      Weight(kg):                    Height(cm):               BMI:            Abdom circ: 
 
BP                                   HR                                                RR 
 
Nodules    Y/N                                             Joint Effusions: Y/N       Where? 
 
??Tinels 
 
Chest: 
 
CVS:      S1         S2         ADDED                MURMURS 
 
Liver / Spleen  enlarged?       Y/N                  Size (cm): 
 
L.nodes:                                Y/N                  Location 
 
Peripheral oedema                Y/N                  To what level? 
 
Ankle brachial Index: 
 
Skin rashes                            Y/N               livedo, vitiligo etc                
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      VAS:          physician global assessment of disease activity 
 
Not active--------------------------------------------------------------Very active 
 
                  Patient global assessment of disease activity 
      Not active--------------------------------------------------------------Very active 
                          
                         Patient global assessment of pain 
     Not active--------------------------------------------------------------Very active 
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Appendix B 
 
 
Short form Questionnaire (SF-36) 
 
1. In general, would you say your health is (circle one)     
 Excellent    ……………………………………………………………… 1 
 Very Good ……………………………………………………………… 2 
 Good …………………………………………………………………. 3 
 Fair …………………………………………………………………. 4 
 Poor …………………………………………………………………. 5 
  
2.         Compared to one year ago, how would you rate your health in general now? 
 Much better now than one year ago  …………………………………… 1 
 Somewhat better now than one year ago  ……………………………… 2 
 About the same as one year ago   ……………………………………… 3 
 Somewhat worse now than one year ago  ……………………………... 4 
 Much worse now than one year ago …………………………………… 5 
 
3. The following questions are about activities you might do during a typical 
day.  Does your health now limit you in these activities?  If so, how much? 
 
ACTIVITIES Yes, Limited 
A Lot 
Yes, Limited A 
Little 
No, Not Limited At 
All 
Vigorous activities, 
such as running, lifting 
heavy objects, 
participating in strenuous 
sports 
 
 
1 
 
 
2 
 
 
3 
Moderate activities, 
such as moving a table, 
pushing a vacuum 
cleaner, bowling, or 
playing golf 
 
 
1 
 
 
2 
 
 
3 
Lifting or carrying 
groceries 
1 2 3 
Climbing several flights 
of stairs 
1 2 3 
Climbing one flight of 
stairs 
1 2 3 
Bending, kneeling or 
stooping 
1 2 3 
Walking more than 
onemile 
1 2 3 
Walking half of mile 1 2 3 
Walking one hundreds 1 2 3 
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yards 
Bathing or dressing 
yourself 
1 2 3 
 
 
 
4. During the past 4 weeks, have you had any of the following problems with 
you work or other regular daily activities as a result of your physical health? 
(Circle one number on each line) 
 YES NO 
Cut down on the amount of time you 
spent on work or other activities 
 
1 
 
2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or 
other activities 
 
1 
 
2 
Had difficulty performing the work or 
other activities (for example, it took 
extra effort) 
 
1 
 
2 
 
 
 
5. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
      (Circle one number on each line) 
 YES NO 
Cut down on the amount of time you 
spent on work or other activities 
 
1 
 
2 
Accomplished less than you would like  
1 
 
2 
Did not do work or other activities as 
carefully as usual 
 
1 
 
2 
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6. During the past 4 weeks, to what extend has your physical health or 
emotional problems interfered with your normal social activities with family, 
friends, neighbours or groups? 
 
Not at all ………………………………………………  1
  
Slightly  ……………………………………………… 2 
Moderately ………………………………………………  3 
Quite a bit ………………………………………………  4 
Extremely ………………………………………………  5 
 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
 
None  ………………………………………………  1 
Very mild ………………………………………………  2 
Mild  ………………………………………………  3 
Moderate ………………………………………………  4 
Severe  ………………………………………………  5 
Very Severe ………………………………………………  6 
  
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and homework)? 
 
Not at all ………………………………………………  1 
A little bit ………………………………………………  2 
Moderately ………………………………………………  3 
Quite a bit ………………………………………………  4 
Extremely ………………………………………………  5 
 
 
9. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give one answer that 
comes closest to the way you have been feeling.  How much of the time 
during the past 4 weeks? 
 
 
 
     (Circle one number on each line) 
ACTIVITIES All of 
the 
Time 
Most of 
the 
Time 
A Good 
bit of the 
Time 
Some 
of the 
Time 
A Little 
of the 
Time 
None 
of the 
Time 
Did you feel full of 
life? 
1 2 3 4 5 6 
Have you been a 
very nervous 
person? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Have you felt so 
down in the dumps 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
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that nothing could 
cheer you up? 
Have you felt calm 
and peaceful? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Did you have a lot 
of energy 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Have you felt 
downhearted and 
low? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Did you feel worn 
out? 
1 2 3 4 5 6 
Have you been a 
happy person? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Did you feel tired? 1 2 3 4 5 6 
 
 
 
 
 
 
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting your 
friends, relatives, etc)? 
 
All of the time               …………………………………………………..      1 
Most of the time   ………………………………………………………2 
A good bit of the time    ……………………………………………………   3 
Some of the time           ………………………………………………………4 
A little of the time ……………………………………………………   5 
None of the time ……………………………………………………      6 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
(Circle one number on each line) 
ACTIVITIES Definitey Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definite
ly False 
I seem to get ill more easily 
than other people 
 
1 
 
2 
 
3 
 
4 
 
5 
I am as healthy as anybody 
I know 
 
1 
 
2 
 
3 
 
4 
 
5 
I expect my health to get  
worse 
 
1 
 
2 
 
3 
 
4 
 
5 
My health is excellent 1 2 3 4 5 
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Appendix C 
 
FMD PROTOCOL 
 
 
 Patient consent, questionnaire and exam 
 Height, weight, hip and waist circumference 
 Collect urine sample 
 Position patient and explain procedure 
 Check BP 
 Take bloods and put PAI sample in cooler bag  
 
 Turn on Echo machine 
 Press scan head button and select ‘Arterial’ 
 Place BP cuff below right elbow and inflate to check the position 
is stable, then deflate 
 Start scan and locate max diameter of brachial artery above elbow 
by moving probe from side to side 
 Clamp probe in position and remind patient to stay very still 
 Adjust gain and colour to improve vessel image 
 Turn on computer and click VIA 
 Select ‘new’ and enter patient details 
 A reference image is required. Select the region of interest (ROI) 
on the artery on computer screen and press ‘Start’ 
 Optimise the image by adjusting gain controls on Echo machine 
and adjust ROI size and position with ROI  controls on computer 
 Check that Images/sec is at least 25 
 When image is optimised, press ’Stop’ and then ‘Start’ to start 
new session, using only optimised images. Now the ‘Study 
Proper’ has begun and gain and controls should be kept constant 
 
 Record a baseline scan for 2 minutes and note times 
 Press ‘Inflate’ button ( green button will automatically inserted in 
the results database) and immediately inflate tourniquet to 
50mmHg above systolic 
 Check BP 
 Monitor sphygmomanometer pressure and check regularly that the 
image box on the computer screen bisects the artery at its 
maximum diameter and adjust the probe from side to side if 
necessary 
 Tourniquet should be kept inflated for 4.5 to 5minutes  
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 A red signal will flash on the computer screen for ‘Doppler On’ 
just prior to the time for deflation, no artery diameter recordings 
occur during Doppler mode 
 At the prompt for tourniquet deflation, immediately deflate the 
tourniquet and note the time and monitor  the image for any 
patient movement ( as this causes erroneous results) and correct 
the image plane as necessary 
 Check BP 
 Continue to scan for 2 minutes 
 Rest for 10 minutes to allow diameter to return to baseline 
 
 Press ‘Stop’ and then press ‘Start’ to record new session for GTN 
part of the study and note which session number for GTN 
 Record baseline scan for 2 minutes 
 Check BP 
 Give 2 puffs of GTN sublingually and immediately click the GTN 
button ( a blue line is automatically inserted into the data analysis) 
and note the time 
 Continue to scan for 5- 6 minutes after time of GTN ( max 
dilatation occurs at approx 3-4 mins post GTN)  
 Check BP 
 Press ‘Stop’ to end study 
 
 Select ‘File: Open: Data’ 
 A graph of results is generated. Click ‘Next’ to get to study 
session required and the click ‘Calculate’ 
 Dilatation is calculated as a percentage change in diameter from 
baseline 
 Peak dilatation post GTN may need to be marker manually on the 
graph ( roughly 3-4 mins after the blue line) 
 
 Perform ABI while patient still lying down after the FMD study 
 
 
 
 
 
 
 
 426 
 
Appendix D 
 
Abstracts 
 
1) Carotid Intima-media Thickness as a marker of pre-clinical atherosclerosis in 
rheumatoid arthritis.  
Miriam OSullivan, Cathy Dewhurst, Michael Molloy, Michael Maher, David 
Kerins, Sinead Harney, Fergus Shanahan. UCC Research Day 2008 
 
2) Rheumatoid arthritis is associated with an increased risk of cardiovascular 
events, even when traditional risk factors are corrected for. Carotid 
ultrasound, assessing intimal medial thickness and plaque, is a validated 
surrogate marker of coronary disease. 
Miriam O Sullivan, Cathy Dewhurst, Michael Molloy, Michael Maher, David 
Kerins, Sinead Harney, Fergus Shanahan. ISR 2008 
3) Endothelial Dysfunction in SLE: a rationale for the use of statin therapy to 
assess reversibility. 
      Miriam O’Sullivan, Patrick Barry, Sinead Harney, Denis O’Mahony.  
     ACR    2008 
4) Endothelial dysfunction as a marker of pre-clinical cardiovascular disease in 
patients with rheumatoid arthritis compared to patients with osteoarthritis. 
Miriam O Sullivan, Cathy Dewhurst, Michael Maher, Sinead Harney, David 
Kerins. ISR 2009 
 427 
 
5) Correlation between diastolic function, carotid intimal medial thickness and 
ankle brachial index, as markers of pre-clinical cardiovascular disease in 
rheumatoid arthritis patients 
Miriam O Sullivan, Orla Murray, Mary Daly, Cathy Dewhurst, Michael 
Maher, David Kerins3, Sinead Harney. Eular 2010. 
6) Comparison of ankle brachial index, as a marker of subclinical 
atherosclerosis, in patients with rheumatoid arthritis versus osteoarthritis 
patients. 
Miriam O’Sullivan, Mary Daly, MGM Molloy, David Kerins, Sinead 
Harney. ISR 2010 
7) Diastolic dysfunction in rheumatoid arthritis patients without cardiovascular 
symptoms is associated with presence of microalbuminuria and subclinical 
peripheral vascular disease. 
Miriam O Sullivan, Orla Murray, Mary Daly, Sinead Harney, David M 
Kerins. ESC 2013. 
 
 
 
 
 
 
 
 
 
 
